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Abstract
Dementia is a condition in which higher mental functions are
disrupted. It currently affects an estimated 57 million people throughout the
world. Dementia diagnosis is difficult since neither anatomical indicators
nor functional testing are currently sufficiently sensitive or specific. There
remains a long list of outstanding issues that must be addressed. First,
multimodal diagnosis has yet to be introduced into the early stages of
dementia screening. Second, there is no accurate instrument for predicting
the progression of pre-dementia. Third, non-invasive testing cannot be used
to provide differential diagnoses. By creating ML models of normal and
accelerated brain aging, we intend to better understand brain development.
The combined analysis of distinct imaging and functional modalities will
improve diagnostics of accelerated decline with advanced data science
techniques, which is the main objective of our study. Hypothetically, an
association between brain structural changes and cognitive performance
differs between normal and accelerated aging. We propose using brain MRI
scans to estimate the cognitive status of the cognitively preserved examinee
and develop a structure-function model with machine learning (ML).
Accelerated aging is suspected when a scanned individual’s findings do not
align with the usual paradigm. We calculate the deviation from the model of
normal aging (DMNA) as the error of cognitive score prediction. Then the
obtained data may be compared with the results of conducted cognitive
tests. The greater the difference between the expected and observed values,
the greater the risk of dementia. DMNA can discern between cognitively
normal and mild cognitive impairment (MCI) patients. The model was
proven to perform well in the MCI-versus-Alzheimer’s disease (AD)
categorization. DMNA is a potential diagnostic marker of dementia and its
types.
Keywords:

Convolutional

Neural

Network,

Structural-Functional

Association, Dementia, Neurodegeneration, Deviation from Model of
Normal Aging.
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Chapter 1: Introduction
Any society’s primary priority should be public health. A typical
public health strategy should aim to reduce the burden on medical staff and
equipment by screening the entire community. The screening programs
enable the early detection and diagnosis of those at risk of diseases. Risk
stratification can help determine the likelihood of a patient’s health
deteriorating. It aids in the planning and management of clinic resources,
among other things.
Risk stratification potentially determines a probability of worsening
of a patient’s health. It helps, among others, to improve the resources
planning and management in clinics. Elder risk assessment [1], dementia
risk score, cognitive testing, and chronic comorbidity count [2], to mention
a few, are some of the procedures used to identify high-risk patients. Those
strategies are solely based on comorbidity analysis. An optimal solution
should be able to precisely diagnose an illness and predict how the disease
will progress [3, 4, 5].
According to the World Health Organization guidelines, there are
three ways to assess the disease’s burden:
• the disability-adjusted life year (DALY).
• the number of years of life lost of dying early.
• the number of years of life lived with disability as the disease
consequence.
One DALY represents the loss of the equivalent of one year of full
health. In high-income countries, the number of DALYs (expressed per
100 000 population) for neurodegenerative disorders (NDs) is extremely
1

high. In the UK, it was 1088.9 for Alzheimer’s disease (AD) and 123.0 for
Parkinson’s disease in 2019, whereas in the US, it was 3837.1 and 513.1.
Between 2000 and 2019, the number of DALYs for Alzheimer’s disease
roughly doubled.

Figure 1.1: Most common causes of dementia

NDs are incurable conditions that result in death of neurons and a
progressive deterioration, i.e. dementia. Higher mental functions, such as
reasoning, planning, judgment, and memorization, are disrupted in
dementia.

AD is the most frequent cause of dementia (Figure 1.1).

Currently, 57 million people worldwide suffer from dementia. By 2050, this
figure is expected to triple, reaching 152 million instances [6].

Figure 1.2: The use of machine learning within clinical practice

The reason for such an exponential increment in dementia is societal
2

aging, which leads to the rise of the incidence of NDs that manifest with
dementia. In the UAE for instance, the life expectancy has increased from
74.3 in 2000 to 78.32 in 2022 [7]. Brain atrophy (BA) is a morphological
basis of both aging and NDs. Therefore, it is important to identify markers of
specific types of brain atrophy, i.e. to segregate pathology versus age-related
conditions (Figure 1.2).
Dementia diagnosis is difficult due to the lack of a standardized test.
Several approaches may aid in the detection of dementia. Brain imaging
may act as a subtle biomarker of the disease, thanks to recent developments
in computing resources and technologies (Figure 1.3).

Figure 1.3: Different modalities of dementia’s biomarkers, including neuroimaging,
genomics, CSF, and peripheral systems

Unfortunately, there are no particular radiological indications of
NDs. However, deep learning (DL) algorithms show significant promise in
the processing of visual modalities. DL has made great progress in medical
image classification, detection, and segmentation problems. It outperformed
even the most expert picture readers. Non-linear patterns concealed in data
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can be extracted using advanced machine learning (ML) and DL techniques
such as convolutional neural networks (CNN). Learning adaptability is
stronger in CNN models than in models with hand-crafted features. As a
result, scientists use CNN models to classify a patient’s diagnosis based on
diagnostic photographs (e.g., brain MRI, CT, PET-CT).
Clinical datasets collect a large amount of data, such as structural
attributes (image modalities), functional data (cognitive test results),
laboratory findings, demographic features (age, gender, ethnicity, family
anamnesis), and so on. They could be a source of accurate diagnostic
models, if properly analyzed using ML. Application of ML and DL to
neurology, for example, could aid in the early diagnosis and prognostication
of NDs.
1.1

Problem Statement
The relationship between brain structural changes and man’s

functional performance is complicated. Neural plasticity accounts for this
phenomenon. Plasticity is a specific feature of biological systems to adjust
to pathology. However, the process of adjusting the system may cause
diminishing to the potential outcomes of the disease. As a result, clinical
appearance may not reflect a true structural impairment, and vice versa. In
AD and mild cognitive impairment (MCI), for example, there is no apparent
association between functional performance and structural abnormalities.
Furthermore,

despite

the

progression

of

today’s

neuroscience,

pathophysiological mechanisms are complex and so remain unstudied.
Future diagnostics should include a wide range of diagnostic modalities and
clinical data, such as structural and functional characteristics, risk factors,
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demographics, etc. These features can be used in conjunction with ML
algorithms to validate the diagnosis and forecast the development of the
disease (e.g., disease severity, outcomes, a response to therapy).
New findings may have valuable impact on earlier detection,
diagnosis and treatment of age-related degenerative diseases.

Many

researchers have created methods to identify the diagnosis using structural
data as DL progressed. They employed both cognitively preserved and
demented patients to train their models. However, such models’ application
and therapeutic utility are restricted.

To that purpose, we identified

outstanding concerns and questions that must be addressed to facilitate the
risk assessment of ND and its severity:
1. The normal aging of the brain is still poorly understood.
2. It is difficult to correctly pinpoint the onset of age-related deterioration
in intellectual performance.
3. Proportionality of changes in cognitive domains and sub-domains are
not yet studied.
4. Neurology lacks a tool for assessing the risk of early cognitive
retardation. The optimal tool should be non-invasive and reliable. A
multimodal approach based on functional and anatomical brain
properties can be used to develop such a tool.
5. Association between the brain structure, cognitive status and executive
functioning (EF) is an issue of ongoing studies. It is not yet clear how
the association evolves in pathology.
6. Physicians lack a viable computer-aided diagnostic (CAD) system for
ND screening.
5

1.2

Objectives
We intend to get an insight into the normal and accelerated brain

aging by developing ML models.

The AI approach to the analysis of

medical data allows us to apply multimodal diagnostics to clinical practice.
The combined analysis of distinct imaging and functional modalities
improves diagnostics of NDs with advanced data science techniques, which
is the main objective of our study.
Hypothetically, there are different types of age- and diseases-linked
changes in brain morphometry, cognitive performance and their association.
We will identify these patterns by comparing the diagnostic images and the
results of psychophysiological and cognitive assessment with ML and DL
techniques.
If there is no distinct patterns there should be a common mode of
structural deterioration and cognitive decline reflecting brain atrophy with
some threshold level indicative of the disease. ML can allow us to distinguish
normal aging from pathology with the help of a classification model.
We devised the tasks mentioned above for addressing the objective:
1. Develop ML models of age-related cognitive decline and study agerelated changes in cognitive subdomains:
(a) Create new indices that measure the ratio of cognitive
functioning

activity

during

the

completion

of

psychophysiological tasks.
(b) Study results in psychophysiological tests (PTs) and split the
examined cohort into an ideal number of age groups. Search for
potential biomarkers of age-group identification by exploring
6

the metrics of the unsupervised ML model.
(c) Examine any probable links between age and the newly
suggested scores, as well as the predictive power of PTs in
determining the values of the indices developed.
2. Create an accurate model describing brain morphologic changes
throughout life:
(a) Use ML to analyze structural changes in main brain
compartments and simulate neurofunctional performance at
different ages.
(b) Choose the mathematical model that best describes the
progression of anatomical and functional changes in the brain
throughout lifespan.
(c) Compare

the

dynamics

in

brain

volumetry

with

psychophysiological performance across the life.
3. Identify patterns of brain structure-function association (SFA)
indicative of MCI and dementia:
(a) Study the dynamics of the performance in cognitive and
neurophysiological tests in patients with MCI and dementia.
(b) Build models of brain SFAs in cognitively normal individuals
and patients with MCI or dementia.
(c) Create a method for categorizing the examinees into two groups
based on the pattern of SFAs: cognitively normal seniors and
patients with MCI or dementia.
4. Improve screening for MCI and dementia and prognosticate
progression of MCI:
(a) Conduct an exploratory analysis of structural and functional
7

changes in cognitively preserved population and patients with
MCI or dementia.
(b) Propose a reliable marker of disease-related cognitive decline.
(c) Justify the proposed marker as a screening tool for MCI and
dementia.
(d) Assess

the

novel

marker’s

diagnostic

capability

in

distinguishing stable from progressing MCI and Alzheimer’s
amyloidopathy from other types of NDs.
1.3

Literature Review
Diagnosing dementia in its preliminary phase is hampered by the

shortcomings of reliable screening methods within neuroscience (see
Table 1.1). These persisting limitations can delay the accurate clinical
diagnosis by more than 12 months, inevitably eliminating the intended
benefit of early treatment, such as memory enhancement, reduced anxiety,
and social activity engagement [8, 9].
Diagnostics of NDs can be enhanced through:
• Identification of the dementia onset with a multi-modal approach.
• An informant-based assessment.

This method is favoured by

scientists and medical professionals as it provides fundamental
insight into the patient’s personality, which is critical during initial
diagnostics.

Panegyres et al.

reported that this method is more

dependable than the mini-mental state examination (MMSE) [10].
• Evolution of the screening strategy to the point where it can be
incorporated into routine clinical diagnostics. Brain aging should be
the foundation of this novel test. The predominant solution consists
8

of three steps: 1) researching the new potential origin of brain aging;
2) evaluating the reliability of the test in an unaffected population;
and 3) similarly evaluating the tests’ reliability in dementia patients.
The cognitive changes of the aging brain have been attracting
increasing interest from researchers, which has led to an accumulation of
data that present partial insights regarding changes in reaction time (RT),
working memory [11, 12], executive functions [13, 14], memory, linguistic
skills, and cognition [15, 16]. To delineate the procedure of cognitive
decline associated with advancing age, scientists have conceptualised brain
reserve and cognitive reserve. These concepts alleviate the repercussions of
head trauma, senescence and NDs [17]. Nevertheless, a comprehensive
theory for medical practitioners remains absent.

Hence, this set of

unanswered questions remain:
• Cognitive and brain reserves are not exhaustively studied.

Brain

reserve is predicted by anatomical quantification (cranial volume,
height, and length) [18]. However, [19] stated that the list of brain
reserve predictors should include the total number of neurons,
synapses, and dendrites. In addition to these structural discoveries,
the cognitive reserve consists of psychological factors and various
lifestyle activities during a lifespan [18]. Nevertheless, [20] suggested
that neural reserve and compensation constitute cognitive reserve.
• The brain’s resilience against cognitive decline is not entirely
understood. Research has suggested that the primary defence is the
brain reserve and that it defines the cognitive reserve’s potential [21].
Hence, the potential onset of dementia is delayed in patients with
more neurons, compared to patients with a lower brain reserve [22].
9

On the other hand, neuroplasticity is determined by intelligence
preceding the onset of dementia, the level of education, and
individual lifestyle (cognitive reserve). Hence, patients cope better
with dementia if they have had a higher level of education and higher
intellect.

Furthermore, symptoms of dementia are independently

moderated by cognitive and brain reserves [23].

The need for

additional research regarding the brain reserve and cognitive reserve
relationship persists.
• Presently, the widely used PTs in the assessment of cognitive
domains remain understudied and under-established regarding their
accuracy and association. A meta-analysis study reviewing cognitive
tests reported that the frequently used MMSE presented the lowest
sensitivity during MCI diagnostics [24].

This finding is further

supported by an additional review stating that the limited predictive
power associated with MMSE and Montreal Cognitive Assessment
(MoCA) exceeds that of recall tests [25].
1.3.1

The Relevance of Researching Cognitive Decline in a Healthy
Population
Novelty in research regarding age-related changes in cognitive

subdomains: Numerous studies focused on comparing NDs patients to a
cognitively normal population [26, 27], however, considering that the
normal aging process is understudied. Hence, such a comparison is of little
value [28, 29, 30].

These studies fail particularly to address the

pathophysiological changes associated with aging. Age-related cognitive
decline seems to be controlled by fundamental neurobiological changes, for
example vascular changes and buildup of neuropathology [31, 32, 33].
10

Table 1.1: Reliability and shortcomings of dementia diagnostic methods
Method
MRI
Tractography

Diseases investigated
Progression of MCI
Parkinson’s Disease
Multiple sclerosis
Amnestic MCI
Parkinson’s disease

Sens,%
87
61
93
96
40-86

Spec,%
66
68
81
94.2
41-94

Ref
[34]
[26]
[36]
[37]
[38]

fMRI

mild AD

77.3

70

[39]

PET

AD vs FTLD
AD vs MCI
Amyotrophic lateral
sclerosis

69.4
81.8

93.2
86

[41]
[43]

94.8

80

[44]

93

87

[45]

69
61
87-100

68
70
90-96

[46]
[48]
[49]

81

85

[50]

90
60
77 vs 85
88 vs 84

100
90
97 vs 88
70 vs 86

[51]
[54]
[53]
[55]

88 vs 79

74 vs 80

[55]

Angiography
MRI
Brain
perfusion

SPECT

Dementia with
Lewy bodies (DLB)
AD vs FTLD
Dementia
DLB vs AD

SPECT
DLB vs AD
+ MMSE
FBI
FTLD
Mini-Cog
Cognitive Impairment
Cognitive
MoCA
Vascular dementia
tests
MMSE
full vs short MCI vs dementia
MoCA
* AD - Alzheimer’s disease;
BOLD - blood-oxygen-level-dependent
DLB - Dementia with Lewy bodies;
FBI - Frontal Behavioral Inventory;

FTLD - fronto-temporal lobe dementia;
MCI - mild cognitive impairment;
MMSE - Mini Mental State Examination;
MoCA - Montreal Cognitive Assessment;

Shortcomings
It is crucial to avoid coming across
as over confident, since imaging
features are not pathognomonic
in most cases [34, 35, 26, 36, 37, 38]
Altered BOLD signals found in AD/MCI
patients indicate potential impairments in
haemodynamic processes apart from
alterations in neuronal activity [39, 40]
Irrespective of the auspicious reliability and accuracy,
the implementation of PET/MRI remains predominantly
research-based, due to its unique radiotracer requirements
[41, 42, 43, 44]
During this method patients are exposed to radiations, as
well as potential kidney function impairment and an allergic
reaction, associated with the iodinated contrast
Assessing the damaged brain function in FTLD,
through ASL perfusion, can fluctuate
regionally despite extensive
atrophy [46, 47, 48, 49, 50]
This method may present insensitivity
to elusive brain abnormalities.
Transferring the test outcome
between varying cognitive impairments
should be done attentively [51, 52, 53, 54, 53, 55]
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The increasing support for an alternative purposing explanation
regarding the estimations of the cognitive change in the elderly might have
been unfavourably influenced by pathologies commonly associated with
older age, especially NDs such as AD [56]. Research regarding accelerated
brain aging is rendered of little value in the persisting absence of scientific
data describing what can be considered as regular cognitive changes [57].
These studies have recurrent restrictions and a disarranged bias.
Differentiating between pathological cognitive declines and normal
cognitive aging remains problematic in these studies, especially regarding
the age group above 65 years [58, 59, 60].
There are numerous NDs and classification models [61], for
example, a neuropathological based classification enumerates more than 10
groups with various nosologies associated with each group [62]. Scientists
experience difficulty when considering this substantial amount of diseases
within a consolidated system.

Clinical impression, together with

non-invasive diagnostics, does not provide adequate details to discriminate
between these diseases.

High number of invasive neuropathological

examination is required [62]. Granted, in this situation, comparative studies
can incorporate the entire scope of NDs. For this reason, scientists prefer
non-invasive methods, such as cognitive tests and MRI, to investigate the
normal process of aging [32, 58, 63, 64, 65, 66, 67, 68]. Brain aging
researchers have not investigated the comparison between healthy adults
and patients suffering from neurodegeneration. The point of focus is not on
identifying the specific disease. Instead, the researcher focuses on permitted
changes within a healthy population, leading to a conjecture regarding
accelerated brain aging in noticeable cases. In our earlier research, we
12

mirrored this approach [69, 70, 71, 72]. The rate of information processing
speed and its change related to age is a subject of ongoing research
[73, 74, 75]. The vast interest in information processing speed is based on
its correlation to functional abilities in older adults [74, 76]. However, the
current formulated research questions regarding this field are inadequate.
The correlation of structural and biochemical changes to information
processing has been a recent research topic of interest. For instance, a
recent study on normal decline found an inverse correlation between the
interleukin-6 level and information processing speed. As well as an inverse
relationship between the fractional anisotropy of corpus and information
processing speed [77, 78]. Furthermore, an additional study underlined the
correlation between a substantial volume of corpus callosum, decreased
levels in insulin and the inflammatory markers, and intact older adults
self-reporting an increase in physical activity [79].
Research has ascribed the decline of white matter (WM) integrity
to the age-related decrease in cognitive speed [75, 80, 81]. However, the
main contributing factors to WM changes remain unclear. A sufficient
explanation for observing neurocognitive slowing associated with aging is
still absent. Continuing research aims to establish the cause of change in
information processing speed during normal aging.

Patients with

neurodegeneration can be compared to a healthy population to underline
risk factors associated with neurodegeneration.
genetics [82] and changes in WM [83].

Risk factors include

Studying aging in a healthy

population could benefit future identification and differentiation of the
preliminary signs associated with NDs.
Depending on the conducted assignments, inconsistent findings
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have been reported regarding changes in the information processing speed
related to age. For example, younger adults were more proficient in coding
and symbol searching assignments, while on the other hand, older adults
were more skilled in inspection time assignments [84].
explanation has not been produced for this finding.

A satisfactory

A parallel study

reported that the slowing of performance speed occurs over the lifespan
[85]. However, research has reported that the decrease in sensory function
is linked to the decline in processing speed [86, 87]. Furthermore, studies
have also claimed that the general cognitive status in adults above 40 years
is predicted by the cognitive processing speed. However, this is not the case
in adults younger than 40 years. Additional research is required to verify
the findings [32].
1.3.2

Processes Behind Neutocognitive Slowing
A few processes contribute to neurocognitive slowing, such as

atrophy and neuroplasticity.

However, these two processes have been

reported as direct theoretical opposition [88]. Brain atrophy has been linked
to numerous factors such as vascular factors [89], inflammation [90], diet
[91], metabolic disorders [92], and dysbiosis [90]. These factors provide
insight into dementia-related mechanisms and uphold the notion of
cognitive impairment management through manipulation of these factors.
Contradictory to this is the idea of neuroplasticity. According to the idea,
cognitive and low-intensity physical training can reduce noticeable brain
aging and delay the appearance of dementia [77, 88].
Concurrent changes in cognitive domains associated with aging:
Declines could vary according to cognitive domains. Numerous declines
14

progressively worsen over time, while some remain stable, such as
language. Generally, the change in reaction speed related to age is linked to
numerous changes in the cognitive domains [67]. EF, the cognitive domain
accounting for individual goal-directed behaviour, is affected by decreased
information processing.

Two explanations are offered for this finding.

Firstly, relevant operations cannot be performed within a predetermined
time interval. Secondly, slow processing reduces the amount of information
which is concurrently available. Hence, the delayed supply of information
leads to the collapsing of the higher-level processing [93]. Consequently,
EF deficit can potentially affect performance in numerous cognitive
variables, this inducing cognitive decline [67].
Research has proposed numerous interdependent cognitive aging
mechanisms. Irrespective of commonality among findings presented by
various speed-based tasks, the decline in abilities is not a general factor of
cognitive slowing [88, 94]. For instance, working memory is responsible for
task-recall, which is associated with reasoning. It is logical to conclude that
its impairment will have a significant impact on older adults’ cognitive
performance.
EF and cognitive control: Cognitive control is the capability to
arrange our thoughts and actions according to internal goals [77]. EF is an
umbrella term under which EF and cognitive control fall. Furthermore, it
also covers a set of higher-order (cognitive) processes associated with
arranging conscious behaviour during an unfamiliar situation [95].
consist of three subdomains:

EF

inhibitory control, which includes the

prevention of insignificant information and prohibiting prepotent responses;
task switching, which is the capability to switch between mental sets
15

effortlessly.

Finally, it is updating, the continuous monitoring and

instantaneous addition/deletion of content to the working memory.
Age-related cognitive decline is associated with declining inhibitory control
[96]. Moving between different assignments requires working memory in
the absence of a cue, and a decrease in the memory domain over time might
impact this EF [97, 98].
Attention is commonly split into two comprehensive subdomains.
The first subdomain is selective attention, for example, concentration, while
the second subdomain is sustained attention or vigilance, for example,
divided attention [99]. A declining capability in paying attention to selected
stimuli is associated with the elderly. Age-related declines in selective
attention interact with other cognitive domains and other changes related to
age [77, 100].
There are additional attention subsystems. For example, it has been
proven that the relationship between goal-guided attention and habitual
spatial attention is affected by aging [101].

The authors of this study

interpret habitual spatial attention as the attention attracted regularly to a
target, such as a space with a heightened possibility of triggering stimuli.
Older adults experience difficulty with interrupted goal-guided attention,
yet they are relatively unhampered in utilising spatial attention through
coincidental habit-based learning.

Therefore, the decrease in certain

attention subdomains can be counterbalanced through teaching searching
habits to older adults.

Age-related decline influences attention since

attention skills have EF elements [99].

A deficiency in obstructing

insignificant information is associated with older adults, which could be
attributed to changes in the prefrontal cortex [100].
16

Memory, as a cognitive domain, could be subjected to influence
from multiple processes such as working memory, executive control
operations, speed, and sensory declines.

The loss of memory could

originate from an inadequate capability to pay attention and move between
functional brain networks. Change in older adults’ structural and functional
brains causes them to experience difficulty disregarding distractions, which
leads to significant and insignificant information being co-encoded.
Inevitably this causes an overload on the limited cognitive resources [100].
Irrespective of the well-known fact that with age, memory
performance decreases, it is interesting that all memory aspects are not
equally

impaired

[102].

The

procedural

memory

is

manifested

automatically without intentionally recalling past events, while on the other
hand the declarative memory depends on intentionally recalling past
experiences. It includes episodic memories of specific experiences and the
semantic memories, which mirror our common comprehension of facts and
the definitions of words. Generally, the older adults experience the most
severe memory loss in long-term episodic memory due to its significant
attention demand.

Negligible age-related changes are generated in the

sensory, semantic, and procedural memory due to their small attention
demand [100, 102].
Memory is mediated with other cognitive domains.

Semantic

memory can be seen as an arranged data storage of words or concepts “nodes”. These nodes are linked through associative pathways [77]. When
a node is activated by a person paying attention, it initiates an escalation
within the network, which ultimately activates various nodes and enables
processing [102].
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Working memory acts as a buffer.

It stores data for cognitive

processing and is subjected to age-related changes such as the decline in
capacity and processing speed. A decrease in the processing speed and
disintegration of primary control processes is responsible for the change in
working memory.

Primary control processes in this context refer to

resistance to unwanted influence, memory updating, binding, assignment
coordination,

top-down

control.

This

knowledge

derived

from

neuroimaging data. Furthermore, age-related changes in working memory
have a more significant influenced on spatial material than on the verbal
[11].
Perceptual and sensory deficiency worsens cognitive decline as
well as increases the difficulty of fulfilling cognitive assignments. Declines
in these domains are associated with a decreased capability to identify a
stimulus from the sensory modalities and limit the process and
incorporating the obtained information.

Clinically, older adults can

experience various challenges when using their five sensory modalities. For
example agnosia is when experiencing difficulty in identifying formally
recognisable objects [99]. Other domains are impacted by the age-related
cognitive changes in the sensation and perception domains. For example,
auditory memory and language comprehension issues result from a hearing
deficit [88]. However, the intervention of decreasing perceptual processes is
also possible. Davis’s “posterior-to-anterior shift in aging” model proposes
intervening in the decrease of perceptual processes linked to the occipital
regions through increasing prefrontal activities. However, this assumes that
task performance in young and older adults can be compared, even though
the process depends on different neural mechanisms [100].
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Motor skills are defined as the primary components of motor
activity and construction is defined as the capability to duplicate or create
sketches of ordinary objects.

Motor skills and construction could be

compromised in critical dementia cases, nondominant hemisphere trauma,
or by parietal cortex lesions [99].

It has been reported that cognitive

processes linked to language remain constant or even enhances up to the
age of mid-70s [88]. Language deficits could be linked to an EF deficit (for
example, the capability to retrieve semantic storage effectively) or to a
decreased processing speed [99].

A crucial element in comprehensive

impairment is a primary lag of the neurologic response.

Furthermore,

change in attention and declined memory influence speech comprehension
[103]. Intercorrelation and inseparability of cognitive domains: One should
not consider the intercorrelation of cognitive domains as an insufficient
cogency.

Compelling evidence has indicated that common domains of

cognitive dysfunction are inseparable in in a variety of patient groups,
including individuals with schizophrenia and bipolar illness [99].
1.3.3

Normal Brain Aging
Normal brain aging can be described in terms of the brain atrophy

and neurocognitive slowing.

The first term covers the brain structural

changes across the life. The second term denotes the functional outcomes of
the process. Atrophy is a process by which the size or number of cells in
response to a stimulus [104] is decreased. Brain atrophy is a common
feature of brain aging and of numerous diseases that affect the brain.
Macroscopically, BA results in brain shrinkage, and compensatory
enlargement of cerebrospinal fluid spaces, the ventricles and the
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subarachnoid space.

Ventricular volume trajectory shows a strong

association with age and pathologic measurement because it is a summary
marker of atrophy, both of gray matter and white matter (as a result of glial,
myelin, axonal and/or neuronal loss) [105]. But there is no simple, sensitive
quantitative marker which is well associated with the extent of cognitive
impairment or highly specific to any particular ND.
Features of brain atrophy: Normally, decreasing of brain size does
not automatically lead to cognitive impairment until the age of 65 years
[106]. MRI allows researchers to accurately quantify the atrophy of cortical
and subcortical gray matter regions (in terms of volume loss,
macro-morphological changes and cortical thinning), and to evaluate white
matter structural damage [106].

Ventricular volume trajectory is

significantly associated with age, the presence of infarcts, neurofibrillary
tangles and neuritic plaque scores, the presence of some gene alleles and
dementia diagnosis.

The total brain volume trajectory is significantly

associated with age and mild cognitive impairment diagnosis.

The

hippocampal volume trajectory is significantly associated with amyloid
angiopathy [105].
Brain atrophy is an authentic subject of relevant research due to the
tendencies of the world-wide civilization, such as the aging of population
accompanied with the increasingly high rate of NDs. Many publications state
the issue of either the structural changes or the functional impairment of the
nervous system (e.g., cognitive decline). Unfortunately, it is still unclear, to
what degree brain atrophy contributes to the malfunctioning of the nervous
system. Structural MRI studies have revealed that the extent of age-related
brain changes varies markedly across individuals [107]. Other studies of
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brain functioning bared inconsistencies in both onset and the rate of episodic
memory loss in the elderly cohort, which accounts for different inherited
and life-style factors [108]. However, there is no evidence of a direct link
between structural and functional impairment.
Brain atrophy is observed overall in (normal) brain aging and
neurodegeneration.

Regarding normal brain aging, there were some

attempts to establish structural-functional association, but the evidence
provided us with inconsistent data.

For example, the association was

significant for older participants (65–80 years) but not middle-aged (55–60
years) participants [106]. However, findings show that brain atrophy starts
almost after puberty. What may account for these discrepancies? Does a
compensation of functioning take place? If so, in what way? Therefore,
does the process last typically until the age of 60 years?
Some studies have demonstrated that brain atrophy in normal aging
participants is characterized by several trends. Firstly, in the volumetric
reduction within the human cortex. The second is the shrinking of the
neuronal networks suddenly, from a more distributed arrangement to a more
localized topology in the middle-aged group (30-58 years). Afterwards, it
maintains this localized topology in the older participant group.

The

researchers concluded that there are variations in topological organization
of neuronal networks during normal ageing [109].

Therefore, they

specifically describe such components of brain atrophy as volume
reduction, structural and functional connectivity impairment. However, this
still fails to provide us with evidence of how the structural changes and the
disconnected state affect simple physiological reactions. To clarify these
issues, it is imperative that new research should be conducted and
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concluded.
1.3.4

AD Dementia
Alzheimer’s disease accounts for more than half cases of dementia

which can be defined as an acquired and persistent generalized disturbance
of higher mental functions, such as reasoning, planning, judgment, memory
and additional thought processes, in an otherwise alert person [104].
According to the age of onset and leading etiological factors, it can be
classified into several categories. The senile demetia’s typical onset is after
65 years of age. It is an age-related condition; however, it can hardly be
distinguished from the vascular dementia. The pre-senile cases of dementia
refer to such causes as NDs, cerebrovascular disease, infections, acute or
chronic traumatic brain damage, metabolic diseases, toxic and chronic
alcoholism, nutritional deficiency, myelin disorders, primary or secondary
brain tumours, occlusive hydrocephalus.
ND is a term surrounding a wide variety of disorders that are
characterized by the progressive dysfunction and/or death of glial / nerve
cells. This leads to a typically slow and progressive disease with variable,
gradual neurologic dysfunction.

Numerous classifications have been

described in the past. However, the better NDs are understood, the more
classifications shift towards focusing on changes at the biochemical level
[35]. Tau proteins (or τ proteins) – proteins that stabilize microtubules (a
part of the cytoskeleton which provides structure and shape to the
cytoplasm of cells) [110]. In pathological conditions of tauopathy, tau is
hyperphosphorylated. Other modifications include acetylation, nitration,
glycation, conformational change and C-terminal truncation [111].
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Tauopathies are a class of ND characterized by neuronal and/or glial
inclusions composed of the microtubule-binding protein, tau [111]. These
NDs derive from the pathological pathway which leads from soluble and
monomeric to hyperphosphorylated, insoluble and filamentous tau protein.
They could be inherited (mutations of genes encoding tau protein), however
there are generally non-inherited forms. Apart from molecule structure
differences, tauopathies vary in the cell types (neurons or glia) and
anatomical regions (i.e. limbic/neocortex, basal ganglia and brainstem)
most vulnerable to tau-mediated neurodegeneration. Clinically, tauopathies
can present with a range of phenotypes that include both movement- and
cognitive/behavioral-disorders or non-specific amnestic symptoms in
advanced age [111]. The distribution of pathologic accumulations of tau
proteins in ND defines the clinical symptoms: e.g., Alzheimer’s disease is a
dementing illness and Parkinson’s disease is namely a movement disorder
[110]. A major limitation for pharmacologic prevention of pathological tau
transmission is the inability to readily detect tauopathies [111].
AD is the ND which accounts for approximately 70% of all cases of
dementia. For this reason, NDs are usually classified into AD and non-AD
forms [104, 106]. MRI-derived structural patterns of cortical atrophy have
been shown to accurately track disease progression and seem to be promising
in distinguishing AD subtypes. Disease progression has also been associated
with changes in white matter tracts. Recent studies have revealed two areas
often overlooked in AD, namely the striatum and basal forebrain with more
focal atrophy, although the impact of these changes regarding cognition is
still unclear [106].
Brain atrophy assessed on structural magnetic resonance imaging
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(MRI) has been demonstrated as a valid marker of AD-related
neurodegeneration at the late stages of the disease [106]. However, reliable
means of identifying cognitively-normal individuals at higher risk to
develop AD are more likely to derive from psychophysiological testing
(e.g., event-related potentials) [112]. So, the full understanding of the
pathophysiological mechanisms underlying AD- and MS-related functional
impairment of the brain and its structural bases remains incomplete [113].
1.3.5

Other Types of Dementia
Dementia with Lewy bodies (or Lewy body dementia) is the second

most common type of progressive dementia after Alzheimer’s disease
dementia. Protein deposits, called Lewy bodies, develop in nerve cells in
the brain regions involved in thinking, memory and movement (motor
control) [114].
Parkinson disease is a ND which mainly affects the motor system.
It is more common in men (1:3.5) and women have a lower rate of decline.
The official data by the department of measurement and health information
of the World Health Organization (WHO) allow us to compare the burden
which Parkinson’s disease (PD) and AD put on the society. For instance, in
the UAE, age-standardized disability-adjusted life year was 584 for AD and
61.1 for Parkinson’s Disease in 2016 [115]. From the 2016 annual report of
the GBD 2016 Dementia Collaborators, high-income countries such as the
United States of America (USA) and the United Kingdom (UK) had a higher
rate of AD per 100 000 population: 1278 in the UK; 1247 in the USA. In the
UAE, the rate of the disease was 110 per 100 000 people [116]. For PD, the
prevalence was just 26 in the UAE, 176 in the UK and 218 in the USA per
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per 100 000 population in the same year [117].
Life expectancy is constantly increasing in the UAE [118]. This
contributes to the rise of ND morbidity, but the summary death statistics do
not claim NDs as a common cause of death. Both dementia and PD are rated
to 0.7 cases of death per 100 000 population according to the Global Burden
of Disease study in 2016 [119]. The numbers for the UK are 46.7 and 9.09
respectively. However, even drug use disorders which are non-typical for
the population of the UAE are responsible for much more cases of mortality
according to the same source of the statistical data: 8 cases per 100 000
[119].
Frontotemporal dementia (FTD) is a class of disorders characterized
by the loss of nerve cells in the frontal and temporal lobes of the brain. These
lobes decrease in volume and as a result behavior, demeanor, language, and
mobility can all be affected by FTD [120]. Depending on whatever section of
the brain is affected, the signs and symptoms will differ. Some patients with
FTD have major personality changes, becoming socially inept, impetuous,
or emotionally apathetic, while others lose their capacity to communicate
effectively [120]. FTD is sometimes misdiagnosed as a mental illness or
AD. FTD, on the other hand, tends to strike at a younger age than AD. FTD
usually develops between the ages of 40 and 65, however it can sometimes
develop later in life. FTD is responsible for 10% to 20% of all dementia
cases [120]. There are common types of FTD, such as Frontal variant (affects
behavior and personality) and primary progressive aphasia (affects ability to
communicate or understand the language).
Myelin disorders (e.g., multiple sclerosis, leukodystrophy) are
myelin sheath abnormalities or a myelin breakdown (demyelination)
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resulting either from a primary attack on myelin sheath or the
oligodendrocyte or simultaneously [121]. Cognitive decline also occurs at
the late stages of the diseases.
Vascular dementia – is a general term describing dementia caused by
impaired blood flow to the brain, e.g., multi-infarct dementia, arteriosclerotic
dementia, global hypoxia/hypoperfusion, vasculitis [104].
Dementia Resulting From Traumatic Brain Injury is a long-term
consequence of traumatic brain injury. According to estimates, 2% of the
US population has long-term disability as a result of a previous traumatic
brain injury, with percentages significantly higher in underdeveloped
nations [122]. Multiple epidemiologic studies demonstrate that having a
traumatic brain injury in early or midlife is related with an elevated risk of
dementia in later life, making dementia one of the most feared long-term
outcomes of traumatic brain injuries [122].
1.3.6

Structure-Function Association
Studying the relationship between a system’s structure and actions

provides an understanding of the normal brain and body function, enabling
more effective diagnostics and treatment of abnormal or disease states. To
enhance the diagnostics one may use an innovative approach to data
analysis

by

incorporating

newly

computer-aided diagnosis systems.

developed

ML

methods

into

This may give an insight into the

importance of specific data features and calculate the weights of potential
predictors.

The proposed solution should be based on state-of-the-art

methods, which will allow us to assess overall functioning at the level of
organ systems and the whole body. To become a popular tool for screening
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dementia, a test must comply with physiology of brain changes across the
life. The optimal solution consists of the following steps. The first one is
investigating possible new causes of aging. The second step is testing
reliability in a healthy population. And the third step is testing in patients
with emergent dementia [77].
Researchers have gathered diverse information, but have not yet
been able to develop a general theory. They have concentrated on diverse
aspects of cognitive aging that focus on changes in EF, memory, and
linguistic abilities and knowledge. However, all these processes cannot be
addressed in a single study. To date, no systematic analysis or review has
produced a well-defined theoretical approach that could be easily put into
practice. The diagnostics of NDs is challenging, since neither structural
signs nor functional tests are sensitive enough or specific. Thus, a long list
of unresolved issues remains to be covered. First, despite the well-known
advantages of multimodal diagnostics it has not yet been incorporated into
screening for early-stage dementia. Second, there is no reliable tool to
predict whether pre-dementia will progress.

Third, it is impossible to

perform the differential diagnostics of exact ND with non-invasive tests.
For instance, the early differential diagnosis between MCI due to AD and
MCI due to other ND conditions is particularly challenging in clinical
settings. To improve the current situation, we propose a combined analysis
of structural findings and functional data. The best way to carry out such
analysis is to apply ML [123].

The strengths and limitations of brain

structural and functional assessment are briefly discussed below. As seen
from the references, there is no agreement between authors on which
non-invasive diagnostic modality is most promising for screening purposes.
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We chose to focus on multimodal diagnostics to benefit from both types of
data.
1.3.7

Functional Tests for Cognitive Assessment
Physicians can use functional tests to improve early diagnostics of

NDs, but such tests have multiple disadvantages. They are time-consuming;
they require a special testing environment to keep the subject focused; and
there is no understanding of the pathophysiological mechanisms underlying
cognitive decline whose structural bases are not studied well [124].
However, psychophysiological, and cognitive tests and evoked potential
studies can detect purely pre-symptomatic stages of dementia.

Many

models of developing dementia include cognitive test scores as predictors
[125]. The most widely employed cognitive tests are the MMSE [126],
Alzheimer’s disease assessment scale cognitive subscale (ADAS-cog)
[127], Rey auditory-verbal learning test (RAVLT) [128], digit symbol
substitution test (DSST) [129], trail making test (TMT) [130], clinical
dementia rating (CDR) [131], logical memory tests, and immediate and
delayed recall test [132].
When combined with structural data to form a multimodal
diagnostic tool, cognitive tests identify NDs more reliably [133, 134]. Few
studies have focused on the prediction of cognitive status from brain
structural images (see Table 1.2). Some authors have predicted MMSE
scores from resting state functional MRI scans of patients with AD [135].
Others have calculated MMSE, ADAS-cog, and CDR scores from structural
MRI images [136]. Prediction of results in tests that reflect a lower number
of cognitive domains (e.g., RAVLT) was less accurate than in tests covering
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a larger set of domains (ADAS or MMSE). One research team predicted
MMSE and ADAS-cog scores with a model which integrated
spatial-temporal features of the brain received from MRI findings [137].
Recent studies have provided an insight into the neurophysiological and
morphological characteristics of the brain in patients with dementia
[133, 134, 135, 136, 137]. However, the clinical utility of the proposed
models remains limited.
1.3.8

Brain Morphology Studies with MRI
Structural MRI is a valid marker of the late stages of AD [138],

however, at an early stage, it is not particularly revealing of the difference in
the brain’s structural change in normal and accelerated aging. For this
reason, some authors believe that electrophysiological diagnostics (e.g.,
event-related potentials) can be used to reliably identify those at risk of AD
[125, 139]. Contrarily, there is evidence that neuropathological changes can
be detected through neuroimaging much earlier than cognitive decline
becomes apparent [140]. The level of age-related brain change differs
markedly between people, according to structural MRI studies [141].
Inconsistencies in the onset and rate of episodic memory loss in the elderly
have been discovered in studies on brain functioning. Inherited and lifestyle
factors may account for these discrepancies. There is no direct link between
structural and functional impairment.

Researchers have attempted to

discover the structure-function relationship in the brain through advanced
methods of neuroimaging and have shown the importance of visual rating
scales, volumetric assessment, and structured reporting [124, 142].
A few brain regions are vulnerable to atrophy in NDs, namely the
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hippocampus, amygdala, entorhinal cortex, fusiform gyrus, putamen, and
medial temporal lobe. The aforementioned structures are neural centers
responsible for learning, memory, navigation, processing information,
emotions, behavior and time perception. Some authors have studied the
brain at the macrostructural level.

With MRI, they have assessed the

enlargement of gray matter (GM), WM, ventricles, and accumulation of
WM lesions that show up as hyperintense areas in the T2-weighted
sequence [143, 144]. Other research has focused on the microstructural
effects of NDs, such as neuronal death and the accumulation of β -amyloid
and τ-protein in the hippocampus [145, 146].

The macrostructural

characteristics of the brain (tissue volumes) can be identified with MRI and
used for screening for NDs.

Microstructural characteristics (tissue

organization) serve as the gold standards of diagnostics.
1.3.9

Machine Learning Methods
Processing biomedical images with ML techniques is a field of

ongoing study [147]. It has already been demonstrated that ML may be
used to investigate the link between morphological and functional changes
in the brain. [123]. Numerous conventional ML and DL methods have been
proposed to distinguish AD patients from cognitively preserved people
using structural MRI data [8]. For instance, Altaf et al. used a combination
of textures (i.e., a gray level co-occurrence matrix) and clinical features
(i.e., MMSE) to predict the final diagnosis [148]. Ahmed et al. resorted to
the bag-of-visual-words approach to generate a unique signature of an
individual brain from the hippocampus and posterior cingulate cortex [149].
Khedher et al. analyzed tissue-segmented MRI (i.e., WM and GM images)
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to diagnose AD at early stages [150]. Other authors have used slices or 2D
patches extracted from T1-weighted (T1w) MRI as predictors in designed
2DCNN models [151, 152, 153, 154]. Recently, 3D patches extracted from
MRI were used to segregate healthy individuals from patients with MCI or
AD [155]. The authors extracted voxels corresponding to the hippocampus
and used them as an input to a 3DCNN classification model [156]. 3D
images of the whole brain also served as an input to 3D subject-level CNNs
[152, 157, 158, 159, 160, 161, 162, 163]. Qiao et al. used a 3DCNN with
sharing weights to extract the features from MRI, followed by multiple
sub-networks which transformed the MMSE regression models into a series
of binary classification models[162]. We presume that new findings on the
brain SFA may foster further research on earlier detection and treatment of
NDs. The multimodal diagnostics that we are developing with ML brings
together the advantages of both morphological and functional findings.
All the methods discussed are summarized in Table 1.2. In contrast
to previous studies, we intend in the current research to find a difference
in the SFA of the brain of the healthy population and cognitively impaired
individuals. The finding may serve diagnostic purposes. The brain SFA may
have features that are specific either to cognitive deterioration in a disease or
to normal neurocognitive slowing in aging. We propose to predict a cognitive
status of the examinee from the brain MRI data and compare the prediction
with an actual result of cognitive testing. We hypothesize that the larger
the gap between the predicted and observed values, the higher the risk of
dementia. We name the difference “deviation from the model of normal
aging” (DMNA). It is supposed that this change in SFA patterns may serve
as an early sign of ND.
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Table 1.2: Recent papers about diagnostics of MCI and AD

MRI
MRI
MRI
MRI
MRI

CN+AD
CN+MCI+AD
CN+MCI+AD
CN+MCI+AD
CN+MCI+AD

✓
✓
✓
✓

MRI

CN+MCI+AD

✓

MRI
MRI
MRI
MRI

CN+MCI+AD
CN+MCI+AD
CN+MCI+AD
CN+MCI+AD

✓
✓
✓
✓

CT

CN+MCI+AD

✓

MRI
MRI
MRI
MRI
MRI + PET
MRI + PET
MRI
MRI + tests
MRI
MRI
MRI
MRI
MRI
rs-fMRI
MRI
MRI
MRI
MRI
MRI
MRI
MRI

CN+MCI+AD
CN+MCI+AD
CN+MCI+AD
CN+MCI+AD
CN+MCI+AD
CN+MCI+AD
CN+MCI+AD
CN+AD
CN+MCI+AD
CN+MCI+AD
CN+MCI+AD
CN+MCI+AD
CN+MCI+AD
CN+AD
CN+MCI+AD
NC+MCI+AD
CN+MCI+AD
CN+AD
CN+MCI+AD
CN+AD
CN

✓
✓
✓
✓
✓
✓
✓
✓
✓

SFA
✓

✓
✓

✓

✓

✓

✓

✓
✓
✓
✓
✓
✓
✓
✓
✓

✓

✓

✓

✓
✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

✓

TMT

ADNI + in-house
ADNI
ADNI
ADNI
ADNI
ADNI +
AIBL[166] +
Sorensen et al. [165]
2015
Metropolit[167]
Li et al. [168]
2015
ADNI
Khedher et al. [150]
2015
ADNI
Hosseini-Asl et al. [169]
2016
ADNI
Suk et al. [170]
2016
ADNI
Navy General
Gao et al. [171]
2017
Hospital ( China)
Zhang et al. [172]
2017
ADNI
Korolev et al. [157]
2017
ADNI
Cui and Liu [156]
2018
ADNI
Billones et al. [160]
2017
ADNI
Liu et al. [173]
2018
ADNI
Altaf et al. [148]
2018
ADNI
Lee et al. [153]
2019
ADNI
Lahrimi and Shmuel [134] 2019
ADNI
Basaia et al. [158]
2019 ADNI + in-house
Lei et al. [137]
2019
ADNI
Fang et al. [174]
2019
ADNI
Liu et al. [155]
2020
ADNI
Wang et al. [159]
2020
ADNI
Duc et al.[135]
2020
In-house
Zhang et al. [175]
2021
ADNI
Sathiyamoorthi et al. [176] 2021
ADNI
Qiu et al. [177]
2022
ADNI+OASIS
Soliman et al. [161]
2022
ADNI
Qiao et al. [162]
2022
ADNI
Gao et al. [163]
2022
ADNI
Proposed
ADNI
CDR - clinical dementia rating score [131]

Diagnosis

DSST

2010
2013
2013
2015
2015

Training
dataset

CDR

Stonnington et al. [136]
Liu et al. [164]
Gupta et al. [151]
Payan and Montana [152]
Ahmed et al. [149]

Dataset

RAVLT

Year

ADAS

Reference

Cognitive tests
MMSE

Prediction
Image
modality

✓

✓

✓

Chapter 2: Materials and Methods

2.1

Data Collection

2.1.1

Alzheimer’s Disease Neuroimaging Initiative Dataset
The data used in this study were obtained from the Alzheimer’s

disease neuroimaging initiative (ADNI) dataset [178]. ADNI1 covers 400
subjects diagnosed with MCI, 200 subjects with early AD and 200 elderly
control subjects with an age range of 55 to 90 years. For more information
about ADNI datasets, please visit the link https://adni.loni.usc.edu/ (see
inclusion and exclusion criteria at [179]). In this study, we acquired MRI
and clinical information on all the cases collected from the ADNI dataset in
a cross-sectional and longitudinal study design. This provided us with a
total

of

1,421

study

cases

28.56/25.97/45.67%; male/female:

from

800

subjects

59.47/40.53%).

(CN/MCI/AD:

We collected the

following information:
• Clinical data on the final diagnosis.
• Demographic data (i.e., age, gender, ethnicity).
• Morphometric data (i.e., volumes of brain areas mostly affected by
ND).
• Results of cognitive assessment generated using the MMSE, RAVLT,
TMT (part B), DSST, and ADAS-cog tests.
• Pre-processed T1w MRI files.
ADNI data availability and ethical issues: The dataset can be
downloaded from adni.loni.usc.edu. The use agreement form was signed to
allow us access to the data.
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2.1.2

Psychophysiological Outcomes of Brain Atrophy Dataset
Psychophysiological outcomes of brain atrophy (POBA) repository

is a set of results in a battery of PTs.

The battery was proposed by

Charykova et al. to screen maladjustment in athletes [180]. We examined
231 people with cerebral MRI and asked them to pass PTs. The age of the
study participant ranged from 4 to 84 years. Examinees with periodic
headaches and concern about having organic brain abnormalities were not
included in the study. Literacy was used as an inclusion criterion, which
meant that only adults who had completed at least one professional course
after graduating general education were considered.

Organic brain

pathology, mental problems, head injuries, and radiological indicators of
NDs based on MRI findings were all considered exclusion criteria. The year
ranges within the age groups are described below. The number of full years
of life for the Adolescents class was less than 20 years. Young adults were
20-39 years old. The range of years of Midlife adults was from 40 to 60
years. Finally, the age of Older adults was 60 years and over. From the
comprehensive POBA dataset we acquired the following data:
• Demographic data (i.e., age, gender).
• EF testing ( simple (SVMR) and complex (CVMR) visual-motor
reaction; technique: "Reaction to a moving object").
• Wrist dynamometry and asymmetry coefficient (left and right hands
maximum muscular strength, asymmetry coefficient or a fraction of
the maximum muscular strength of the contralateral arms).
• Psychological testing (attention study technique (AST) and
interference resilience technique(IRT) with response time to visual
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interference).
• Raw T1w and FLAIR MRI scans.
POBA data availability and ethical issues: The UAEU Human
Research Ethics Committee granted ethical approval for the retrospective
analysis of data provided as standard of care (Notice Number: ERH_2019_
4006 19_11). No potentially identifiable personal information is presented
in the study. The POBA dataset is available on request from the link
https://bi-dac.com.
2.2

Research Design
Figure 2.1 offers an overview of the suggested methodology.

Research design developed for each objective is described in the following
sections.
2.2.1

Development of Machine Learning Models of Age-Related Cognitive
Decline, Study of Changes in Cognitive Subdomains
For the primary objective, we sought to improve the diagnostics of

age-related alterations in cognitive processes. The goal was to ascertain if
different executive functions deteriorate in proportion to age. By assessing
individuals without dementia, we created a series of experiments and
generated an open-access POBA dataset.

The assessments and their

dependent output variables represent cognitive subdomain performance
(e.g., switching and inhibitory control, information processing speed, etc.).
Cognitive functions are hypothetically linked, and the rate of their
age-related decrease is assumed to be relatively similar. Furthermore, there
is a theory that links normal neurocognitive decline to slowed core or
computational processing, which is universal to all cognitive functions
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[181, 182]. Disproportional alterations, on the other hand, could suggest
faster brain aging.

Figure 2.1: Overview of the suggested methodology

The first sub-objective was to create new indices that measure the
ratio of functional cognitive processes during the completion of
psychophysiological tasks. We looked at the structure of the CVMR, also
known as the choice reaction, to come up with a suitable solution. The
choice reaction, like SVMR, has sensory acquisition (visual perception) and
motor responding elements.

CVMR also includes the decision-making

aspect that is involved in processing an inhibitory condition that is provided
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in the task (see Figure 2.2). There is a time delay (DMT) as a result of this
procedure. In a recent study, we looked at the age-related heterogeneity of
DMT. We focused on the fraction between DMT (the switching and
inhibitory control estimate) and SVMR (the information processing speed
estimate) in this section of the investigation. The age-related dynamics of
the dependent variable of the reaction to a moving object (RMO) test,
which indicates the coordinated involvement of numerous cognitive
domains, were also examined.

Figure 2.2: Simple and complex visual-motor task estimates, and the cognitive
functions they describe during the lifespan

The second sub-objective was to determine the best number k of
separate nonoverlapping age divisions.

To accomplish this, we used a

heuristic strategy based on the elbow method. The K-means algorithm used
the distortion score, or the sum of squared distances from each point to its
associated centroid, as an assessment metric for each chosen k.

The
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minimal distortion score matched the ideal cutoff k value.

After

determining the ideal k, we used the K-means clustering approach to
evaluate the separability measure by age group. Each cluster had a centroid,
and we calculated the number of relevant and irrelevant data points in each
group.
In the third sub-objective, we employed ML classification methods
to predict an individual’s age group based on their performance in PTs. The
40-year-old age limit was taken into account. This age is justified as a
cutoff value for the cognitive deterioration that may be detected by test
performance, according to our recent study [32]. In this case, we used
conventional ML (Gaussian NB, Gradient Boosting, Random Forest,
AdaBoost, linear and non-linear SVM, Ridge, Lasso) classification models
and trained them in the stratified 10-fold cross-validation technique.
The projected results in each fold were blended and subsequently
averaged to determine the models’ ultimate accuracy. We compared the
model performance with and without indices to predict age by evaluating
and comparing the model performance measures. We created an averaged
receiver operating characteristic (ROC) curve to assess the performance of
the predictive model.

The mean area under the ROC curve (AUC),

specificity (Spec), sensitivity (Sens), and accuracy (Acc) values were also
computed.

Because the sample was uniformly distributed across age

groups, these performance measures were deemed to be appropriate. For
each index used as a predictor we calculated Mean ± SD to average the
accuracy of the framework. Finally, we employed the Kruskal-Wallis test to
ascertain if the variation of accuracy for one index was significantly
different (p < 0.05) from that of other indices.
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In the fourth sub-objective, we examined if the proposed indices
could be utilized to produce a summary of the results of individual
psychophysiological testing.

As a result, we employed ML regression

models to forecast the new indices’ values. We used all of the features in
the POBA dataset as predictors, excluding those that can be used to derive
the values of the indices. With the exception of the SVMR_IES variable, we
utilized the same predictors to estimate the value of the index of
performance in an SVMR and CVMR with account for accuracy (ISCA).
These features were eliminated because ISCA can be obtained using
SVMR_IES. We used mean absolute error (MAE), root mean squared error
(RMSE), and a fraction of MAE to a range of values (max − min) to assess
the quality of the regressor outcome.
2.2.2

Patterns of Brain Structural Changes in Normal Aging
We started with the first sub-objective which was to use ML

approach (regression) for the assessment of the structural alterations of the
major brain regions and to find the patterns of neurofunctional performance
in different age groups. We looked at a pairwise distribution of voxel-based
brain morphometry (VBM) results (Subsection 2.3.1) over different age
groups to achieve this sub-objective. Formulae 2.1-2.5 were used to adapt
the data to the individual’s full skull volume. We investigated variables
related to attention, reaction speed, and task switching using pairwise
distributions of psychophysiological attributes across ages. For each age
cohort and gender we presented the VBM and PT results as IQR,
Mean ± SD, and conducted the Kruskal-Wallis test to compare the
distribution of the group data across the overall cohort.
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CSF% = CSF / T IV

(2.1)

iCSF% = iCSF / T IV

(2.2)

GM% = GM / T IV

(2.3)

W M% = W M / T IV

(2.4)

W MH% = W MH / T IV

(2.5)

The Ridge Regression model with a linear least-squares
optimization function and L2-norm regularisation was used to examine the
association between anatomical brain features and functional performance
across time in different life periods. We evaluated the derived linear models
for significant age-related dynamics using the t-test (a zero slope value was
taken as the null hypothesis). If the p-value for the slope was less than 0.05,
the dynamics of a variable in a given age cohort were deemed to be
significant.
In the second sub-objective, we chose the mathematical model that
best reflects the progression of anatomical and functional changes in the
brain throughout time. Several tasks were included in this sub-objective.
We looked at the relationship between the VBM, the findings of the PT, and
age. The underlying assumption was that performance in some cognitive
domains would fall linearly with age, whereas performance in other
domains would exhibit a non-linear relationship with age.
In the first part of sub-objective two, we studied both linear and nonlinear (polynomial) relationships between age, VBM, and PTs.
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f eature = f (age)

(2.6)

As an independent variable, we employed the age exponent:

f eature = A · age + B

(2.7)

f eature = A · age2 + B · age +C

(2.8)

where the feature is a value of either the functional (DMT, SVMR_mean,
CVMR_mean, IRT_mean, AST_mean, TRVI, and RMO_mean) or the
structural (e.g., the volume of CSF, GM, WM) attribute; A, B,C ∈ IR.
A regression model given in Formula 2.8 is non-linear with respect
to age. Despite this, the model remains linear for the dataset-estimated
parameters A, B, and C. As a result, we could use a linear regression (LR)
approach to fit the data for both linear and non-linear functions (refer to
Formulae 2.7-2.8). We generated a new feature matrix using polynomial
features to determine the optimal parameters for the non-linear function.
The constructed matrix was then fed into the LR model. Despite the fact
that this technique allowed us to employ high-dimensional feature spaces,
we limited the analysis to first- and second-order relationships.
In the second part of sub-objective two, we looked at algorithm
performance indicators to ascertain which model best fit the data.

To

communicate changes in VBM and PTs througout life, we employed linear
and non-linear (polynomial kernel) regression models. The 95% confidence
intervals (CIs) for both the parabolic and the linear trendline functions were
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determined using the bootstrap approach. We performed a comparison of
the linear and polynomial models for generalization purposes. We used
MAE, RMSE, and R2 metrics to evaluate the model’s performance.
The third sub-objective was to contrast the kinetics of functional
and structural changes in the brain across different age cohorts. We began by
looking at the relationship between cognitive performance and volumetric
brain data. We did this by calculating correlation coefficients across the full
study cohort’s data. Subsequently, using the t-test, we looked for statistical
difference between the slopes in age cohorts in the linear models of brain
anatomical and functional changes.
2.2.3

Patterns of Brain Structure-Function Association Indicative of Mild
Cognitive Impairment and Dementia
First sub-objective: We assessed changes in the cognitive and

neurophysiological test scores in normal and accelerated aging.

We

explored the age-related variability of cognitive scores in the tests most
commonly used either to diagnose MCI and dementia or improve the
accuracy of multimodal diagnostics.

The first group of tests included

MMSE and ADAS-cog which reflect global cognitive functioning. The
second group of tests covered a few cognitive domains, i.e., information
processing in DSST, memory in RAVLT, and information processing in
TMT (part B). To present the change in test scores with disease progression,
we built linear trendlines for the cognitively preserved group and patients
with MCI or dementia.
Second sub-objective:

We built regression models predicting

functional performance in cognitive tests from brain radiomics.

The

vulnerability of distinct neuronal cells to atrophy in accelerated aging
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differs among cell groups and brain regions.

Reasonably, SFA are

considered to have pathology-specific features. Therefore, we trained the
regression models on each study cohort separately. The input to the model
was the data acquired from VBM and surface-based brain morphometry
(SBM). The VBM is a computational approach to neuroanatomy that
measures the differences in local concentrations of brain tissue through a
voxel-wise comparison of multiple brain images.
complementary

structural

imaging

analysis

for

The SBM is a
quantifying

GM

abnormalities. The feature selection technique allowed us to identify the
most valuable structural neuroimaging measures. The models reflect SFA
patterns which are unique for each study cohort.

We also looked for

significant correlations between cortical parcellation volumes and test
scores in the cohorts to investigate neuroanatomical differences in relation
to cognitive status.
The third sub-objective was to assess the diagnostic value of the
proposed models. We classified individual findings according to the model
which best described the case, i.e., the model with the minimal absolute error
in prediction in identifying the CN, MCI, or dementia group. In this case, the
ML model trained on the cases of CN, MCI or Dementia groups describes
a disease-specific SFA pattern. The pattern serves as a unique "stamp" of
the disease on which the model was trained. Therefore, one can find the
"stamp" which best fits the case. To boost the performance of the multigroup
classification, we employed the model blending technique. As an ensemble
algorithm, we chose the majority voting method. Since it required an odd
number of constituent classifiers, we selected the three most accurate models
which predict results in MMSE, ADAS and RAVLT.
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2.2.4

Improving Screening for MCI and Dementia
The first objective was to conduct a comparative analysis of the

brain structure and function in CN subjects, and MCI and AD groups. We
used non-parametric statistical methods to assess the separability of the
three groups, namely the Kruskal-Wallis test for continuous data and the
Chi-square test for quantitative features.
The second sub-objective was to propose a new marker of
accelerated cognitive decline. In line with the hypothesis of this objective,
we proposed to predict the cognitive status of a cognitively preserved
examinee from brain MRI data and used the SFA model. Then we applied
the SFA model to the findings of the study group. When the findings of a
scanned individual did not fit the standard SFA model, accelerated aging
was suspected. We calculated the deviation from the model of normal aging
(DMNA) as the error of cognitive score prediction (see Formula 2.9).

DMNA = y predicted − yactual

(2.9)

where y is a result of the cognitive test.
Modeling cognitive performance from MRI is a complex problem.
To reduce its computational complexity, we transformed MRI images into
two-dimensional data (see Subsection 2.3.2). Then we designed a CNN
model and trained it on images of CN individuals. To generalize the model
to a true rate error, we utilized the five-fold cross-validation technique. As
(CN)

an input, we used the pre-processed MRI data, both 3D and 2D (Daxial ,
(CN)

(CN)

Dcoronal ,Dsagittal ). The output variables were the results of the following
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cognitive tests: MMSE, RAVLT, TMT (part B), DSST, and ADAS-cog.
After the prediction of cognitive performance we calculated DMNA (see
Formula 2.9).
The third sub-objective was to justify the reliability of DMNA. It
was a three-fold task. First, we employed non-parametric statistical tests to
compare the DMNA values of the CN group with those of MCI and AD
patients. Second, we created ML models that distinguished the following
study cohorts by DMNA values: CN people from patients with MCI, and
the latter from those with AD. The models were trained with the ten-fold
cross-validation technique. Finally, we evaluated their performance. The
performance of the regression models was expressed as MAE. The accuracy
of the classification model was assessed with Sens, Spec, F-measure, ROC,
AUC, Acc and balanced accuracy (BAC).
The fourth sub-objective was two-fold.

In the first part of

sub-objective four, we tested whether the proposed marker could
prognosticate the conversion of pre-dementia to dementia. To find the cases
of stable and progressive MCI, we carried out an exhaustive search of all
longitudinal studies: ADNI1, ADNI2, ADNI-GO, and ADNI3. Then, we
built the conventional ML model segregating the cases according to
stability/progression. We used DMNA in MMSE and ADAS-cog as more
reliable predictors because the tests covered the global cognition
functioning. To compare the distribution of DMNA in two groups, we
applied the non-parametric Kruskal-Wallis test. We also assessed the Sens
and Spec of the model, classifying MCI cases as stable or progressive. The
second part of sub-objective four was to check whether DMNA could
differentiate cognitive decline due to AD from other NDs. To address the
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research question, we used ATN criteria [183] and adopted a two-step
analysis.

Firstly, we dichotomized each biomarker category as either

normal (-) or abnormal (+) with the following cutoff thresholds. A case was
considered as A- if the CSF concentration of β -amyloid was higher than
81/ml [184, 185], as T- if the level of τ-protein was less than 56 pg/ml
[184, 186], and as N- if the uptake of fluorine-18 deoxyglucose was larger
than 1.21 [187].

Secondly, we classified all the cases with MCI and

dementia into groups and calculated mean values of DMNA for them.
Finally, we identified the difference in DMNA between demented
individuals with Alzheimer’s continuum (A+) and those with either normal
AD biomarkers or non-AD pathologic change (A–). Figure 2.3 shows the
general idea of the proposed SFA model, and Figure 2.4 illustrates the
proposed framework.

Figure 2.3: Preparation and application of the proposed SFA model to clinical
practice
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Figure 2.4: Pipeline of proposed framework

2.3
2.3.1

Methods
MRI Acquisition and Brain Morphometry
In ADNI dataset brain images were obtained with 1.5 or 3 Tesla

scanners. The detailed information about MRI acquisition can be found from
the link http://adni.loni.usc.edu/methods/mri-tool/mri-acquisition. In POBA
dataset brain images were acquired with a 1.5T MRI scanner. The structural
acquisition settings were as follows. 3D-T1w images had 1 mm voxel size.
The scanning matrix was 224 × 256. TE was 6.21 ms, and TR - 13 ms [188].
The FLAIR sequence had a 4mm slice thickness. The scanning grid was 260
× 320. TE was 104 ms, and TR - 9,130 ms. We used FLAIR for measuring
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WM hyperintensities (WMHs) (see Figure 2.5).

Figure 2.5: Brain MRI changes throughout 4 stages marked from A to D:
adolescence, early adulthood, middle, and old age. T1w sequence with isometric
(3D) vowel is used to reconstruct sagittal and coronal views; FLAIR sequence is
used to retrieve axial images

VBM was employed to quantify the brain structural changes. Then
we calculated volumes of WM hyperintensities and the following
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structures: interventricular CSF, hippocampus, putamen, caudate nucleus,
amygdala, WM, enthorinal cortex, fusiform gyrus, middle temporal lobe,
GM, cortical GM and total intracranial volume. The segmentation of the
brain into its major compartments (WM and GM, SCF) was done as below.
We applied the 12-th version of the computational anatomy toolbox
(http://www.neuro.uni-jena.de/cat/) for the statistical parametric mapping
software (http:// www.fil. ion.ucl.ac.uk/spm/) [188]. We resorted to the
lesion segmentation toolbox LST v2.0 to segment the changes in
FLAIR-hyperintense WM lesions [189, 190].

Subcortical, cortical and

parcellation volumes were computed with FreeSurfer 7.1.0 software [191].
We resorted to Desikan/Killiany atlas as a reference. All morphometric
features were expressed as percentage to the total intracranial volume and
used as an input to the ML model predicting the cognitive scores.
2.3.2

Data Pre-processing
All the retrieved images passed through grad-warping and intensity

correction and were scaled to gradient drift with the phantom data (for more
details, see [178]). The pre-processed T1w structural MRI images were
downloaded in NIFTI format. We also retrieved the corresponding clinical
data from the dataset. Then the images were registered to an MNI152 space
with FLIRT tool from FSL package [192]. As brains differ in size and
shape, each brain image was translated into a common reference space
(normalized) to ensure consistency of orientation. To correct low-frequency
intensity non-uniformity, we used N4 bias field correction algorithm [193].
Then we normalized the voxel intensities by scaling them to the standard
normal distribution parameters. To enhance the predictive performance, we
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extracted the brain parenchyma with Brain Extraction Tool from FSL
package [192]. Pre-processed 3D T1w images were downsampled to the
size of 64 by 64 by 64 pixels and used as an input to the 3DCNN models.
One of the major challenges of studies on MRI is a high dimensionality of
data [194]. We used the following approach to reduce the dimensionality.
An MRI image was defined as

I = {(vx , vy , vz ) : x = 1, X, y = 1,Y , z = 1, Z},

(2.10)

where X,Y ,Z were the dimensions of the MRI scan in axes x, y and z.
Then the jth sagittal, coronal or axial slice s of the I image could be
defined as:

( j)

( j)

( j)

ssagittal = ( j, vy , vz ), scoronal = (vx , j, vz ), saxial = (vx , vy , j)

(2.11)

The corresponding averaged images were generated as follows:

Isagittal =

Icoronal =

Iaxial =

1
X

X

(i)

∑ ssagittal

i=1

1 Y (i)
∑ scoronal
Y i=1
1 Z (i)
∑ saxial
Z i=1

In this way, we averaged voxel intensities along the sagittal,
coronal and axial axes and created two-dimensional datasets Daxial , Dsagittal ,
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and Dcoronal :
1
2
N
Daxial = {Iaxial
, Iaxial
, ..., Iaxial
}

1
2
N
Dsagittal = {Isagittal
, Isagittal
, ..., Isagittal
}

1
2
N
Dcoronal = {Icoronal
, Icoronal
, ..., Icoronal
}

Then, we removed the background by cropping the image to the
size of the brain mask.

We downsampled brain images with

nearest-neighbor interpolation to 150 by 150 pixels, normalized them to the
values between 0 and 1, and saved in JPEG format as shown in Figure 2.6.
To unify the pre-processing workflow, we used Nipype which is an
open-source community-developed initiative under the umbrella of NiPy
[195]. To automate the deployment of the applications within the software
containers, we installed Neurodocker which wraps up the aforementioned
software in a complete file system.

Figure 2.6: Skull-stripped images averaged along axial (a), coronal (b), and sagittal
(c) axes

2.3.3

Psychophysiological Tests
To assess individual psychophysiological status, we used a battery

of neurophysiological tests [180]. The battery included a variety of tasks
that tested cognitive areas such as attention and EF, with an emphasis on the
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inhibitory control and task switching and subdomains. The tests facilitated
an evaluation of information processing speed. We modelled changes in the
dependent variables listed below throughout the course of a lifetime [188]:

• Simple visual-motor reaction (SVMR) is a test in which the only way
to respond is to look at a single form of visual stimulus.

The

information processing speed is reflected by the mean reaction time.
SVMR_mean is calculated in a group of successive attempts.
• Complex visual-motor reaction (CVMR) is a “go/no-go” test. In this
test the participant must choose between two different types of
triggering stimuli. The mean reaction time is typically longer than in
the previous test (CVMR_mean > SVMR_mean). One can calculate
the decision-making time (DMT) by subtracting the SVMR_mean
from the CVMR_mean (see Formula 2.12).

Task switching and

inhibitory control is reflected by DMT.
• Attention study technique (AST) is a variant of SVMR that includes
the attention domain. In AST, however, the participant must maintain
a constant gaze on the display screen because triggering stimuli are
delivered at various times. The average reaction time (AST mean) is
recorded by the tester.
• Interference resilience technique (IRT). The participant is instructed
to reply to targeted stimuli while ignoring interfering stimuli. The
last ones overlay and obscure the target. The average reaction time
is recorded by the tester - IRT_mean – of a set of attempts. Formula
2.13 determines time delay because of visual interference value. Its
acronym is TRVI. TRVI reflects inhibitory control and task switching.
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• Reaction to a moving object (RMO) is a method for determining a
balance of inhibition and excitation in the central nervous system. The
test’s mean reaction time (RMO_mean) reveals whether the excitatory
or inhibitory processes are dominant. We also looked at the variance
in reaction time across attempts (RMO_variance).
• To determine the maximum muscular strength of the hands we
employed wrist dynamometry.

Asymmetry coefficient (AC) was

computed as the ratio of the maximum muscular strength of the right
wrist (WDR_MMS) and the left (WDL_MMS) wrist (see
Formula 2.14).

DMT = CV MR_mean − SV MR_mean

(2.12)

T RV I = IRT _mean − AST _mean

(2.13)

AC =

2.3.4

W DR_MMS
W DL_MMS

(2.14)

Cognitive Tests
The purely pre-symptomatic and early stages of dementia are likely

to be identified by PT. The existing dementia risk models mainly comprise
demographics, subjective cognitive complaints, lifestyle factors, health state
estimates,

and

other

variables

[125].

Cognitive

test

scores

or

neuropsychological test batteries are incorporated as predictors into many
models of developing dementia.
Alzheimer’s disease assessment scale, cognitive subscale (ADAScog). ADAS-cog is an informative tool for monitoring the progression of
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ND in clinical routine practice [196]. The test distinguishes between MCI
and mild AD with a sensitivity of 0.86 and a specificity – 0.89 [197]. It
can also identify “questionable dementia,” as its results in immediate recall
and object naming tasks correlate with performance in the Category Verbal
Fluency Test [198]).
The Mini-mental state examination (MMSE) is the most common
method of diagnosing cognitive impairment in a single domain or multiple
domains [199]. Although it detects various types of dementia with a high
sensitivity and specificity (over 90%), the test should be accompanied by a
full and detailed assessment of the patients [200]. For this, clinicians use
neurophysiological tests (e.g., TMT, DSST) [201].
Trial making test (TMT). The primary purpose of the TMT is to
provide information about neurophysiological conditions; therefore, it is
used to diagnose NDs in combination with other tests and diagnostic
modalities [201, 202, 203]. Its clinical implication is multifold. First, TMT
helps to define the impaired cognitive domain and improves the assessment
made with MMSE or MoCA [201]. Second, there is evidence that the
inclusion of TMT (part B) boosts the performance of the models
discriminating AD from non-AD MCI based on CSF and structural
biomarkers [204]. Third, the test can sensitively distinguish a case of mild
AD from amnestic MCI and healthy aging [205].
The Rey auditory verbal learning test (RAVLT) examines verbal
learning and memory. It is capable of detecting cognitive impairment in
multiple sclerosis [206]. The test differentiates between AD dementia and
behavioral variants of fronto-temporal dementia [207] with a high
sensitivity and specificity (over 81%). It also helps physicians to distinguish
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AD from Lewy body dementia [208].
The Digit symbol substitution test (DSST) identifies early stages
of dementia [209] and MCI by detecting working memory impairment and
multimodal amnesia [210]. It also shows significantly impaired performance
in early Lewy body dementia [211].
2.3.5

Machine Learning
Objective 1:

To determine the best number k of separate

nonoverlapping age divisions we used a heuristic strategy based on the
elbow method. The K-means algorithm used the distortion score, or the sum
of squared distances from each point to its associated centroid, as an
assessment metric for each chosen k. The minimal distortion score matched
the ideal cutoff k value. After determining the ideal k, we used the K-means
clustering approach to evaluate the separability measure by age group. Each
cluster had a centroid, and we calculated the number of relevant and
irrelevant data points in each group. To predict an individual’s age group
based on their performance in PTs we used several classification
algorithms, such as support vector machines [212] with linear and nonlinear
(radial basis function) kernels, Gaussian Naive Bayes [213], Bagging
meta-estimator [214], an extra-trees classifier [215], a random forest
classifier [216], Gradient Boosting [217], AdaBoost [218]. Classification
models were trained with the stratified 10-fold cross-validation technique.
Objective 2: The Ridge Regression model with a linear least-squares
optimization function and L2-norm regularisation was used to examine the
association between anatomical brain features and functional performance
across time in different life periods. A regression model given in Formula 2.8
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is non-linear with respect to age. Despite this, the model remains linear for
the dataset-estimated parameters A, B, and C. As a result, we could use a
linear regression (LR) approach to fit the data for both linear and non-linear
functions (refer to Formulae 2.7-2.8). We generated a new feature matrix
using polynomial features to determine the optimal parameters for the nonlinear function.
Objective 3: We employ conventional ML regression models
predicting functional performance in cognitive tests from brain radiomics.
We trained the regression models on the three study cohorts separately (CN,
MCI, dementia). The predictors of the model were the data acquired from
voxel- and surface-based brain morphometry.

The models reflect SFA

patterns specific for each study cohort. We also looked for significant
correlations between cortical parcellation volumes and test scores in the
cohorts to investigate neuroanatomical differences in relation to cognitive
status.

Finally, to assess the diagnostic value of the proposed models

classified individual findings according to the model which describes the
case best. The idea was that the ML model, when trained on the cases of
this of that group, describes a disease-specific SFA pattern. The pattern
serves as a "stamp" of the disease on which the model was trained.
Therefore, one can find the "stamp" which fits the case best. We employed
the majority voting technique to assess the performance of the multigroup
classification.
Objective 4: To predict cognitive scores from structural data, we
developed 2D CNN and 3D CNN regression models. 2D CNN: In the
proposed CNN regression model, six convolution layers were followed by
two fully connected dense layers. L2 regularization technique with penalty
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and α = 0.0001 was employed. Network was trained for 200 epochs or
until convergence with RMSProp optimizer. To optimize a learning rate
hyperparameter we monitored the validation loss during the training
process. When the metric stopped improving for 10 continuous epochs, we
reduced the learning rate value by a factor of 0.2. To optimize the training
time, we also monitored the validation loss. If it did not decrease for 20
continuous epochs, we terminated the training process. In this case, 20% of
the training data were used for validation purposes. The model was trained
on the CN cohort in the five-fold cross-validation technique. There were
several arguments in favor of the necessity to train the models of SFA on
non-demented cases exceptionally. As the model reflected the brain SFA of
the healthy controls, it could be used as a reference norm. If trained on a
mixed cohort of healthy individuals and patients, the model would fail to
identify patients out of the reference range and would lose its diagnostic
value. The trained model from the last fold was tested on MCI and AD
groups.
For each case we obtained 2D images by averaging brain MRI in
three planes: axial (A), coronal (B), and sagittal (C). We could use these
either separately or in combination. For the combined approach we used
both options: data and model blending. The first was fusing predictions,
which was an ensemble estimator or voting regressor that averaged model
outcomes. The second was model blending. We trained the LR model on
the outcomes of three CNN models trained on axial, coronal, and sagittal
(CN)

averaged images. As an input, we used the pre-processed MRI data (Daxial ,
(CN)

(CN)

Dcoronal ,Dsagittal ). The output variables were the results of the following
cognitive tests: MMSE, RAVLT, TMT (part B), DSST, ADAS-cog.
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3D CNN: We also developed a 3D CNN model and trained it on
images of CN individuals from the ADNI dataset. Pre-processed 3D T1w
images were downsampled to the size of 64 by 64 by 64 pixels and fed to
the regression model. The model consisted of four convolutional layers
followed by max pooling.

Then, global average pooling was applied,

followed by a fully connected layer. We used an Adam optimizer and
trained the network for 100 epochs or until convergence. To optimize the
learning rate hyperparameter we monitored the validation loss during the
training process. When the metric stopped improving for 10 continuous
epochs, we reduced the learning rate value by a factor 0.2. To optimize the
training time, we also monitored the validation loss. If it did not decrease
for 20 continuous epochs, we terminated the training process. The data
were randomly split into training (80%) and testing (20%) subsets. Hence,
20% of the training data were used for validation purposes. To increase the
number of training samples, we applied the rotation augmentation
technique with the following angles: -25,-20, -10, -5, 5, 10, 20,25. The
outcomes of the predictive algorithms were the results of mental status tests
such as MMSE, RAVLT, DSST, ADAS-cog, and TMT (Part B). We
compared the distribution of the DMNA absolute values in the healthy
population and patients with MCI and Dementia. Moreover, we calculated
95% confidence intervals (CIs) for DMNA values using the t-test.

To

control the familywise error rate related to multiple comparisons we
employed the Bonferroni correction. All statistical tests were performed in
Python v. 3.6.9 with SciPy v. 1.16.4 library [219].
To determine a diagnosis from DMNA values, we employed nine
conventional ML classifiers (SVM linear and non-linear, Gaussian NB,
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Extra Trees, Bagging, Random Forest, Logistic Regression, Ridge
Regression, Neural Network).

DMNA values were obtained from (i)

skull-stripped brain images averaged along the axial, coronal, and sagittal
axes; (ii) skull-stripped 3D brain images. The ML models were evaluated
with the ROC AUC metric.
The experimental work was performed on a Linux Ubuntu 18.04
Nvidia DGX-1 deep learning server with 40 CPU cores and 8x NVIDIA
Tesla V100 GPU with 32 GB memory each, accessed with a web-based
multi-user concurrent job scheduling system [220]. The tensorflow-gpu
v.2.3.1 library was utilized to implement the proposed solution.
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Chapter 3: Results and Discussions

3.1
3.1.1

ML Models of Age-Related Cognitive Decline
Estimates of the Proportional and Disproportional Changes in
Cognitive Domains
We introduce the index of simple reaction time to decision-making

time (ISD), which is derived from the analysis described in section 2.2.1
[77]. The index represented the proportion of processing speed to decisionmaking time (see Formula 3.1). The time estimates were susceptible to agerelated neurocognitive loss; nevertheless, there is no convincing evidence
that the rate of decrease is equal across cognitive areas. As a result, the
derivative variable might be used to track any disproportional deterioration.

ISD =

SV MR_mean
DMT

(3.1)

The ISD index takes into account two markers that make up the
visual-motor task’s reaction time under the switching situation.

It is

inherently flawed in that it fails to take performance accuracy into account.
As a result, we presented a supplemental derivate variable, the index of
simple reaction time to decision-making time with accuracy performance
(ISDA) [77]. The proposed index, in comparison to the previous one,
includes the fraction of accurate responses in the denominator (see
Formula 3.2).

ISDA =
60

SV MR_mean
DMT × (1 −CV MR_mistakes, %)

(3.2)

Calculating the inverse efficiency score (IES) for each of the tests
independently and then computing the ratio between these tests represents a
further technique to integrate the speed and accuracy estimations of SVMR
and CVMR. As a result of this solution, we determine the index of
performance in simple and complex visual-motor reactions with account for
accuracy (ISCA) per Formula 3.3 [77].

ISCA =

IESSV MR
SV MR_mean × (1 −CV MR_mistakes, %)
=
IESCV MR CV MR_mean × (1 − SV MR_mistakes, %)

(3.3)

Index of Simple Reaction Time to Decision-Making Time: We did
not plan to evaluate all potential ratios of performance indicators in distinct
cognitive tasks in this current research. Our objective was to demonstrate
the approach’s efficacy when testing multiple domains and estimating their
correlated divergent changes.
From the encoding of a provided stimulus to the execution of a
response, reaction time covers a sequence of linked processing activities.
Regrettably, response time does not display each of these transactions
individually; instead, it is limited to a total time length. Some researchers
have proposed that the transactions can be measured sequentially utilizing
the time latency of evoked potentials [221]. Our strategy was to employ a
battery of tasks with the following characteristics. We created a range of
tests in which the testing modalities (SVMR and CVMR) contain the
identical perceptual and motor response components, but the central
processing differs.

We adopted this approach as opposed to assessing

reaction time in a single task or utilizing divergent tasks (DMT). This
allowed us to investigate Birren et al.’s complexity hypothesis, which states
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that neurocognitive degradation is limited to central nervous system
processing. The extent of deterioration increases as the task complexity
increases [181, 182]. However, this is true for non-lexical activities, but not
for word processing tasks, where slowing is unrelated to complexity
[77, 221].
The strong form of the complexity theory is supported by the
findings of the current study. According to the strong version, all aspects of
information processing (such as reasoning, perception, and response)
diminish in the same pace. The ISD index remains steady as the amount of
time spent thinking in CVMR decreases over time at the same rate as the
total of the receiving, encoding, and reacting elements. On a population
basis, this keeps the the proportion of DMT and SVMR_mean steady
throughout lifespan on a population scale.
The strong form of the complexity theory offers several advantages.
It backs up the theory that age-related impairment is linked to a general
slowing of processing speed rather than specific information processing
components aspects. It also makes it much easier for neuroscientists to
identify brain structure-functional correlations as individuals age [221].
This is consistent with prior research [221] that used reaction time as an
aggregate measure of processing speed.
The complexity hypothesis’s weak version asserts that the severity
of the deterioration in perceptual, motor, decision-making, or attentional
processes might vary.

Some researchers have found that "age-related

slowing in simple repetitive tasks is mainly related to slowing at the stage of
perceptuomotor processes, and after 60 years, to additional decline in
attention" [222]. The length of the transactions linked to acquisition of
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stimulus and processing of response should be measured using an
event-related potentials approach in future studies.
Supplying ISD with Performance Accuracy (ISDA): In the CVMR
test, DMT stands for the time it takes to inhibit an automatized activity and
transition between tasks. The percentage of choosing and perceptive motor
elements of choice RT is indicated by the SVMR to DMT ratio. The
cognitive demands of the decision and perceptive-motor components of
CVMR are distinct. We can ascertain whether age-related neurocognitive
impairment begins with cognitively demanding behaviours (task switching)
or includes both intellectual and nonintellectual processes (generalized
slowing) by comparing them.
We provided the ISD index with the accuracy metric to acquire the
total efficiency of the examinee in the test (see Figure 3.2). The index’s goal
is to look at the ratio of cognitively demanding to non-demanding tasks’
processing speed while also taking performance accuracy into account.
Ratio of IES for Simple and Choice Reactions (ISCA): The IES
ratio between SVMR and CVMR reflexes is shown in the final index. The
entire efficiency of decision-making is summarised by the IES score. IES
takes into consideration several cognitive subdomains and may represent
their disproportional changes over time [77]. Some researchers have found
disparities in SVMR and CVMR evolve over time [223], but none have
found the same is the case with IES scores. The process for generating the
IES score could be one of the reasons why this has yet been done.
Neuroscientists primarily employ choice errors produced while doing
"go/no-go" tests (e.g., CVMR_false_reaction) to determine performance
accuracy. Two more types of errors were recorded by the equipment we
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used: (i) missing the desired events (e.g., SVMR_passes) and (ii) reacting
prematurely (e.g., SVMR_falstart). By adopting this approach, we were
able to compute IES for the basic vosial-motor reaction and contrast it with
the equivalent data for the complex reaction.
We believe that examining the link of IES for strongly correlated
simple and choice reactions is more informative than researching the
association of reaction time. Simple reaction time is responsible for 45% of
the variance in choice reaction time [223].
3.1.2

Optimal Number of Age Cohorts
We employed used two dependent variables (age and a novel index)

in the cluster analysis and the K-means approach to divide the data points
into groups. To identify the optimal number of homogenous clusters, we
adopted the K-means method. We discovered the most acceptable number
of groups using the elbow approach, and it was further validated by a
distortion score (the separability measure). The sum of squared distances
between each location and its allocated centroid determines the score.
Iteratively, all cluster centers (centroids) are found by optimizing
intracluster proximity while increasing the distance between data points
from different clusters. The elbow approach was applied to data points
made up of the participants’ ages and related index values (ISD, ISDA, or
ISCA).
For each proposed index, the knee point detection method [224]
returns the ideal value of clusters equal to four. The optimal number is
marked with a black dashed line in Figure 3.1, which was created for two
attributes (age and ISCA). The line in blue on the graph represents the
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distortion score values as a function of cluster number, whilst the dashed
line in green represents the time required to train the unsupervised model
per k.

Figure 3.1: Elbow approach with the knee point detection algorithm to select the
best number of clusters for the ISCA index

The age distribution of the participants in our sample was not
uniform; nevertheless, with the appropriate selection of bin width, the age
histogram can come very near to being uniform. Another source of concern
is the comparatively small number of patients above the age of 75 compared
to the number of participants under 15. To ensure that each group had a
roughly similar number of participants, we opted to count the 20-year
intervals from birth as opposed to the youngest examinee’s age.
We evaluated how accurate the clustering method is by observing
the values of the indices (ISD, ISDA, ISCA) as age-group determinants. We
investigated the age values of the points obtained by the clustering approach
by plotting them with their centroids. On the age axis, the centroids were
65

relatively equally spread, with a step of around 20 years (see Table 3.1).
Because the cluster center coordinates were determined as the average value
of all the points in the particular cluster, we used the resulting age granulation
to create our groupings.
Table 3.1: Clusters based on distribution of samples over age and proposed indices
ISD Index

ISDA Index

ISCA Index

Group

Capacity
(females:males)

Centroid

In

Out

Centroid

In

Out

Centroid

In

Out

Adolescent
Young adults
Midlife adults
Older adults

48 (19-29)
64 (36-28)
64 (39-25)
55 (40-15)

11.853
31.302
53.089
70.647

48
62
57
46

0
2
7
9

12.047
31.600
53.529
71.018

48
60
56
46

0
4
8
9

11.661
30.075
49.908
68.274

48
64
59
55

0
0
5
0

As a result, we divided our sample into four groups: Adolescents
(below 20 years), Young adults (from 20 to 40), Midlife adults (from 40 to
60), and Older adults (above 60 years). We reported the number of points
properly identified by the clustering approach (classified column) vs.
misclassified points in Table 3.1. The best results were achieved on the
ISCA. Only five examples of adults in their forties and fifties were
misclassified as teenagers. In the POBA dataset that we collected, the ISCA
index accurately captures age-related psycho-physiological shifts [77].
We used a heuristic technique and clustering approach to choose
and justify the age cohort ranges. We subsequently ran a review to see what
biological alterations might be at play in the selection of such subcohorts.
The time intervals between the end of neurodevelopment and the
appearance and the acceleration of cognitive decline are represented by the
group boundaries.
Healthy educated adults begin to experience age-related cognitive
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changes during their 20s-30s [225]. Before the age of 20, there is a period
of rapid neurodevelopment, during which people exhibit skill acquisition,
knowledge development, and a growth in intellect. Cognitive functions
exhibit conflicting developments during the next 20 years of life. Early in
life, basic physiological cognitive functions deteriorate. As a result, early
lowering of fluid intelligence, memory, and processing speed may appear in
young adults. Simultaneously, crystallized intelligence rises [226]. The
authors of a study on simple reaction time found that consistency of
response increases with age from 8 to around 30, after which it begins to
diminish. The fastest response was recorded in people over the age of 20,
but the most consistent response in terms of time variance was observed in
people over the age of 30 [227]. Another study found a roughly similar
chronology of changes: the shortest reaction time occurs in the mid-20s of
the participants [228].
The total volume of the brain WM increases until early middle
adulthood (age 35 years or more) [229, 230]. Then there is a subsequent
period when WM volume and cognitive performance are plateaued
[229, 230].

Midlife adults’ cognitive capacities may be harmed by

neurocognitive slowdown throughout this stage of life.

Neuroplasticity

induced by physical and mental exercise has been shown to reduce
alterations and improve cognitive function [231, 232]. Nevertheless, in the
middle-aged population, cognitive deterioration is already discernible
[233]. However, the precise timing of its commencement remains a point of
contention [233]. After late middle age (55–60 years), accelerated cognitive
decline commences [229, 230]. It is characterized by a significant decrease
in WM volume, while the GM volume decreases at a consistent rate
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throughout life.
3.1.3

Proportional Changes in the Cognitive Domains with Age
Figures 3.2-3.4 show a pairwise distribution of age with each

proposed index. The linear horizontal trendlines for the linear regression
model estimates with a 95% confidence interval reflect inclinations toward
maintaining a balance between cognitive functions pertaining to several
connected domains.

Figure 3.2: Distribution of ISD values throughout life

We used statistical significance tests to examine the indices’
distribution across age groups.

We resorted to nonparametric statistics

because none of the indices data per the Gaussian distribution exhibited in
the Shapiro-Wilk test (p < 0.05). The Kruskal-Wallis test, which revealed
significant changes in the distribution of the four age cohorts (p < 0.05),
was used to test the null hypothesis that the cluster medians were equal.
We followed the step-down procedure to run a post hoc Dunn test
to ascertain which groups had different medians. To control the familywise
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error rate, we employed Bonferroni corrections (Holm’s step-down
approach). The median of the Adolescents group differed from the other
three cohorts’ indices values.

The distribution patterns of the three

remaining groups were similar (p > 0.01). The indices maintained nearly
constant values during a period of neurodevelopmental alterations and
maturation, with a modest trend toward functional deterioration.

Figure 3.3: Distribution of ISDA values throughout life

However, the RMO test revealed a further tendency.

Pairwise

comparisons of RMO_mean data revealed that the median of Midlife
adults’ group differed significantly from the remaining three age cohorts
(p < 0.01). There was no discernible trend in this dependent variable’s
age-related variations (see Figure 3.5).
Finally, the variances of the proposed indices were explored, as
well as selected psychophysiological characteristic values for various
groups. For the abovementioned values, Levene’s test demonstrated no
significant difference (p > 0.05) in the variances across age ranges.
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Homoscedasticity also backed up our theory of a steady linear relationship
between observed traits and age.

Figure 3.4: Distribution of ISCA values throughout life

Figure 3.5: Pairwise distribution of reaction time and age in RMO test

Trends in Cognitive Subdomains with Age and Proportionality of
their Changes: Table 3.2 shows the statistically significant differences in PT
performance across age groups. The study aimed to assess the possible
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association between ISD, ISDA, and ISCA; the participant’s general
psychophysiological condition; and his or her age. Furthermore, we used a
machine learning approach to estimate the examinee’s age group, i.e.,
whether he or she was under or over 40 years old. We aimed to ascertain
how well the variables produced from the test results could reflect the
individual’s whole psychophysiological state.

As an individual’s

psychophysiological status changes with age, one may anticipate the
derivative indices to reflect this change as well. Our recent study [32] has
previously justified the cutoff level utilized. We investigated the latter’s
information value for such a forecast by feeding the models with values of
the novel indices. The models’ performance measures are listed on the left
side of Table 3.3.
Table 3.2: Comparative analysis of results in PTs
Total
n=231

Adolescent
n1 =48(20.78%)

SVMR_mean
SVMR_variance
SVMR_mistakes
SVMR_IES
CVMR_mean
CVMR_variance
CVMR_mistakes
CVMR_IES
DMT
RMO_mean
RMO_variance
RMO_errors

260.51[219.63-285.83]
69.88[41.09-80.82]
1.32[0.0-2.0]
280.06[224.94-304.73]
360.77[307.45-395.57]
108.91[70.7-118.64]
2.87[1.0-4.0]
402.91[336.52-448.65]
100.26[63.6-122.43]
0.32[-18.5-31.35]
167.86[84.7-224.35]
20.95[18.0-24.0]

282.03 ± 70.91*
89.01 ± 73.36
2.69 ± 3.83*
339.43 ± 236.3*
360.8 ± 107.74
121.55 ± 94.58
3.65 ± 2.45*
416.17 ± 143.57
78.76 ± 52.97*
-8.99 ± 69.28
168.85 ± 103.5
19.96 ± 5.22

ISD
ISDA
ISCA

3.82[1.97-4.13]
4.35[2.15-4.87]
0.7[0.61-0.77]

Young adults
n2 =64(27.71%)

Midlife adults
n3 =64(27.71%)

Older adults
n4 =55(23.81%)

p1 −4

288.52 ± 53.75*
79.54 ± 42.92*
1.49 ± 1.54*
305.56 ± 64.35*
400.32 ± 71.9*
136.69 ± 74.86*
3.4 ± 2.26*
455.62 ± 95.44*
111.79 ± 57.81
-3.12 ± 75.59
242.81 ± 105.18*
23.62 ± 3.34*

1.61005e-14
7.05157e-06
2.8462e-06
7.00503e-15
9.41694e-08
2.0683e-07
0.000253234
5.88309e-09
0.00056484
0.00646979
5.6846e-12
5.24218e-11

3.76 ± 3.59
4.26 ± 3.99
0.68 ± 0.12

5.53179e-06
8.10003e-07
1.82596e-05

Psychophysiological tests (performance)
221.03 ± 28.92*
49.41 ± 22.39*
0.83 ± 1.32*
227.9 ± 32.9*
324.89 ± 56.55*
91.82 ± 80.43*
2.58 ± 2.81*
359.93 ± 81.36*
103.86 ± 48.64
-2.14 ± 54.25
111.84 ± 67.33*
18.14 ± 4.14*

259.76 ± 55.48
67.69 ± 36.54
0.62 ± 1.11*
265.77 ± 59.02
362.64 ± 65.15
92.65 ± 30.46
2.14 ± 1.75*
390.66 ± 66.29
102.88 ± 51.65
12.73 ± 104.22*
158.75 ± 93.83
22.22 ± 3.82*

Proportionality of changes in cognitive subdomains
4.53 ± 2.29*
5.22 ± 2.75*
0.81 ± 0.37*

3.02 ± 2.98*
3.57 ± 4.48*
0.65 ± 0.1*

4.14 ± 4.9
4.55 ± 5.65
0.68 ± 0.11

*Data for various age groups are provided as Mean ± SD. If the distribution of performance metrics differs conciderably (p < 0.05)
from the other instances combined, its Mean ± SD is denoted with an asterisk.

Identification of the proposed indices values and their predictive
potential: In this case, we intended to ascertain if the variables derived from
the test results could accurately describe the individual’s overall
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psychophysiological state. We constructed a regression model to forecast
the values of the suggested indices based on the array of PTs which
illustrates the individual psychophysiological status.

The performance

metrics are shown in Table 3.3 (see on the right side). Figure 3.6 shows the
accuracy of the forecast with regard to the ratio of MAE divided by the
range of the index values in different age groups in the form of a notched
boxplot.
Table 3.3: Outcomes of the classification and regression models on POBA dataset
Binary classification models
two age groups (cutoff value set to 40 years)
Index
predictor
ISD
ISDA
ISCA

Regression models

Sens.

Spec.

ROCAUC

ACC

0.7 ± 0.056
0.72 ± 0.06
0.73 ± 0.04

0.73 ± 0.03
0.73 ± 0.04
0.73 ± 0.03

0.78 ± 0.04
0.8 ± 0.03
0.8 ± 0.02

0.715 ± 0.29
0.727 ± 0.28
0.73 ± 0.024

Predicted
feature
ISD
ISDA
ISCA

MAE

RMSE

MAE
range , %

2.15 ± 0.14
2.58 ± 0.19
0.102 ± 0.004*

3.56 ± 0.31
4.34 ± 0.44
0.18 ± 0.013*

7.62 ± 0.5
7.56 ± 0.55
3.49 ± 0.14*

*The model outcomes are represented as Mean ± SD values among the following classifiers and regressors: Gradient Boosting, Random
Forest, AdaBoost, Gaussian NB, Ridge, Lasso, LR, SVM linear and non-linear. If the distribution of metrics differs significantly (p < 0.05)
from the other instances combined, its Mean ± SD is denoted with an asterisk.

The distribution of the indices across age cohorts supports the
premise that ISCA more accurately reflects psychophysiological status than
ISDA or ISD. According to Table 3.3, the proportion of MAE to a range of
values in ISCA is significantly smaller (7.57 ± 0.55% in ISDA and
3.49 ± 0.14% vs 7.62 ± 0.5% in ISD; p < 0.05). In Figure 3.6, the CI and
IQR are considerably lower in all age group for ISCA compared to ISD or
ISDA.
We anticipated that one index (e.g., ISDA) might replace the PT
battery’s dependent variables. In this case, the proposed index may reflect
the psychophysiological status and serve as its marker. If this is the case,
ML algorithms can calculate its value from other PT outcomes. In Table 3.3,
the ability of PTs to predict ISCA values is demonstrated. The quality of
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models’ outcomes are excellent; the MAE to a range of values proportion
is modest (3.49 ± 0.14%). From our analysis, all of the ML models that
were constructed are reliable. In this example, the Random Forest regressor
performed the best (3.36%). The suggested model’s accuracy was higher
than that of a previously developed model for predicting IES scores from PT
features (3.36 – 3.77% vs 3.37 – 5.15%) [77].

Figure 3.6: Distribution of MAE to range of index values in different age cohorts

All of the age groups analyzed exhibited relatively similar
prediction accuracy. In contrast, the accuracy of forecasting IES varied with
age, with the maximum accuracy for Adolescents and a somewhat reduced
accuracy for Older adults [77]. This diminishes the IES’s dependability,
making ISCA the best index for evaluating performance in PTs and
comparing results regardless of the examinees’ age. Because it is difficult to
distinguish between normal versus accelerated aging, the index which is not
susceptible to aging may enhance current screening tools fro dementia.
Strengths and limitations of ML models of age-related cognitive
decline: The study’s known disadvantage - a relatively low number of
participants - is very usual in this type of investigation. In general, there is a
trade-off seen between the quantity of examinees in an aging study and the
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precision with which participants are chosen. The study cohort will be
smaller if the inclusion criteria are more stringent. As a result, studies on
normal aging exhibit limitations in terms of cohort size and evidence. No
providers can cover the costs of MRI, which is the gold standard of
non-invasive dementia screening in population-scale research.

Some

neuroscientists use low-strength magnetic field MRI to save money on
research [234]. We presented a balanced approach based on the use of a
high-field MRI and a careful selection of research participants in this
investigation (see exclusion criteria in subsection 3.2). The study cohort
was kept small due to the need to carefully select participants who met the
inclusion criteria. At the same time, its analysis produced a degree of proof
that a population-scale survey with less stringent inclusion criteria could
never achieve [223]. Most of the existing work are done based on low
number of participants [235, 236, 237, 238, 239, 240, 241, 242] or similar
to the number of participants we considered in our experimental work
[227, 243].
In our study, we were fortunate in that each age group had a similar
number of individuals. This enabled us to construct plots that spanned the
whole population without the need for years of approximation. Previous
longitudinal studies have exhibited certain drawbacks, such as focusing on
the onset of cognitive decline and omitting people younger than middle age
[233]. People of all ages are rarely included in equal proportion in studies
with a higher number of participants [244, 245, 246].
In this circumstance, we did not evaluate the participants’
educational level beyond ensuring they met the inclusion requirements (e.g.,
literate). In the literature, there is no consensus on the subject. While some
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researchers looked at the length of time spent in school, others argued that
education, rather than other cognitive capacities, slowed the decline of
crystallized intelligence. This is why, in tests, a lower educational level
does not indicate a decrease in cognitive speed, memory, or reaction time
[247]. As a result, the lack of control over years of education cannot be seen
as a drawback in the current study, which is concerned with reaction time
and accuracy.
3.2
3.2.1

Patterns of Structural Changes in Normal Aging
Age Related Brain Morphometry Changes
Figures 3.7-3.8 show a distribution of the major brain

compartments across time using regression trendlines of ordinary least
squares (OLS). Figures 3.8E-3.8H, and 3.9 demonstrate the brain
anatomical changes for each age cohort using linear regression trendlines.
The total intracranial volume (TIV) decreases steadily from adolescents to
young and middle-aged adults to older individuals (p = 0.0068). Growth in
the size of the head and body across generations is thought to be the cause.
The significant difference warrants adjusting individual brain volume to
TIV. We were able to compare the age groupings as a result of this.
Table 3.4 shows the average data and Kruskal-Wallis test findings
for four age groups. Asterisks indicate group data with a distribution that
appears to deviate from the overall cohort. The P-values in the table’s right
column indicate whether there is a significant variation between all of the age
groups studied. The rate of the CSF (CSF%) steadily increases over time,
and its accumulation implies brain parenchyma atrophy. The pace of growth
of the cerebral subarachnoid space is faster than that of the brain ventricles
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during all life stages [188].

Figure 3.7: Voxel-based brain morphometry results throughout lifespan. Linear
trends with 95% CI highlighted in red, second-order trends are drawn in green
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Throughout life, there is a decline in the ratio of GM (GM%) to
TIV. A reversed slope for GM% loss throughout lifespan in adolescents is
significantly steeper than an incline for CSF% buildup. A buildup of WM
during active neurodevelopment and myelination may be able to compensate
for the GM loss. A slope for CSF% buildup in older persons is substantially
shallower than a reversed incline for GM% loss. This can be attributed to the
rapid accumulation of WM in minors which slows down as they get older.
With aging, the proportion of cGM (cGM%) in TIV decreases. In contrast
to GM percent, the percentage of total WM (WM%) follows an age-related
pattern of change. It increases throughout time; however, the pace of change
varies depending on the age group. Adolescents exhibit a significant rise in
WM. There is a little increase in WM% from 20 years to the end of life. After
the age of 60–65 years, the non-linear model of the WM volume distribution
across time shows a modest decline in volume.
The major predictor of life-long structural alterations in the brain is
not WM vascular lesions. We can consider them as a symptom of brain
illness rather than a normal part of the aging process. The percentage of the
TIV occupied by CSF% increases throughout life and peaks in Older adults,
but the percentage of the TIV occupied by WMHs (WMH%) remains
nearly stable in normal brain aging. The linear trendlines for WMH% are
shallower than CSF% in all age categories. The relative sizes of the brain
compartments (e.g., CSF%, WM%, GM%, etc.) do not differ significantly
between sexes in Adolescents and Young adults when corrected for skull
volume.

After the age of 40, the tendency shifts.

The sex-related

discrepancies can be explained by variations in the rate or start of atrophic
alterations in GM. In men, it begins sooner or moves more quickly. A
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significant difference in the proportions of iCSF and total CSF demonstrates
that elderly males are predisposed to age-related brain shrinkage [188].

Figure 3.8: Changes is indices of brain morphometry througout lifespan (A-D) and
in four age groups (E-H). Linear trends with 95% CI highlighted in red, secondorder trends are drawn in green

Various studies dedicated to neuroimages of degenerative disease
are far higher than those focused on normal brain development.
Neurobiologists and neurophysiologists use alterations in the structure or
function of the brain to describe clinical groups. The lack of data about the
baseline morphology and physiology of the "normal" brain during aging
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makes clinical data explanation much more difficult [248]. To fill this
knowledge gap, we sought to draw conclusions about the natural patterns of
brain structure and function in a healthy population.
Figures 3.10A-3.10D, 3.11A-3.11D show how the dependent
variables that measure speed of information processing in PTs using
different task paradigms develop with age. The parabolic trendline shown in
green shows a better fit to the distribution of test results across time than the
linear trendline indicated in red.

Figures 3.10E and 3.11E present the

distribution of the derivative variables that reflect the time spent on task
switching and inhibitory control (i.e., inhibiting an automatic response,
making a decision, selecting the proper respond, etc.) [188]. The data on
these scatterplots have almost linear distribution that is close to the linear
trendline in red.
The findings support the existence of unique patterns of cognitive
function variations related to age. The explanation for this is that cognitive
domains in the brain lack a common structural representation, and structural
correlates change at different rates as people age. The majority of studies
that have been performed to date have focused on the rate at which cognitive
function improves or declines; however, the pattern of age-related changes
is unique to the cognitive domain and is in need of further investigation.
The findings of the psychophysiological tests show a "U-shaped"
trend of changes in information processing speed. Polynomial kernel ML
models adequately describe the variability in RT in SVMR, CVMR, IRT,
and AST tests throughout lifespan.
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Figure 3.9: Trendlines displaying differences in voxel-based brain morphometry
across four age groups
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Table 3.4: Brain morphometry with regard to the age group and sex
All
TIV
CSF
iCSF
GM
cGM
WM
WMH
CSF,%
iCSF,%
GM,%
cGM,%
WM,%
WMH,%
iCSF/CSF
cGM/GM
GM/WM
WMH/WM

mean
1614.42
304.51
21.54
533.15
366.93
652.5
19.26
18.88
1.33
33.15
22.8
40.52
1.19
6.73
68.66
84.61
2.83

CI
[1515.99-1724.63]
[249.28-343.44]
[12.51-24.56]
[462.62-603.28]
[306.94-426.57]
[566.76-719.3]
[11.81-23.28]
[15.54-21.25]
[0.79-1.51]
[29.18-36.46]
[19.26-25.86]
[35.98-43.85]
[0.75-1.39]
[4.94-7.53]
[66.48-71.58]
[66.5-100.54]
[2.0-3.41]

Mean ± SD
1653.39 ± 151.51
229.93 ± 36.1*
14.07 ± 7.59*
640.98 ± 47.03*
463.22 ± 37.73*
595.06 ± 83.52*
17.8 ± 4.67
13.87 ± 1.53*
0.84 ± 0.42*
38.97 ± 3.24*
28.18 ± 2.7*
35.93 ± 3.18*
1.08 ± 0.26
5.95 ± 2.39*
72.61 ± 1.97*
109.53 ± 15.05*
2.98 ± 0.64*

Adolescents
female
1555.01 ± 130.92
217.33 ± 39.12
12.99 ± 6.41
616.3 ± 35.47
446.42 ± 28.16
551.51 ± 63.94
15.6 ± 4.1
13.91 ± 1.8
0.83 ± 0.38
39.82 ± 2.87
28.87 ± 2.53
35.46 ± 2.85
1.01 ± 0.27
5.77 ± 1.87
72.76 ± 1.81
113.29 ± 14.76
2.82 ± 0.65

male
1724.22 ± 123.11
239.0 ± 30.71
14.84 ± 8.25
658.74 ± 46.31
475.31 ± 39.1
626.41 ± 81.89
19.39 ± 4.41
13.84 ± 1.3
0.85 ± 0.45
38.36 ± 3.36
27.68 ± 2.71
36.26 ± 3.35
1.12 ± 0.24
6.09 ± 2.69
72.51 ± 2.08
106.82 ± 14.67
3.1 ± 0.6

p
0.0002
0.0298
0.178
0.0012
0.0077
0.0022
0.0047
0.4171
0.4559
0.0715
0.0981
0.1211
0.1366
0.3885
0.2415
0.0785
0.0785

Mean ± SD
1649.87 ± 211.35*
282.31 ± 52.47*
16.74 ± 6.62*
551.91 ± 76.92*
377.75 ± 66.71
662.41 ± 122.08
19.01 ± 10.69
17.15 ± 2.44*
1.02 ± 0.42*
33.66 ± 4.0
23.0 ± 3.55
42.21 ± 5.89*
1.16 ± 0.66
5.92 ± 2.07*
68.34 ± 4.01
86.12 ± 19.05
2.74 ± 1.16

Young adults
female
1561.71 ± 192.26
266.68 ± 48.91
15.39 ± 5.77
529.66 ± 69.12
362.6 ± 65.1
627.54 ± 107.18
17.87 ± 11.08
17.15 ± 2.68
1.01 ± 0.46
34.19 ± 4.25
23.35 ± 3.79
41.91 ± 6.29
1.15 ± 0.71
5.85 ± 2.39
68.26 ± 4.63
86.91 ± 17.98
2.7 ± 1.26

male
1784.03 ± 162.99
306.08 ± 48.64
18.78 ± 7.28
585.76 ± 75.84
400.81 ± 62.38
715.46 ± 124.25
20.74 ± 9.82
17.14 ± 2.04
1.04 ± 0.35
32.86 ± 3.44
22.48 ± 3.09
43.01 ± 4.56
1.17 ± 0.58
6.02 ± 1.45
68.47 ± 2.82
84.92 ± 20.52
2.8 ± 0.98

p
<0.001
0.0012
0.0173
0.0028
0.0086
0.0034
0.0492
0.3753
0.1508
0.0935
0.1046
0.1847
0.2422
0.1075
0.2227
0.2323
0.2134
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All
Midlife adults
Older adults
mean
CI
Mean ± SD
female
male
p
Mean ± SD
female
male
p
p-value
TIV 1614.42 [1515.99-1724.63] 1597.45 ± 160.86 1528.18 ± 131.34 1722.78 ± 130.75 <0.001 1564.78 ± 167.75* 1506.75 ± 137.35 1719.54 ± 141.23 <0.001
0.0068
CSF 304.51
[249.28-343.44]
314.81 ± 60.94*
296.61 ± 49.8
347.76 ± 65.29
0.0011
375.2 ± 90.53*
343.44 ± 66.61
459.88 ± 91.43
0.001
0.001
21.54
[12.51-24.56]
22.4 ± 12.47
20.04 ± 10.44
26.68 ± 14.54
0.0444
31.53 ± 17.25*
26.77 ± 13.5
44.2 ± 19.6
0.0005
<0.001
iCSF
GM 533.15
[462.62-603.28]
493.04 ± 60.99*
485.2 ± 61.04
507.24 ± 58.28
0.0806
472.1 ± 48.94*
463.46 ± 47.55
495.12 ± 45.0
0.0176
<0.001
cGM 366.93
[306.94-426.57]
332.26 ± 56.52*
329.67 ± 56.0
336.93 ± 57.14
0.3432
317.43 ± 43.51*
311.19 ± 44.78
334.06 ± 34.82
0.0491
<0.001
WM
652.5
[566.76-719.3]
676.91 ± 100.46*
642.04 ± 86.79
740.01 ± 92.41
0.0001
660.78 ± 116.99
631.51 ± 111.24
738.82 ± 93.84
0.0011
0.0019
WMH
19.26
[11.81-23.28]
20.82 ± 12.16
18.69 ± 12.07
24.67 ± 11.33
0.0102
18.99 ± 12.45
17.45 ± 12.77
23.08 ± 10.49
0.0138
0.6672
CSF,%
18.88
[15.54-21.25]
19.65 ± 2.86*
19.37 ± 2.49
20.17 ± 3.38
0.2029
23.8 ± 4.25*
22.68 ± 3.33
26.79 ± 4.94
0.0036
<0.001
iCSF,%
1.33
[0.79-1.51]
1.38 ± 0.7
1.3 ± 0.63
1.53 ± 0.77
0.2406
1.97 ± 0.93*
1.75 ± 0.79
2.54 ± 1.02
0.0033
<0.001
GM,%
33.15
[29.18-36.46]
31.0 ± 3.79*
31.85 ± 3.96
29.46 ± 2.86
0.009
30.37 ± 3.48*
30.94 ± 3.65
28.87 ± 2.38
0.0145
<0.001
22.8
[19.26-25.86]
20.89 ± 3.57*
21.64 ± 3.68
19.54 ± 2.91
0.0142
20.43 ± 3.03*
20.78 ± 3.26
19.49 ± 2.01
0.101
<0.001
cGM,%
WM,%
40.52
[35.98-43.85]
42.49 ± 5.65*
42.17 ± 5.71
43.08 ± 5.49
0.1985
42.21 ± 5.89*
41.91 ± 6.29
43.01 ± 4.56
0.1847
<0.001
WMH,%
1.19
[0.75-1.39]
1.31 ± 0.78
1.23 ± 0.81
1.45 ± 0.71
0.0737
1.2 ± 0.77
1.15 ± 0.82
1.34 ± 0.59
0.0883
0.6518
iCSF/CSF
6.73
[4.94-7.53]
6.86 ± 2.87
6.61 ± 2.81
7.32 ± 2.92
0.2659
8.04 ± 2.81*
7.59 ± 2.72
9.25 ± 2.7
0.0076
<0.001
cGM/GM
68.66
[66.48-71.58]
67.31 ± 4.03*
67.84 ± 3.8
66.36 ± 4.27
0.116
67.35 ± 3.32*
67.19 ± 3.63
67.78 ± 2.24
0.4736
<0.001
GM/WM
84.61
[66.5-100.54]
74.84 ± 15.8*
77.43 ± 15.81
70.17 ± 14.65
0.0375
74.01 ± 16.8*
76.18 ± 17.77
68.22 ± 12.14
0.0741
<0.001
WMH/WM
2.83
[2.0-3.41]
2.92 ± 1.33
2.76 ± 1.37
3.22 ± 1.19
0.0595
2.71 ± 1.43
2.58 ± 1.51
3.04 ± 1.1
0.0511
0.0602
Structural features are expressed as Mean ± SD in cm3 or % of TIV. The variables with the distribution significantly different (p < 0.05) in the age group compared to the overall study cohort are marked
with an asterisk. Data expressed as Mean ± SD.

Figure 3.10: Distribution of DMT and RT with its variance in SVMR and CVMR
tasks

As the first power of age increases,

so too does the

psychophysiological measurements that reflect task switching and
inhibitory control (e.g., DMT, the temporal delay due to visual
interference). Linear machine learning models fit the age dependency of
these test outcomes.

The linear distribution of the RMO test results

throughout lifespan is depicted in scatter plot 3.12A. After the age of 20,
age has no effect on reaction time in the RMO test.

One possible

explanation for this stems from the fact that RMO is tested using a
completely different paradigm than the other activities. During the RMO
test, the individual is instructed to reply to stimuli which come at specified
intervals. Tester asks the participant to await for an unexpected event (e.g.,
an presentation of a targeted stimulus in IRT and AST or a light flash in
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SVMR and CVMR tests) before taking the remaining tests. However, the
RMO test’s accuracy varies with age. As a result, in Figure 3.12B, the
variation of response time (RMO_variance) fits a parabola trendline in
green.Participants between the ages of 35 and 40 have the best performance.
Figures 3.12C and 3.13 show linear regression trendlines that
reflect changes in psychophysiological performance across lifespan. The
findings in PTs follow a consistent age-related trend. After the age of 20,
the participants’ performance begins to deteriorate.
Skull morphometry: TIV variations with age have been the subject
of research in the past, and they are still being debated. The study findings
may differ due to inconsistency in the following settings: (i) population
selection, (ii) the study design (e.g., longitudinal or cross-sectional), and
(iii) methodology. For instance, TIV did not change between generations in
another cross-sectional investigation of persons aged 24 to 80 years. The
results of the studies are allegedly incongruent due to social-economic
aspects that could explain the inconsistencies [249, 250]. A cross-sectional
survey of individuals born within a 40-year period demonstrated that
younger participants had bigger mean TIV. The size of the individual’s skull
was also directly related to their height [251].
Our research was conducted in a cross-sectional manner. We were
able to identify the highest mean value of TIV among members of the
adolescent population. This explains why growth in volume of skull is in
line with the natural trend of human body enlargement in the following
generations.
Subarachnoid space:

A rise in the proportion of the CSF

compartment to the brain parenchyma has been associated with cerebral
83

atrophy in older people [244]. The increase in CSF volume has resulted in a
reduction in liquor turnover to three times per day from four to five times
per day [252]. The time it takes to replace the expanded volume is longer
[253].

Figure 3.11: Studies of attention with (B, D) and without interference (A,C).
Distribution of mean reaction time with its variance and time delay because of
distraction

CSF turnover decreases in the elderly for a variety of causes. The
first explanation is, as previously stated, an increase in subarachnoid space
volume. Another reason is that the choroid plexus produces a smaller
amount of CSF [188]. The amount produced drops by nearly twice in
animals and humans [254]. The final explanation is in a reduction in the
capacity of lymphatic outflow channels to filter both small and large
molecules in elderly [255]. In a study of brain morphology changes from
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birth to late adulthood, volume of sulcal CSF remained steady until the age
of 20 years, and increased curvilinearly throughout maturity. After 50
years, the acceleration was higher [256]. It’s possible that the rise in CSF
volume as people get older is due to atrophic processes such as cell
shrinking. Another investigation found that the proportion of volume of
sulcal CSF to intracranial volume was shown to be higher in seniors (above
55 years) than in younger adults [241]. Other authors [236] found a linear
decrease in brain volume and a rise in CSF [236].

Figure 3.12: Distribution of RT and its variance in responding to moving object
test (A-B). Linear trendlines of performance in responding to moving object in age
groups (C)

An earlier study looked at the global and regional effects of age on
CSF volume in people aged 18 to 79. The researchers found that the volume
of CSF gradually increased (R2 = 0.377). The CSF components distributed
between sulci and inside ventricles were the same. Researchers discovered
a relatively small increase of the CSF volume in the pontine cistern,
including its caudal reach around the medulla, in regional effects of age.
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The supracerebellar and chiasmatic cisterns, cisterna magna, Sylvian, third
ventricle, and interhemispheric fissures all showed the greatest symmetrical
increase in the CSF space. The regional effects tended to follow a linear
pattern.

When they employed the second and third-order polynomial

expansion of age, the data fit showed no improvement. They found no
evidence of a relationship between CSF volume and gender, either generally
or in localized effects [245]. A nonplanimetric approach for assessing
intracranial CSF volume in senior volunteers aged 60–84 found a
substantial association between age and CSF but a modest correlation
between TIV and CSF. This finding demonstrated that the normal brain
volume shrinks over time [238].
Brain ventricles: Researchers have gained fresh insight into the
neurobiological underpinning for cognitive changes related to age and their
impact on cognitive function by studying the brains of healthy people. The
bulk of prior studies has found that as people age, their brain volume
decreases and their ventricle volume increases, implying that brain
shrinkage in humans is linked to aging. The shrinkage of periventricular
brain tissue is thought to cause age-related ventricular hypertrophy [257].
With the help of a CT scan, other researchers were able to validate this
finding by tracking the ventricles of healthy people aged 60 to 99 [258].
Between the ages of 80 and 99, a more noticeable growth was observed.
This backs up other researchers’ results that the expansion of the lateral
ventricles peaks in the ninth decade.

According to their findings, the

volume climbed steadily from the adolescence to the seventh decade but
rose more rapidly after the age of 70 [259]. This outcome helps to explain
why a ventricular volume abnormality is easier to detect in younger people.
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Figure 3.13: Linear dependencies of performance in PTs across lifespan
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Subjects in two age groups (16–40 and beyond 60 years) exhibited
varying diameters of ventricles and sulci, according to data from prior
studies. The ventricles were larger in the elderly [260]. The earlier CT
findings were validated by an MRI-based analysis of the lifetime dynamics
of the lateral ventricles and CSF volume. The ventricular capacity rose in a
linear fashion until the age of 40, then skyrocketed after 60 [242].
The authors concurred that the pace of change in ventricular size
observed across longitudinal studies may be of great relevance. For instance,
the mean rate of ventricular enlargement was 650 mm3 /y in a longitudinal
study of participants between the ages of 31 and 84. After 60 years of age,
the enlargement of the ventricles regularly accelerated. Over time, some
investigations found a significant increase in ventricular, and frontal lobe
measurements [237].
In healthy adult men between the ages of 19 and 92, the right
temporal lobe was larger than the left one. This rise in volume of the
temporal horn of the lateral ventricle supports the notion of a smaller
volume of the hippocampus in the older group [256]. A previous study
found that ventricular CSF volume grew significantly, with substantial
linear and quadratic increases in the left and right lateral ventricle. It also
found pronounced linear trends in the third ventricle and left temporal horn,
with a 17 percent variance in volume. Investigators discovered a significant
rise in the steepness of the lateral ventricle curve in the elderly population
[261].
Several researchers established normal age-related values for brain
morphometrics in healthy males between ages of 21 and 80 [262]. They
discovered a positive relationship between CSF volume and age, as well as
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an increase in the volumes of the third and lateral ventricles in the senior
people [262]. These findings corroborate data from postmortem material, in
which linear measures in pneumoencephalograms and CT scans revealed a
rise in volume of ventricles and an overall increase in volume of CSF in the
elderly [259].
Gray matter: Past research has produced findings that confirm our
conclusions about a progressive reduction in the volume of GM throughout
lifespan.
Total gray matter: The volume of GM begins to decrease at a very
young age and proceed changing throughout maturity. Within 2.5 years of
birth, there is evidence of a rise in GM volume [263]. From early childhood
through the age of 6–9 years, the GM volume expands by 13%. After first
decade of life, there is a steady decrease in the volume of GM by
approximately 5% per 10 years [263]. Another research study involving
healthy, well-developed children between ages of 5 and 18 years (IQ-score
> 80) verified this. GM levels grew until 9 years old, both in absolute and
normalized terms. After that, there was a fall until the age of 15 and then a
minor gain [264]. In conflict, a study of children aged 4.5 to 18 years found
that the GM volume decreased by 6.56 cm3 every year [265].
The normalized GM volume decreases at a rate of 0.183 percent per
year after age 55, compared to 2.37 cm3 for the absolute volume of GM
[266]. Another study found a 0.40 cm3 annual reduction in GM volume
in persons aged 59–89 years [240]. To our knowledge, there is no strong
agreement on the pace of the changes. Such disparities in findings could be
explained by differences in study methods. A study that used both a crosssectional and longitudinal design yielded mixed results. In participants over
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35, a longitudinal phase of the study found that an insignificant proportion
of change in volume of GM (p > 0.05) remained steady over 3.5 years. A
cross-sectional research study, on the other hand, found a substantial link
between advancing age and a loss in all brain sizes, including GM [267].
Cortical gray matter: Absolute cGM increases and peaks throughout
early childhood, much like total GM. The volume of GM then falls in the
second decade before stabilizing in the third [268]. A research of cortical
regions showed that GM atrophy begins in the dorsal parietal cortex and
progresses in the temporal and frontal cortex [269].
The current study generated evidence of GM volumetric changes as
people age. cGM atrophy has been studied extensively as a cause of NDs and
mental illnesses. In chronic schizophrenia, for example, there is evidence of
a rapid decrease in cGM [270]. Researchers have focused on the thickness
of cGM rather than the volume while studying this phenomenon [271, 272,
273, 274].
White matter: The pattern of WM volume change with age differs
from that of GM volume change. This is supported by our findings and
previous research. However, there is no clear agreement on whether WM
lesions are due to normal aging or are caused by age-related disease.
Total WM: The quantities of WM and GM increase during
childhood and during puberty, albeit at distinct rates. Before 12–15 years,
the volume of GM rises by 13%, whereas the volume of WM changes by
74%. The WM volume increases less dramatically in adolescence than it
does in childhood, peaking in the fourth decade of life. The average annual
rate of WM volume expansion from 4 to 20 years is 0.77% [275]. The WM
volume is steady between 40 and nearly 50. Some scholars claim that the
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volume of the WM begins to decline at the age of 50 [276], while others
claim that it begins at the age of 60 [245]. According to our findings, after
60–65 years, the volume of the WM decreases slightly (see Figure 3.7E, the
green curve). Over time, the detrimental effects of aging on the WM
volume accumulate. Between the ages of 40 and 70, the volume of the WM
diminishes by 13% [263]. A postmortem study found a 15% decline in WM
volume in the cohort between ages of 62 and 90 vs.

18 and 57,

corroborating in vivo findings [277]. In adulthood, the volume drop for
WM is less than that observed for GM [278].
A comparative analysis of different age cohorts revealed a
significant difference in volume of WM between group of young (from 22
to 40 years) and middle-aged (from 41 to 59 years) subjects. Furthermore,
the volume of WM in most brain regions was lower in the young group than
in the middle-aged cohort. In comparison to middle-aged adults, the volume
of WM was decreased in the older generation (60–78 years). In this study, a
linear regression analysis revealed a progressive rise in volume of WM
before the age of 40, a peak around the age of 50, and a rapid fall beyond
the age of 60 [279].
WMHs are among the most typical findings in the brain of elderly.
In older persons, the severity of WM lesions differ greatly. WMHs can be
evaluated using a volumetric approach or visually using the Fazekas rating
scale.

When WMHs progressions were evaluated using a volumetric

technique, the connection with age was two times higher [280]. Some
research has found a link between the distribution of WMHs and the
findings of electrophysiologic testing and several frontal lobe functional
measurements [281]. However, we cannot verify this based on the current
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study’s findings. The PTs we used are representative of EF, which includes
representations of the frontal lobe. However, there were no significant
relationships between psychophysiological performance and age or
functional performance in the assessments.
The relationship between the occurrence of lesions and ageing in a
healthy population is still being debated.

Because the lesions usually

represent ischemia insult, the creation of WMHs may represent an indirect
signal of pathogenic alterations [281]. Gliosis, myelin pallor, subclinical
ischemia, neuropil atrophy, and other variables have been linked to WMHs
[282].
WMHs are more commonly found in older people. In one study,
100% of people from 71 to 80 years had WMHs, whereas only 20 percent
of young persons from 21 to 30 years had them. Furthermore, there was a
positive correlation between the size of lesions and age [283]. WMHs have
been found in 92 percent of patients over 60 years old and 22 percent of
those aged 0 to 20 years old [284]. A study of healthy adults found that
WM lesions were not common in individuals under the age of 55, but after
that age, lesions appeared 10-fold more frequently. WMHs were found to be
present in 5.3% of the population. WMHs in the periventricular region were
detected in 3.7% of the participants, while WMHs in the centrum semiovale
were found in 3.7% cases. The participants between the ages of 16 and 25
had the fewest WMHs, while those between the ages of 56 and 65 had the
highest prevalence of the lesions [285]. It took a long time for a new WMH
to emerge [286].
In addition to assessing the severity (size) of the lesions,
radiologists also record the location and evolution of WMHs in follow-up
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examinations. The goal of one study was to determine the number and
magnitude of lesions in three geriatric age cohorts. The WMHs in all of the
cohorts were predominantly tiny (1 - 3 mm). Notably, the number of lesions
rose dramatically between the 6th and 7th decades of life, but only
marginally between the 7th and 8th. In each age subgroup, 1–2 large
(> 10 mm) and 2–5 medium (3 - 10 mm) lesions were found on average
[286].
Additional studies looked at periventricular WMH (PVWMH) and
deep WMH (DWMH) injuries independently. The results revealed that
PVWMH accounts for 2/3 of overall WMH. In adults over 60, both DWMH
and PVWMH are related with a drop in GM. The relationship between
volume of GM and WMH load is regionally unique; for example, DWMH
corresponds with a lower cGM level to a larger extent than PVWMH [287].
WMHs were found to have a weaker correlation with superficial
atrophy than with global deep brain atrophy in a study of 73 ± 1 year old.
The size of the lesions had a negative relationship with total brain volume
but a positive relationship with intraventricular volume. WMHs increase at
the same time as WM and GM volumes decrease [288].
Different methods of selecting the study cohorts can account for
the disparities between the results of prior studies. Some of the studies may
have been limited to clinical population with a history of vascular
pathology, according to reports.

We followed the inclusion criteria

mentioned in subsection 2.1.2 and analyzed subjects representative of the
healthy community. We analyzed the influence of age on structure of the
brain while minimising an additive effect of confounders (cardiovascular
pathology, etc.).
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3.2.2

Mathematical Models of Age-Related Changes
As previously noted, we were able to construct two approximation

functions for different qualities. We applied ridge regression model to the
linear and non-linear functions of age (see Formulae 2.7-2.8). A straight line
and a parabola (second-order line) are two of these forms. Figures 3.7, 3.83.12 show scatter plots with trendlines for linear and second degree nonlinear models, as well as their 95 percent confidence intervals. This resulted
in a more accurate visual selection of the model which fits best.
From Figures 3.7, 3.8A-3.8D, the data for psychophysiological
variables are scattered less than the voxel-based morphometry data over
lifespan. As a result, selecting a good mathematical model based on a visual
trajectory of changes throughout lifespan is difficult.
The scatter plots for the PTs can be divided into two categories, as
shown by the scatter plots (Figures 3.10-3.12). The first category includes
RT variables in SVMR, CVMR, IRT, and AST tests, as well as time
variability in all tests, including RMO. The polynomial kernel regression
model matches this category better because it exhibits a U-shaped
distribution across time. The features which indicate task switching (DMT,
TRVI) and the equilibrium of processes in the central nervous system
(RMO_mean) fall into the second category.

The first-order models

accurately capture variations in these variables.
Performance of the linear and non-linear models: We analyzed the
models’ ability to predict anatomical and functional changes in the brain to
explain our choice of preferred mathematical models. We used performance
measurements to achieve this objective (see Table 3.5). The number of years
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can be employed as an independent variable in regression models because the
relationship between the aforementioned components and age is statistically
relevant (p < 0.05).
Table 3.5: Prediction quality of the first-order and second-order ML regression
models for predicting results of psychophysiological tests out of age
First-order regression model
MAE

RMSE

Voxel-based morphometry
GM, %
2.78
13.82
cGM / GM
2.81
13.58
WM, %
4.2
31.24
WMH / WM
0.92
1.46
CSF, %
2.06
7.56
intraventricular
1.78
6.58
CSF / total CSF
Psychophysiological tests
SVMR_mean
43.65 3466.29
CVMR_mean
55.39 6068.92
DMT
38.32 2786.15
AST_mean
49.67 3745.09
IRT_mean
58.21 5414.28
TRVI
40.92 3089.75
RMO_mean
45.26 6237.70

Second-order regression model
Distance

R2

MAE
range , %

MAE

RMSE

R2

MAE
range , %

0.41
0.18
0.14
0.003
0.64

11.19
12.2
11.74
13.3
7.8

2.72
2.68
4.19
0.91
1.99

12.89
12.5
30.22
1.45
7.2

0.45
0.24
0.17
0.005
0.66

10.95
11.64
11.74
13.2
7.54

0.24
0.56
0.00
0.10
0.26

0.1

10.6

1.75

6.44

0.12

10.39

0.21

0.02
0.06
0.04
0.14
0.13
0.01
0.00

12.11
7.87
10.80
13.66
14.53
9.15
4.73

39.53
53.03
38.14
45.90
54.53
40.15
45.22

2890.73
5585.68
2782.11
3382.66
4697.82
3030.01
6236.17

0.18
0.13
0.04
0.22
0.25
0.03
0.00

10.97
7.54
10.75
12.63
13.61
8.98
4.73

1.14
0.33
0.05
1.03
0.92
0.17
0.00

The prediction models’ low R-squared (R2 ) values imply that there
is a lot of variability around the regression line. The nature of our data
explains this: psychophysiological performance is unstable, and it reflects
an individual’s adjustment to their living environment [32, 68, 289].
Nonetheless, the reproducibility of the PTs and their informative value
allows us to consider the tests as a tool for screening psychological
misadjustment and cognitive decline [180].
The variables with the trendlines (SVMR_mean, CVMR_mean,
IRT_mean, AST_mean) show rise in the quality of forecast obtained with
the second-order regression model. The parabola curvature increases as the
gap in accuracy between the linear and non-linear models grows. The
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percentage of MAE to the range of the examined data (MAE/range) was
used to compare the performance of different models with the underlying
objective of ranking the models’ performance (refer to Table 3.6).
Table 3.6: Importance of psychophysiological and morphological variables based
on performance of the linear and quadratic models

Psychophysiological performance

Morphological variables

Distance

Variable

Distance

Variable

1.14
1.03
0.92
0.33
0.17
0.05
0

SVMR_mean
AST_mean
IRT_mean
CVMR_mean
TRVI
DMT
RMO_mean

0.56
0.26
0.24
0.21
0.1
0

cGM / GM
CSF%
GM%
iCSF / CSF
WMH / WM
WM%

We listed the following psychophysiological variables in the left
column of Table 3.6, ranked according to the difference in performance
between the first-degree and second-degree functions: SVMR, AST, IRT,
CVMR, TRVI, DMT, and RMO. The top factors in the list indicate a
cognitive domain known as informative processing speed.

Polynomial

trendlines considerably better suit the life-long changes in the tests than
linear trendlines. The factors in the end of the list (DMT, TRVI) represent
task switching and inhibitory control performance, which is another
cognitive subdomain.
distribution.

The linear model almost fits their age-related

For RMO_mean values, both the linear and non-linear

polynomial function models have similar performance, since the RMO
test’s results are not affected by age.
We ordered morphological factors in the left column of Table 3.6
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according to the distance between model performance: cGM/GM, CSF%,
GM%, iCSF/CSF, WMH/WM, and WM%. The overall GM (GM%) and its
cortical component (cGM/GM) show a quadratic retardation trend as people
become older. The same can be said for the total CSF (CSF percent) and the
intraventricular portion of it (iCSF/CSF). Because a second-order function
does not show advanced performance, linear models can be used to represent
the spread of total WM (WM%) and its lesions (WMH/WM) over time.
The comparative analysis of Figures 3.10 and 3.11 reveals two
distinct trends of age-related variation in PT performance. There is a clear
"U-shaped" tendency in the findings of PTs that measure information
processing speed. In comparison to a first-order function, a second-degree
function of age enhances data fit. Figures 3.10E, 3.11E demonstrate the
dependent features for task switching and inhibitory control. The change
trend is linear. Furthermore, using a second-order function of age does not
improve the data fit.

To clarify this, we contrasted aging’s functional

consequences to volumetric changes in the brain’s primary regions.
Linear dependency: The linear equations can be employed to
estimate the regional effects of age on volume of CSF (e.g., the growth of
the Sylvian and interhemispheric fissures) [245]. According to our findings,
the volume of WM and the rate of WMHs in total WM fluctuate virtually
linearly across time (refer to Table 3.6). As the first power of age increases,
so do psychophysiological measurements that represent task switching and
inhibitory control (DMT, TRVI). The cortical GM and the overall GM have
different age-related alterations.
The linear slowing of DMT throughout the lifespan can be
explained by the interhemispheric fissure’s tendency to grow.

Task
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switching and inhibitory control may be morphologic correlates of the
enlargement. This cognitive subdomain’s neuronal centre is located in the
medial wall of the frontal cortex, specifically in the supplementary motor
region. The results of the "go/no-go" test imply that the premotor areas of
the frontal lobe’s medial wall play a critical role in delaying response [290].
As a result, the expansion of the interhemispheric fissure is due to the
atrophy of these brain centres. Researchers warn, however, that approaches
based on the assumption of linearity or even monotonicity of the compared
age functions should be utilized with appropriate caution [188, 291].
Second-degree equation:

Researchers have assessed how the

volume of brain structures changes as people get older [291]. After plotting
the dependency between volume and age as a parabola, the effects can be
seen as a U-shaped or inverted U-shape line.
The inverted parabola is indicative of the WM bundles’ age-related
alterations. As a result, cellular piles and WM fibres are characteristic of the
WM and hippocampus [143]. WM buildup exceeds its concealed atrophic
alterations till around the age of 60–65 years. The interval is followed by
WM loss due to myelin breakdown and gradual WM fibre degeneration.
Myelin breakdown has been reported to be linked to processing speed in
previous studies [292]. Demyelination and other WM alterations are at the
root of age-related slowdown [229].
The U-shaped line represents age-related variations in GM volume
and structures with patches of neuronal cells. The current research found
a link between the GM cortex and overall GM volume. An earlier study
found that deep GM structures, such as the thalamus, accumbens, lenticular,
and caudate nuclei, were justified in this way [143]. The formations are
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dense with cell bodies that cannot grow as large as neural fibres. The loss
of neuronal cells is permanent. As a result, interpreting an increase in a
polynomial second-degree trendline in advanced age as GM atrophy leading
to cell disintegration is impossible. This implies that quadratic functions do
not accurately describe GM atrophy.
Third-degree equation: The cubic function of GM nuclei volume as
age-related function describes the data better than the second-order curve in
[143]. In senior age, no expansion of the GM structures was seen.
3.2.3

Comparison of Dynamics of Psychophysiological Performance with
Brain Structural Changes
The correlation coefficients between volumetric brain data and the

RT in the array of PTs are shown in Figure 3.14. The CSF volume and the
reaction delay in SVMR, CVMR, AST, and IRT tests exhibited a strong
positive relationship, as shown in this diagram. In the experiments, the
volume of brain ventricles and reaction time revealed a favourable
relationship. CSF percentage and iCSF percentage both have a positive
relationship with age (r = 0.8 for CSF% and r = 0.56 for iCSF%). As a
result, the indices can be used as indicators of brain atrophy across lifespan.
Because the highest association (maximal r-value) exists between CSF
percent and age, the latter can be regarded the most sensitive measure of
atrophy related to aging.
Surprisingly, the total CSF percent and average RT in the IRT
exhibited the strongest link between brain anatomical data and functional
outcomes (r = 0.36).

Switching and inhibitory control, information

processing, and attention were among the cognitive domains and
subdomains used in the test.
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Figure 3.14: Coefficients of correlation between PTs results and volumes of major
brain compartments

We also discovered that the SVMR test’s variance of RT
(SVMR_variance feature) showed no relation to age; however, it did exhibit
a negative relationship with the portion of WM in TIV (WM%; r = −0.11).
The relative volume of GM (r = 0.21), specifically the GM cortical
component (cGM%; r = 0.23), revealed a moderate positive relationship
with SVMR variance.
SVMR test was the most basic within our battery of tests since it
focused solely on information processing while putting little strain on other
cognitive functions. The relative volumes of the GM (r = 0.16 for GM%;
r = 0.19 for cGM%) and CSF (r = 0.14 for CSF%; r = 0.18 for iCSF%)
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have moderate relationship with the mean reaction time (SVMR_mean) in
SVMR test.

Furthermore, SVMR_mean shows a moderately negative

statistical connection (r = −0.14) with the proportion of WM%. The faster
reaction could be due to improved brain connections in people with a large
relative volume of WM. Because the SVMR test does not need DMT like
the "go/no-go" test and does not demand attention like the AST and IRT
tests, the link is clear. As a result, the link between brain connection and
this test is straightforward.
The relative volumes of CSF are positively associated with
decision-making time (r = 0.16 for CSF%; r = 0.14 for iCSF%) and
negatively associated with the rate of GM in TIV (r = −0.13 for GM%;
r = −0.13 for cGM%). Because judgments are made in the GM cortex,
these findings demonstrate the dependability of the PTs utilized. Despite
the tests’ validity, DMT’s utility as a biomarker of brain atrophy alterations
is limited by its modest relationships (r ≤ 0.16).
There is no link between psychophysiological performance and the
number of WM lesions (WMH%). Nor is there a link between age and
WMH%. The RMO test’s average RT (RMO_mean) has no relation to age
or the major brain compartments’ volumes.
Strengths and limitations of descriptive model of brain structural
changes in normal aging: Instead of investigating all of the probable
regional consequences of brain aging, we focused on the major brain
compartments. Before engaging in a more extensive investigation, the goal
was to link psychophysiological performance with brain atrophy
parameters. The reason we chose this method was due to the fact that
segmentation of brain can yield a large amount of data. Dealing with
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regional effects could be difficult because no one knows which brain areas
are involved in the psychophysiological tasks that were performed in this
study.

The structural correlates of cognitive performance are not

empirically supported in today’s neuroscience. In our investigations, we
integrated findings from MRI and PTs on the neurobiology of aging to solve
the outstanding problem. On the plus side, we used statistical tests to
determine that the effects of age vary among cognitive subdomains and
brain compartments.

We considered the non-negative compositional

character of brain volumes, which add up to the TIV. Because the loss in
absolute volume was less severe in a small structure than in a large one, we
utilized a uniform percent loss each year as a measure to compare the pace
of change. Other researchers agree that ratios are valuable for describing
compositional data, especially while comparing structures with various
scales of volume [291]. The PTs we used addressed several cognitive
functions.

The methodology that underpinned our study was built to

identify changes in EF and brain morphology. We were able to support the
outcomes with the entire collection of solutions.
3.3

3.3.1

Patterns of Brain Structure-Function Association Indicative of
MCI and Dementia

Dynamics of Performance in Cognitive and Neurophysiological Tests
in Patients with MCI and Dementia
We explored the age-related variability of cognitive scores in the

tests that are most commonly used either to diagnose MCI and dementia or
to improve the accuracy of multimodal diagnostics. We started with the
tests of global cognitive functioning:
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MMSE and ADAS-cog.

The

distribution of the test results over age is shown in Figures 3.15-3.16. As
ADNI dataset contains follow-up studies of healthy people and patients
with cognitive impairment, one can judge on the disease progression by
looking at the diagrams. The trends are horizontal for the performance in
MMSE and ADAS-cog in all study groups. This means that the global
cognitive functioning changes slightly with age in the cognitively normal
population. It also remains stable across the disease course. Though there
are patients with reversible or progressive MCI, the number of such cases is
quite low.

Figure 3.15: MMSE scores in the group of cognitively normal adults and patients
with MCI or dementia

ADAS-cog is a very informative tool for monitoring the
progression of ND in clinical routine practice [196]. According to recent
findings, the test distinguishes between MCI and mild AD with sensitivity
of 0.86 and specificity – 0.89 [197]. It can also identify “questionable
dementia” because its results in immediate recall and object naming tasks
correlate with performance in Category Verbal Fluency Test [198]. MMSE
is the most common method for diagnosing cognitive impairment in a
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single or multiple domains [199]. Although it detects various types of
dementia with a high sensitivity and specificity of over 90%, the test should
be accompanied by a full and detailed assessment of the patients [200]. For
this, clinicians use neurophysiological tests (e.g., TMT, DSST) [201].

Figure 3.16: ADAS13 in the group of cognitively normal adults and patients with
MCI or dementia

The second group of tests covers a few cognitive domains, i.e.,
information processing in DSST, memory in RAVLT, information
processing in TMT. Scores in RAVLT test are quite stable throughout life in
normal aging and across the disease course with a slight trend towards
lowering in all the study groups (see Figures 3.17).

The pace of

neurocognitive slowing is moderately higher in the CN group and MCI
patients. Thus, the average result for all the groups would reach a common
value if the observation lasted several more decades. RAVLT examines
verbal learning and memory. It is capable of detecting cognitive impairment
in multiple sclerosis [206]. The test differentiates between AD dementia
and behavioral variant of fronto-temporal dementia [207] with high
sensitivity and specificity of over 81%.
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It also helps physicians to

distinguish AD from Lewy bodies dementia [208].

Figure 3.17: Results in RAVLT test in the group of cognitively normal adults and
patients with MCI or dementia

The tredlines on Figures 3.18-3.19 show clear signs of
malfunctioning in several cognitive domains assessed with DSST and TMT
tests. The performance worsens with time. For this reason, the trendlines of
CN, MCI and AD groups converge at the approximated point of 100 years
of age.

DSST identifies early stages of dementia [209] and MCI by

detecting working memory impairment and multimodal amnesia [210]. It
also shows significantly impaired performance in early Lewy Bodies
dementia [211].

TMT provides information on neurophysiological

conditions; therefore it is used for diagnosing NDs in combination with
other diagnostic modalities [202, 203, 201].

Its clinical implication is

multifold. First, TMT helps to define the impaired cognitive domain and
improves the assessment with MMSE or MoCA [201]. Second, there is
evidence that the inclusion of TMT (part B) boosts the performance of the
models that use CSF and structural biomarkers to discriminate between AD
and non-AD MCI [204]. Third, the test can sensitively distinguish a case of
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mild AD from amnestic MCI and healthy aging [205].

Figure 3.18: Performance in DSST in the group of cognitively normal adults and
patients with MCI or dementia

Figure 3.19: Executive functioning assessed with TMT test in the group of
cognitively normal adults and patients with MCI or dementia

As seen from the diagrams 3.18-3.19 the trendlines of the
performance in neurophysiological tests (TMT and DSST) and the
degeneration of the GM show the same dynamics in the correspondent
cohorts (see Figure 3.20). But the slopes for the GM volume adjusted to the
TIV are steeper than the trendlines for the results in DSST or TMT.
Presumably, brain plasticity helps an individual to adjust to aging and
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disease and compensates for the loss of the GM volume.

Figure 3.20: Gray matter volume in the group of cognitively normal adults and
patients with MCI or dementia

3.3.2

Models of Brain Structure-Function Associations in Cognitively
Normal Individuals, Patients with MCI or Dementia
Examining the feasibility of employing brain morphometry for

predicting neurofunctional performance in CN, MCI, and dementia cohorts,
we designed an ML regression model. The performance of these algorithms
is presented in Table 3.7. As the test scales differ in size, we adjusted MAE
to the range of results in each test. This allowed us to compare the accuracy
of the algorithms trained on MMSE, ADAS-cog, RAVLT, TMT and DSST.
The test results in MMSE can be predicted much more accurately than in
other tests (MAE/range = 4.5 ± 0.23 in the CN group). Despite a markedly
higher mistake of the model for the ADAS-cog score (p = 1.84e − 95), its
prediction also has credible performance (MAE/range = 5.04 ± 0.22% in
the CN group). The error of the RAVLT, TMT and DSST score prediction is
significantly higher (10.62 ± 0.5, 10.57 ± 0.68 and 10.81 ± 0.51%). The
dissimilarity in the accuracy of the model goes in line with the trends
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described in the previous subsection.

In MMSE and ADAS-cog the

trendlines are parallel and do not intersect. The same trends for RAVLT,
TMT and DSST merge if approximated to future life.
Table 3.7: Performance of models trained on cognitively preserved population,
subjects diagnosed with MCI or dementia with adjustment to the maximal score
of the scales (MAE/range, %)
DX

CN

MCI

Dementia

Data
VBM
SBM
VBM+SBM
VBM
SBM
VBM+SBM
VBM
SBM
VBM+SBM

MMSE
4.5 ± 0.23
4.61 ± 0.23
4.61 ± 0.23
9.28 ± 0.29
9.0 ± 0.28
9.06 ± 0.28
13.22 ± 0.54
12.67 ± 0.54
12.78 ± 0.55

ADAS
5.04 ± 0.22
4.96 ± 0.22
4.94 ± 0.22
7.62 ± 0.22
7.48 ± 0.21
7.41 ± 0.21
10.3 ± 0.42
9.09 ± 0.42
9.11 ± 0.41

p-value
1.84e-95
1.84e-95
1.84e-95
3.63e-211
2.46e-206
1.65e-206
6.98e-121
3.27e-99
1.75e-92

RAVLT
10.62 ± 0.5
10.38 ± 0.49
10.07 ± 0.48
9.52 ± 0.3
9.59 ± 0.31
9.46 ± 0.3
8.65 ± 0.33
7.97 ± 0.34
7.9 ± 0.33

TMT
10.57 ± 0.68
10.75 ± 0.67
10.62 ± 0.66
20.13 ± 0.65
18.8 ± 0.59
18.81 ± 0.59
26.97 ± 0.75
25.75 ± 0.76
25.9 ± 0.77

DSST
10.81 ± 0.51
10.24 ± 0.53
10.23 ± 0.51
10.95 ± 0.33
10.12 ± 0.33
10.03 ± 0.32
12.67 ± 0.46
11.03 ± 0.42
10.85 ± 0.42

p-value
2.99e-142
4.15e-131
1.92e-129
1.43e-212
9.38e-210
1.01e-209
2.14e-187
3.43e-172
1.94e-171

VBM - voxel-based morphometry; SBM - surface-based morphometry.

We ranked the structural predictors according to the information
gain value. The top valuable predictors of MMSE score are the volumes of
the total brain, cerebral cortex, accumbens, cerebral WM, inferior lateral
ventricles, and hippocampus. However, the results in TMT have a weaker
association with the brain structures listed above.
In each study cohort we found clusters of cortical parcellations
closely associated with performance in cognitive tests. The volume, surface
area of the clusters and their number differ evidently among the studied
cohorts.

This is because each of the SBM metrics provides unique

information regarding cortical anatomy and possibly different SFA patterns
[293].
From Table 3.8 one can observe the variations in the capacity of
projecting cognitive scores among CN, MCI and dementia groups. The
majority dementia cases arise from protein aggregation disorders (e.g., the
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accumulation of β -amyloid, τ-protein, etc.).

Genetic variability in the

expression level of the deposited protein is important in pathogenesis of
neuronal diseases [294].

It accounts for different solubility of the

aggregation-prone protein and the efficiency of clearance mechanisms that
keep misfolded proteins in check. Besides this, the clinical appearance of
dementia varies because of selective neuronal and regional vulnerability
that differs among misfolding diseases [294].
In all the tests, the informative value of brain structures in the
prediction of cognitive scores differs by the study group (CN, MCI,
dementia).

This justifies the presence of different SFA patterns in the

healthy cohort and patients with a pathology. We analyzed the SFA patterns
in the demented patients of ADNI dataset and discussed the findings. As
AD accounts for the majority of dementia cases, we pointed out the
structures vulnerable for change in β -amyloidopathy. Other NDs selectively
damage different groups of neuronal cells and brain regions, which would
result in another SFA patterns.
Table 3.8: Metrics of models trained on cognitively preserved population, subjects
diagnosed with MCI or dementia (MAE)
CN
Test

MMSE

ADAS-cog

RAVLT

TMT(part B)

DSST

MCI

Data

Mean ± Std

CI

Mean ± Std

CI

VBM
SBM
VBM+SBM
VBM
SBM
VBM+SBM
VBM
SBM
VBM+SBM
VBM
SBM
VBM+SBM
VBM
SBM
VBM+SBM

0.81 ± 0.04
0.83 ± 0.04
0.83 ± 0.04
3.24 ± 0.14
3.19 ± 0.14
3.18 ± 0.14
7.33 ± 0.35
7.16 ± 0.34
6.95 ± 0.33
28.32 ± 1.83
28.81 ± 1.81
28.47 ± 1.77
8.43 ± 0.4
7.99 ± 0.41
7.98 ± 0.4

[0.73 - 0.89]
[0.75 - 0.92]
[0.75 - 0.91]
[2.96 - 3.51]
[2.91 - 3.46]
[2.9 - 3.45]
[6.65 - 8.01]
[6.5 - 7.82]
[6.31 - 7.6]
[24.73 - 31.9]
[25.26 - 32.35]
[25.0 - 31.95]
[7.65 - 9.21]
[7.19 - 8.79]
[7.19 - 8.77]

1.67 ± 0.05
1.62 ± 0.05
1.63 ± 0.05
4.9 ± 0.14
4.81 ± 0.14
4.77 ± 0.14
6.57 ± 0.21
6.62 ± 0.21
6.53 ± 0.21
53.94 ± 1.73
50.38 ± 1.57
50.4 ± 1.58
8.54 ± 0.26
7.89 ± 0.25
7.82 ± 0.25

[1.57 - 1.77]
[1.52 - 1.72]
[1.53 - 1.73]
[4.62 - 5.17]
[4.53 - 5.08]
[4.5 - 5.03]
[6.16 - 6.98]
[6.2 - 7.04]
[6.12 - 6.93]
[50.55 - 57.33]
[47.29 - 53.46]
[47.3 - 53.49]
[8.03 - 9.04]
[7.4 - 8.39]
[7.32 - 8.31]

Dementia
Mean ± Std
CI
2.38 ± 0.1
2.28 ± 0.1
2.3 ± 0.1
6.63 ± 0.27
5.85 ± 0.27
5.86 ± 0.26
5.97 ± 0.23
5.5 ± 0.23
5.45 ± 0.23
72.28 ± 2.02
69.0 ± 2.03
69.41 ± 2.07
9.88 ± 0.36
8.6 ± 0.33
8.46 ± 0.33

[2.19 - 2.57]
[2.09 - 2.47]
[2.11 - 2.49]
[6.09 - 7.16]
[5.32 - 6.38]
[5.35 - 6.38]
[5.52 - 6.42]
[5.04 - 5.96]
[5.0 - 5.9]
[68.32 - 76.24]
[65.01 - 72.99]
[65.36 - 73.47]
[9.18 - 10.57]
[7.95 - 9.24]
[7.81 - 9.1]

p-value
3.97e-239
1.34e-234
8.23e-232
6.53e-239
5.12e-230
1.44e-227
2.86e-231
4.14e-220
2.48e-213
2.26e-229
5.56e-184
1.38e-180
4.88e-230
3.28e-192
6.89e-187

VBM - voxel-based morphometry; SBM - surface-based morphometry.
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3.3.2.1

MMSE
The test is one of the most frequent tools for screening cognitive

impairment in older adults. It is also used to evaluate cognitive impairment
progression in follow-up visits.
domains:

MMSE examines various cognitive

temporo-spatial orientation, memory recall, concentration,

language, visuospatial function, and working memory. The top valuable
structural predictors of MMSE results are listed in Figure 3.21 and
described below.
Precuneus volume is the most informative predictor. It is a cortical
region located in the posterior portion of the medial parietal cortex. Recent
functional imaging findings in healthy subjects suggest its involvement in a
wide spectrum of highly complex functions, including visuo-spatial
imagery, episodic memory retrieval, working memory, and orientation
[295, 296]. Consequently, its integrity determines successful achievement
of several MMSE tasks, such as the intersecting pentagon copying test,
short-term memory recall, and orientation to time and place. The relative
volume of intracranial arteries is the second in the list of structural
parameters with the greatest prognostic gain. The lumen of the vessels
decreases in atherosclerosis which is associated with impaired cognitive
function due to reduced cerebral blood flow and ischemic damage. Recent
studies reported that intracranial stenosis of arteries and increased plaque
number correlate with more lacunes, larger volume of WM lesions and
memory decline [297, 298].

Hence, the decreased total volume of

intracranial arteries is implicated in the performance deficiency in the word
registration-repetition task and short-term memory recall of MMSE test.
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The pars triangularis relative volume is the third index that
produces the most informative input. The structure refers to the triangular
shaped cortical region of the inferior frontal gyrus in the frontal lobe. It is a
segment of Broca’s area which takes part in expressive aspects of the
spoken and written language. More characteristically, the pars triangularis
is involved in the semantic processing of language and syntax.

The

relatively high predictive value of the pars triangularis in MMSE can be
explained by its essential participation in the language tasks: sentence
repetition, instructions comprehension, reading sentences and doing as they
say, writing short sentences, recognition and naming of two common
objects.
MMSE in patients with MCI: In the MCI cohort, the hippocampus
contributes the most to the information gain. Its involvement in working
memory, memory recall and language processing and production might
affect the successful fulfillment of the following tasks:

repetition,

instruction comprehension, recognition and naming of objects, spelling
“WORLD” backward, and short term memory recall. The superior parietal
lobule is the next best estimator for MMSE test scores. It is topographically
close to the occipital lobe and is employed in some aspects of concentration
and visuospatial perception.

Its participation in the tasks of copying

pentagons and spelling “WORLD” backward might explain the high
informative value.
MMSE in patients with dementia: MMSE test scores in the
dementia patients are best forecasted from the volumes of the brain parts
different from those observed in the CN and MCI cohorts. The fusiform
gyrus has the greatest informative potential in the dementia group. Its
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function mainly comprises visual processing, i.e., word and object
recognition, visuospatial perception. Hence, it’s a key partaker in the tasks
of copying of intersecting pentagons, reading a sentence, recognising and
naming common objects.

Next, the transverse temporal gyrus, caudal

middle frontal cortex, and cGM have the highest information gain value.
The transverse temporal gyrus is the first cortical region to process
incoming auditory information. Thus, its impairment could be associated
with less efficient processing of speech-related stimuli, which could, in turn,
impede learning and perceiving speech sounds thus affecting the
performance in sentence repetition and instruction comprehension tasks of
MMSE. The caudal portion of the middle frontal gyrus contains the frontal
eye fields which control saccadic eye movements. It is these movements
which make it possible to scan numerous details within a scene. The role of
the structure in visual attention might be relevant to the visuospatial and
language tasks including recognition of common objects, reading a
sentence and doing as it says, copying intersecting pentagons. Finally, the
GM of the cerebral cortex also has a relatively high information gain value.
Since it comprises the four lobes, i.e., frontal, parietal, temporal, and
occipital, it is involved in a wide range of cognitive processes.

cGM

participates in memory and learning, sensory perception such as seeing,
hearing, speech, language comprehension, concentration, visuospatial
processing, orientation, spatial attention and mapping. Hence, its integrity
is required for the successful completion of all MMSE tasks.
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Figure 3.21: Brain structures ranked according to information gain value for MMSE score prediction. Inflated cortical representations showing
significant correlations between cortical volumes and test score
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Figure 3.22: Brain structures ranked according to information gain value for ADAS13 score prediction. Inflated cortical representations
showing significant correlations between cortical volumes and test score
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Figure 3.23: Brain structures ranked according to information gain value for RAVLT score prediction. Inflated cortical representations
showing significant correlations between cortical volumes and test score
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Figure 3.24: Brain structures ranked according to information gain value for DSST score prediction. Inflated cortical representations showing
significant correlations between cortical volumes and test score
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Figure 3.25: Brain structures ranked according to information gain value for TMT score prediction. Inflated cortical representations showing
significant correlations between cortical volumes and test score.

3.3.2.2

ADAS
ADAS is a brief cognitive test battery that evaluates learning and

memory, language production, language comprehension, constructional and
ideational praxis, etc. In this study we resorted to average values of ADAS ADAS13. The reason for the choice of this dependent variable is explained
in Subsection 3.4.1. The information gain value of the brain volumes in
predicting ADAS13 in the CN, MCI and dementia cohorts is illustrated in
Figure 3.22. For the CN subjects, the middle temporal volume provides
the highest information gain value. The hippocampus, amygdala and other
structures constitute the medial temporal lobe which is essential for episodic
memory. Encoding, consolidation, and retrieval are the processes composing
the memory function of the lobe while word recall and remembering test
instructions are among the tasks assessing memory in the ADAS-cog test.
Intraventricular CSF is the second top-informative predictor of
performance in ADAS-cog in the CN cohort.

The rise in the volume

suggests larger ventricles and indicates brain atrophy which hampers
cognitive abilities. Larger ventricles are strongly correlated with lower WM
integrity due to the small vessel disease [299]. Increasing intraventricular
CSF volume is significantly associated with increasing severity of cognitive
impairment and reaction time in the tests.
WM hypointensities and the inner CSF are predictors of roughly
the same informative value. The hypointensities are areas of attenuated
signal on T1-weighted MRI scans. Pathological lesions in these regions
include myelin pallor, tissue rarefaction associated with a loss of myelin
and axons, and mild gliosis [300]. They are also associated with a faster
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deterioration in global cognitive performance as well as in memory,
learning, praxis, and language [188].

These functions are believed to

depend on some brain structures including subcortical neural networks and
cortical-subcortical circuits.

The latter can be damaged while passing

through WM. Reasonably, the WM integrity is the key index to predict
ADAS13.
Inferior horns of the lateral ventricles have the information gain
value almost identical to that of the inner CSF and WM hypointensities.
Inferior lateral ventriculomegaly is caused by passive enlargement of the
inferior (temporal) horns of the lateral ventricles.

Typically, the

enlargement follows neuronal loss and brain parenchymal atrophy in the
temporal lobe. Therefore the temporal horns have been repeatedly used as
the index for middle temporal lobe atrophy [301] which is the top
informative biomarker in our study. They may also reflect the level of
cognitive impairment. Accordingly, subjects who suffer from cognitive
decline exhibit greater temporal horn enlargement compared to their
cognitively stable counterparts. Notably, the information gain of the inferior
horns is twice as high as that of the total lateral ventricles. This can be
explained by the fact that the temporal horn volume is a measurement of the
middle temporal lobe atrophy while the size of lateral ventricles is
indicative of the global cerebral atrophy. Consequently, it is less specific for
neuropsychological decline compared to the temporal horns and has lower
significance in projecting ADAS.
The fifth most informative predictor is the ratio of the brain segment
to the TIV. The brain segment includes voxels of all intracranial structures
with the exception of the brain stem and background. It also includes vessels,
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the optic chiasm and CSF.
The information gain of the cuneus is approximately 75% bigger
than that of the lateral ventricles. The cuneus is a wedge-shaped area on the
medial surface of the occipital lobe. It is most known for its role in primary
visual processing (receipt, segmentation, and integration of visual input)
and secondary visual processing (analysis and discrimination of visual
information in terms of motion, shape, and position). These functions are
necessary for the accurate and prompt completion of ADAS tasks such as
naming and word recognition.

The cuneus is also involved in reward

response, anticipation, attention, and working memory manipulations.
Thus, it contributes to higher cognitive functions involving visual
information.
The information value of the hippocampus is two times lower than
that of the total middle temporal lobe. The hippocampus is a complex brain
region crucial to semantic, episodic, and spatial memory, learning, and
language comprehension and production.

A decrease in hippocampal

volumes is strongly associated with worse ADAS scores. To accomplish
pattern recognition and memory encoding tasks of ADAS-cog, the
hippocampus acquires an input from the entorhinal cortex. It is better to
combine the volumetric analysis of these substructures that comprise the
middle temporal lobe than to explore each of them individually.
The next information valuable structure is the putamen - a deep
brain nucleus and a component of the basal ganglia.

Through the

cortico-striato-thalamocortical neural pathways, the putamen is involved in
language learning functions and motor execution, including speech
articulation.
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Its impairment leads to hindered fluency, dysarthria with

clumsy hands and other clinical manifestations.

ADAS requires intact

motor responses, language and cognition to successfully fulfil different
tasks including constructional praxis and spoken language ability.
Therefore, the putamen is related to the ADAS-cog score.
The volumes of the frontal lobe, ventral diencephalon, entorhinal
and temporal lobe also provide information for the prediction of ADAS13,
since they contain neuro-centres for language, voluntary movement, object
and language recognition. Although the parahippocampal gyrus volume
correlates significantly with language and praxis subscale scores, it has a
relatively low information gain value in our models predicting ADAS13.
ADAS-cog in patients with MCI: The middle temporal lobe
volume is not high informative in the MCI group. Instead, each of its three
main components - the amygdala, the entorhinal cortex and the
hippocampus - achieves the highest values of the parameter. The middle
temporal lobe is composed of several structures that can disproportionately
contribute to the forecast of ADAS results. In our study, the amygdala is the
strongest predictor of ADAS13 in the MCI group. It is known for the key
role in regulating emotions and encoding memory of them. The predictive
value of the amygdala volume can be justified by the fact that emotions
impact several cognitive processes, including memory and learning. The
entorhinal cortex has the second greatest predictive gain in the performance
of the model. Working memory, spatial learning and memory are among the
functions of the entorhinal cortex. Injury to it can impact efficiency in such
ADAS-cog tasks as word recall, remembering test instructions and
orientation. The hippocampus ranks third among the best estimators in the
MCI cohort. Its contribution to learning; language comprehension and
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production; semantic, working and spatial memory makes it crucial for
fulfilling multiple ADAS tasks.
ADAS-cog in patients with dementia: In demented patients, the
volume of the middle temporal lobe and the inferior lateral ventricles are
the top predictors of ADAS13 in our models.
3.3.2.3

RAVLT
RAVLT is a powerful neuropsychological instrument for assessing

episodic memory and attention. It evaluates the ability to learn 15 words in
five immediate trials, to remember the words after an intervening
interference list, then to recall and recognize the words after a 30-minute
latency interval. RAVLT is commonly used to test cognitive abilities in
dementia and pre-dementia patients.

Figure 3.23 exhibits the rank of

different brain regions in predicting RAVLT values.
In the cognitively preserved subjects, the best predictor is WM
hypointensities. According to previous neuroimaging studies, WM damage
increases with aging and cerebrovascular disease, and is linked to episodic
memory impairment in CN older individuals [302, 303].

Age-related

episodic memory deficits are caused by network disruption because injury
to various pathways leads to the disconnection between the frontal and
temporal cortex and frontal-subcortical WM tracts. Next, the volume of the
insula is the second best estimator of the RAVLT score. The insular cortex
is a slender band of GM that is located just beneath the lateral brain surface,
connecting the temporal lobe to the inferior parietal cortex. The structure is
linked to verbal episodic memory tasks, which justifies our findings. The
putamen is the ensuing strongest predictor in CN cohorts. Although our
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understanding of the putamen’s role in cognitive functioning is still limited,
recent discoveries suggest that its damage results in poorer attention [304].
The

assumed

reason

for

this

is

its

involvement

in

the

cortico-striatal-thalamo-cortical pathway that consists of connections
between the basal ganglia, thalamus and multiple brain regions involved in
cognitive control in the prefrontal, parietal and temporal lobes. Therefore,
alterations to this region can be accountable for the impeded execution of
the three tasks in RAVLT neurofunctional test.
RAVLT in patients with MCI: The inferior lateral ventricles exceed
all analyzed brain structures in estimating RAVLT scores in the MCI cohort.
Since they reflect the temporal lobe volume, the ventricles can be used as
indicators of episodic memory and attention.
RAVLT in patients with dementia: The middle temporal lobe
outperforms all other brain areas in calculating RAVLT scores. The inferior
parietal lobe and its part - the posterior cingulate cortex - take second place
in the list of predictors. The involvement of the aforementioned structures
in episodic memory and attention helps us to explain the findings.
3.3.2.4

DSST
This is a psychomotor test that requires the participant to match

symbols to numbers according to the key at the top of the page. The DSST
is short and valid, that is why it is widely used in neuropsychology. It
assesses a variety of cognitive functions. Motor speed, working memory,
associative learning, and visuoperceptual functions are required for good
DSST performance.
The structural parameter with the most pronounced information
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gain is WM hypointensities. Lower scores in the pencil and paper DSST are
substantially correlated with a greater volume of WM lesions [305]. A
study showed a notable interaction between WM lesion and accuracy,
working memory, associative learning, psychomotor speed, attention, and
visuospatial functioning [305, 306].

The middle temporal lobe and

hippocampus have the next highest ranking. They play a crucial role in
learning coordination, working memory, attention, and spatial perception
which are essential for satisfactory performance in the DSST [307].
The next informative predictor is the fusiform gyrus - a vast
structure in the inferior temporal cortex. Its role is higher-level processing
of visual information, including identification and differentiation of objects,
word recognition, and perception. Therefore, the successful completion of
the DSST partially depends on the fusiform gyrus integrity.
The pars triangularis receives a rank equal to that of the middle
temporal lobe and hippocampus. It is challenging to justify this result since
the pars triangularis is involved in the language functions irrelevant to the
DSST. The caudate nucleus ranks lower than the pars triangularis. This is
supported by multiple studies that revealed correlations between the
decreased volumes of the caudate nucleus, reduced attention and motor
speed [211].
DSST in patients with MCI: In the MCI cohort, the choroid plexus
is the metric that provides most information for anticipating DSST scores.
It is involved in producing the CSF and certain proteins as well as
transporting solutes to the brain. The choroid plexus volume has been
reported to increase with advancing age. The supposed reasons for this are,
first, modifications in the choroid plexus microstructure or function and,
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second, ventriculomegaly [308].

These lead to dysfunction in CSF

synthesis and clearance as well as reduce the levels of anti-inflammatory
proteins. The disruption of the neuroimmune axis eventually hampers brain
homeostasis and leads to cognitive deterioration [309, 310]. Due to scarcity
of research in this topic, it is challenging to pinpoint which cognitive
domains are impaired with structural alterations to the choroid plexus.
Therefore, it is difficult to identify the DSST tasks that are affected by
change in the volume of the structure.
The brain structures that receive the next rank are the cGM and
inferior parietal lobe. The cGM is critical for all the cognitive domains
assessed by DSST. The inferior parietal cortex plays a crucial role in
auditory-spatial working memory, motor speed, attention, and visuospatial
processing. The rostral middle frontal gyrus - the fourth most informative
region - is associated with working memory and visual attention.
DSST in patients with dementia: The inferior parietal gyrus is the
highest ranking predictor in the model of DSST scores in the demented
patients.
3.3.2.5

TMT
TMT is a neuropsychological test that reflects visuospatial abilities,

information processing speed, sustained attention, motor speed, working
and rote memory. The dependent variable of the TMT shows the time spent
on taking the test. Choroid plexus volume ranks first in forecasting TMT
scores in the cognitively preserved population.

Since the role of this

structure in cognition has not been fully described, it’s challenging to
identify the tasks that are affected by structural alterations to the choroid
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plexus. The volume of WM hypointensities takes second place as a TMT
performance predictor. Since the WM lesions reduce motor and processing
speed, impair memory, visuospatial function and attention, it’s plausible
that they rank high in prognosing the test scores. The middle temporal lobe
is the next valuable structure in the list. It is involved in working memory,
attention and visuospatial perception. The lateral occipital cortex is a neural
center for visual recognition. It also has a high predictive value for the TMT
scores.
TMT in patients with MCI: In the MCI group, the inferior parietal
cortex is the strongest predictor because of its role in working memory,
attention, visuospatial processing, and motor speed.

The second best

predictor for TMT scores is the superior marginal cortex which is involved
in information processing.
TMT in patients with dementia: Finally, the inferior parietal cortex
and the GM outperform all other analysed brain regions in detecting TMT
scores among the demented patients.
3.3.3

Classification of Examinees Into Cohorts According to the Pattern of
SFA Association
We tried to classify individual findings according to the model

which describes the case best. The idea was that the ML model, when
trained on the cases of this of that group, describes a disease-specific SFA
pattern. The pattern serves as a "stamp" of the disease on which the model
was trained. Therefore, one can find the "stamp" which fits the case best.
We used Random Forest model as a regression algorithm to predict results
of cognitive tests. Then we employed the majority voting technique to
assess the performance of the multigroup classification by looking at the
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smallest absolute error in prediction between three regression models.
The highest classification accuracy is achieved with the model
trained to predict MMSE from VBM (see Figure 3.26). In the cognitively
normal cohort, the model identifies 83.91% of individuals as healthy
subjects, and a relatively small portion (14.94%) is misclassified as patients
with MCI. The true prediction rate reaches 86.96% in the MCI group. The
least accurate classification is observed in the group of the demented
patients: it misclassifies over 26% of them. This is the major limitation of
the constructed classification system.

Figure 3.26: Confusion matrix of multigroup classification based on MMSE
prediction from VBM data

The diagnostic algorithm based on ML prediction of MMSE from
SBM is almost as accurate as the previous classification (see Figure 3.27).
The percentage of misclassified cases in the normal cohort is slightly
higher. Still, none of the cognitively preserved individuals are misclassified
as demented. When VBM and SBM predictors are used in combination, the
performance does not increase (see Figure 3.28). Unexpectedly, the true
predictive rate drops to 79.31% and 72.07% for the cognitively normal and
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demented population respectively. The inclusion of SBM predictors to the
model does not boost the accuracy.

Figure 3.27: Confusion matrix of multigroup classification based on MMSE
prediction from SBM data

Figure 3.28: Confusion matrix of multigroup classification based on MMSE
prediction from SBM and VBM data

Classification based on the model trained to predict ADAS13 from
VBM detects the demented patients more accurately than the other
considered models at the level of 78.38% true prediction rate.

The

performance for the CN class is weaker in all the models predicting
ADAS13.
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Figure 3.29: Confusion matrix of multigroup classification based on MMSE, ADAS
and RAVLT prediction from VBM data

Figure 3.30: Confusion matrix of multigroup classification based on MMSE, ADAS
and RAVLT prediction from SBM data

The application of the majority voting technique to models
predicting results in MMSE, ADAS and RAVLT improved the classification
performance (see Figures 3.29-3.31). We observed the highest classification
performance of the algorithm trained on SBM data for the CN group
(TPR=91.95%, see Figure 3.30). The accuracy of identifying MCI was
83.33%. The model trained on VBM data showed the best performance for
dementia cases (TPR=80.18%, see Figure 3.29).
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Figure 3.31: Confusion matrix of multigroup classification based on MMSE, ADAS
and RAVLT prediction from SBM and VBM data

3.4

3.4.1

Deviation From Model of Normal Aging: Application of Deep
Learning to Structural MRI and Cognitive Scores
Association of Cognitive Tests and Structural Data
The structural data are presented in terms of percentage of the

volume of a specific brain area to the total intracranial volume. There are
significant differences among the studied cohorts in the structures most
vulnerable to change in ND (see Table 3.9). The data reveal shrinkage of
the brain parts (the hippocampus, entorhinal cortex, fusiform gyrus, medial
temporal lobe) and enlargement of the ventricles in accelerated aging. No
significant differences in age among CN, MCI and AD groups was detected
(p = 0.1109).
In the MCI cohort, the ADAS-cog score is negatively associated
with the major part of the analyzed relative volumes. The exception is the
relative volume of WM and its lesions, CSF and caudate nucleus. The
association of performance in ADAS-cog with the relative volume of
caudate nucleus is almost significant (p = 0.061). The portion of TIV
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occupied by WM lesions does not correlate with ADAS-cog scores in this
group (r = 0.03; p = 0.38). WM lesions are a typical sign of brain aging.
They result from chronic small vessel disease and can be seen well as foci
or areas hypointensive on T1-weighted images and hyperintensive on
T2-weighted images including FLAIR. There are different patterns of the
emergence of the WM lesions in MCI and AD groups.

Table 3.9: Demographics, cognitive performance and volumes of brain parts in
studied groups
Total
N= 1302

CN
287(22.04%)

MCI
646(49.62%)

Dementia
369(28.34%)

p-value

Age
Gender

75.74[71.7-80.7]

76.62 ± 5.62

75.25 ± 7.16

75.93 ± 7.37

0.0933785
4.19707e-06

Female
Male
Education, years
Ethnicity
White
Black
Asian
Indian/Alaskan
More than one
Marital status
Married
Never married
Divorced
Widowed
Unknown

522(40.09%)
780(59.91%)
15.58[13.0-18.0]

134(46.69%)
153(53.31%)
16.13 ± 2.91

215(33.28%)
431(66.72%)
15.76 ± 2.99

173(46.88%)
196(53.12%)
14.85 ± 3.21*

1210(92.93%)
60(4.61%)
30(2.3%)
1(0.08%)
1(0.08%)

261(90.94%)
21(7.32%)
5(1.74%)
0(0.0%)
0(0.0%)

603(93.34%)
22(3.41%)
19(2.94%)
1(0.15%)
1(0.15%)

346(93.77%)
17(4.61%)
6(1.63%)
0(0.0%)
0(0.0%)

1035(79.49%)
31(2.38%)
79(6.07%)
154(11.83%)
3(0.23%)

196(68.29%)
13(4.53%)
21(7.32%)
54(18.82%)
3(1.05%)

532(82.35%)
6(0.93%)
42(6.5%)
66(10.22%)
0(0.0%)

307(83.2%)
12(3.25%)
16(4.34%)
34(9.21%)
0(0.0%)

19.87[11.67-26.33]
26.18[24.0-29.0]
30.44[23.0-37.0]
36.24[27.0-45.0]
138.13[75.0-187.0]

8.73 ± 4.14
29.06 ± 1.09
43.2 ± 9.76
46.77 ± 11.06
85.03 ± 43.18

18.82 ± 6.6
26.91 ± 2.2
29.79 ± 8.86
37.37 ± 11.1
128.48 ± 72.56

30.37 ± 8.97
22.66 ± 3.03
21.67 ± 7.77
26.05 ± 12.41
200.96 ± 88.57

Cognitive tests
ADAS-cog
MMSE
RAVLT
DSST
TMT(part B)

9.08991e-08
0.198438

4.1773e-08

2.2404e-165
2.1560e-155
3.7071e-120
2.72808e-83
2.20487e-73

Morphometry
Ventricles
2.93[1.82-3.67]
2.52 ± 3.73
2.86 ± 1.35
3.37 ± 1.46
1.13635e-23
Hippocampus
0.41[0.35-0.46]
0.47 ± 0.06
0.4 ± 0.07
0.36 ± 0.07
1.93988e-65
Putamen
0.53[0.48-0.57]
0.55 ± 0.06
0.52 ± 0.06
0.51 ± 0.08
1.54782e-17
Amygdala
0.15[0.13-0.17]
0.18 ± 0.02
0.15 ± 0.03
0.14 ± 0.03
8.82095e-64
WM lesions
0.41[0.17-0.47]
0.32 ± 0.31
0.38 ± 0.38
0.54 ± 0.5
2.23640e-17
Entorhinal cortex
0.21[0.17-0.25]
0.25 ± 0.04
0.21 ± 0.05
0.18 ± 0.05
2.14294e-58
Fusiform gyrus
1.03[0.93-1.13]
1.1 ± 0.13
1.04 ± 0.14
0.95 ± 0.14
2.06811e-30
Middle temporal lobe
1.18[1.06-1.29]
1.28 ± 0.13
1.18 ± 0.16
1.07 ± 0.15
8.55332e-48
Whole brain 63.19[60.16-65.83] 65.51 ± 4.54
63.29 ± 3.92
61.21 ± 3.89
1.84928e-36
P-value is marked in bold if difference among groups is statistically significant (p < 0.05).
Structural features are reported in % to TIV. Statistical data are expressed as IQR, Mean ± SD, or the absolute
number of cases and their percentage in studied cohort.
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The functional data in ADNI1 are obtained with cognitive tests
such as MMSE, ADAS-cog (ADASQ4 , ADAS11 , ADAS13 ), DSST, TMT (part
B), and RAVLT (RAV LTimmediate , RAV LTlearning , RAV LT f orgetting ) [178]. The
association between the major marker of brain atrophy - CSF% - and
performance in ADAS-cog tests is stronger for ADAS13 (r = 0.18;
p < 0.05) than for ADASQ4 (r = 0.15; p < 0.05) and ADAS11 (r = 0.15;
p < 0.05). This goes in line with a research which evidenced a more
pronounced annual decline in ADAS13 than in ADAS11 in AD patients [311].
Similarly, the association of CSF% score with RAV LTimmediate is stronger
than with RAV LTlearning and RAV LT f orgetting scores (r = −0.19 vs −0.10
and 0.12; p < 0.05). Other authors also showed that the accuracy of the
model predicting RAVLT scores from GM density is higher for
RAV LTimmediate score than for RAV LT f orgetting [312]. Therefore, we used
ADAS13 and RAV LTimmediate in this study.

Figure 3.32 shows the

associations of the test results with age and structural data.
SFA: ADAS-cog and MMSE are primary cognitive tests required
in all recent Food and Drug Administration clinical drug trials for AD in
the USA [313]. From our data, the results in ADAS-cog and RAVLT have
the strongest association with the structural markers of brain atrophy in the
CN group. For instance, the coefficient of correlation between hippocampal
volume and ADAS13 score is −0.18 in the CN cohort, −0.34 in patients with
MCI, and −0.20 in the AD group. The same coefficient in RAV LTimmediate is
0.13, 0.24, and 0.18 in the correspondent cohorts (see Figure 3.32).
In our study the structural markers of brain aging demonstrate a
stronger correlation with the results in ADAS-cog than in the other tests.
Other authors also justified the informative value of ADAS-cog by
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predicting its score with a regression model from morphometric features
[314, 137]. We found an obvious correlation of the MMSE score with the
hippocampal volume (r = 0.44; p = 7.25e − 86). This goes in line with
another study that showed their close association (r = 0.51; p < 0.001)
[165].

Figure 3.32: Associations of results in cognitive tests with age, functional and
structural features in healthy cohort (a), patients with MCI (b) and AD (c).
Association is reported in terms of Pearson’s correlation coefficient. Cross-mark
overlays non-significant relationships between features (p > 0.05).

The results we received suggest the presence of different SFA in
healthy aging and ND. For instance, the proportion of WM lesions to TIV
does not show a linear association with ADAS-cog score in subjects
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diagnosed with MCI. In contrast to this, the relationship is strong in AD
patients (r = 0.22; p = 2.61e − 05). Other authors showed that WM lesions
enlarged with age and with the development of dementia [315, 146]. It
remains unclear why the emergence of WM lesions has a common pattern
in the CN adults and patients with AD.
We

reported

a

prominent

relationship

between

cognitive

functioning and the volumes of the hippocampus, amygdala, entorhinal
cortex, and middle temporal lobe.

Other studies also justified the

importance of the hippocampal area, amygdala and the middle temporal
lobe for intellectual activities [316, 317, 318, 319, 320, 321, 322, 323, 324].
3.4.2

Proposed Marker of Disease-Related Cognitive Decline
When applied to distinct cognitive test scores, the proposed 3D

CNN model shows the best prediction performance in the CN cohort. The
worst performance is monitored in the AD group. Data-blending does not
boost the performance considerably, i.e., there is no evident advantage in
using several image reconstructions. In contrast to this, the model-blending
approach shows the top accuracy. It allows us to retrieve maximum data for
assessing SFA (see Figure 3.33). The variability of the results in the studied
cohorts is most apparent in ADAS-cog and MMSE tests and less evident in
RAVLT, DSST, and TMT. The distribution of MAE differs significantly
among the cohorts (see Table 3.10). This justifies that cognitively-normal
people and patients with NDs have different SFA patterns, which can aid to
diagnostics of MCI and AD.
Some authors found marked correlations between the predicted and
actual scores in MMSE (r = 0.44; p < 0.0001) and ADAS-cog tests
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(r = 0.57; p < 0.0001) [136, 137]. We also observed a significant linear
association between the predicted and actual values in the combined group
of the CN subjects, MCI, and AD patients (MMSE r = 0.09, p = 2.28e − 4;
ADAS r = 0.05, p = 2.87e − 2; RAVLT r = 0.11, p = 2.24e − 05; TMT
r = 0.22, p = 2.34e − 18). We recorded conflicting findings (a
non-correlation) in the CN group due to distinct study design. Stonington
et. al [136] trained the model on three cohorts (CN, MCI, and AD), while
we fed the predictive model exceptionally with the CN cases.

Other

researchers managed to predict MMSE results from fMRI data accurately
[135].
Table 3.10: Mean absolute error of voting regression ensemble model trained on
structural brain images averaged along axial, coronal and sagittal axes
CN group
Mean ± SD
95%CI
MMSE
ADAS-cog
RAVLT
TMT(part B)
DSST

0.84 ± 0.73
3.44 ± 2.42
7.94 ± 5.86
29.67 ± 31.42
8.67 ± 7.0

MCI group
Mean ± SD
95%CI

[0.75 - 0.92]
[3.16 - 3.72]
[7.26 - 8.62]
[26.03 - 33.31]
[7.86 - 9.48]

2.38 ± 2.08
10.29 ± 6.15
14.63 ± 7.21
55.74 ± 62.73
11.93 ± 8.51

[2.23 - 2.54]
[9.82 - 10.77]
[14.07 - 15.18]
[50.9 - 60.58]
[11.27 - 12.58]

AD group
Mean ± SD
95%CI
6.46 ± 3.04
21.56 ± 8.94
21.78 ± 7.84
120.08 ± 79.28
21.26 ± 11.73

p-value

[6.15 - 6.77]
[20.64 - 22.47]
[20.98 - 22.58]
[111.98 - 128.18
[20.06 - 22.45]

4.8422e-142
4.3343e-150
1.08195e-91
8.91918e-53
3.51058e-54

Table 3.11: Performance of models trained on cognitively preserved population and
tested on three different cohorts (MAE)

Data
Axial(A)
Coronal (C)
Sagittal (S)
3D
VR(C+S)
VR(A+C)
VR(A+S)
VR(A+C+S)
MB(A+C+S)

Method

CN

CNN
CNN
CNN
3DCNN
ensemble
ensemble
ensemble
ensemble
CNN+LR

1.12
1.09
1.17
0.95
1.13
1.11
1.15
1.13
0.84

MMSE
MCI AD
2.54
2.5
2.46
2.25
2.48
2.52
2.5
2.5
2.38

6.54
6.08
6.37
4.09
6.23
6.31
6.45
6.33
6.46

CN
5.74
3.69
3.56
3.52
3.63
4.72
4.65
4.33
3.44

ADAS-cog
MCI
AD
10.54
12.51
10.89
10.96
11.7
11.53
10.72
11.32
10.29

21.95
24.19
22.15
22.33
23.17
23.07
22.05
22.76
21.56

CN

RAVLT
MCI

8.74
8.4
9.9
7.24
9.15
8.57
9.32
9.02
7.94

14.41
12.84
14.31
11.25
13.58
13.63
14.36
13.85
14.63

AD
21.4
19.42
21.18
17.4
20.3
20.41
21.29
20.67
21.78

CN
44.39
47.09
47.6
25.06
47.34
45.74
46.0
46.36
29.67

TMT(part B)
MCI
AD
109.44
114.97
58.08
65.14
86.52
112.21
83.76
94.16
55.74

183.62
189.33
123.65
136.02
156.49
186.47
153.64
165.54
120.08

CN

DSST
MCI

9.5
9.06
9.51
8.21
9.28
9.28
9.51
9.36
8.67

12.39
11.34
11.84
9.56
11.59
11.86
12.11
11.85
11.93

AD
20.8
18.3
20.24
16.65
19.27
19.55
20.52
19.78
21.26

A, S and C correspond to skull stripped images averaged along appropriate axis; VR - Voting Regression meta-estimator;
MB - Model Blending; LR - Linear Regression; RR - Ridge Regression.

The calculation of cognitive scores is more precise from the
radiomics data than from the images (see Table 3.11). The first reason for
135

this is the noise of the 2D images averaged along axes. The second reason is
the relatively low number of cases used for training the deep learning
model. The high-dimensional computational model needs a larger number
of training samples because of the dimensionally cursed phenomena [325].
The idea of using the deviation between the model and actual
values is not new for diagnostics. There is a large body of evidence that the
difference between the computed and actual age - biological age gap - is a
reliable marker of dementia [326, 327, 328].

A study suggested an

association between the gap and cognitive performance. It also reported that
BAG is related to worsening in performance on the DSST and TMT tests
[329]. We applied the same idea to prediction of cognitive performance.

Figure 3.33: Distribution of deviation from model of normal aging among study
cohorts

3.4.3

Justification of DMNA as Marker of Dementia
Diagnosing from DMNA values is most accurate with Random

Forest classifier jointly trained on DMNA MMSE and DMNA ADAS-cog
(see Table 3.10, Figures 3.34 and 3.35).

The performance of the

CN-versus-AD classification model (AUC = 1.0) is comparable to the
accuracy of state-of-the-art models trained on ADNI dataset (see
Table 3.12). From the table, DMNA can accurately distinguish CN subjects
from MCI patients (AUC = 0.9957).
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We also achieved creditable

performance in the MCI-versus-AD classification (AUC = 0.9793).
Therefore, DMNA can be potentially used as a marker of dementia and can
help to identify the disease.

Figure 3.34: Performance of Random Forest model classifying cases into healthy
and AD groups. DMNA values are input to the model

Figure 3.35: Performance of Random Forest model classifying cases into CN and
MCI cohorts (a); patients with MCI and AD (b). DMNA values are input to model
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Table 3.12: Classification model performance reported in recent studies
Reference, Year

Gupta [151],2013
Payan [152],2015
Ahmed [149], 2015
Khedher [150], 2015
Suk [170], 2016
Korolev [157], 2017
Cui [156], 2018
Billones [160], 2017
Altaf [148], 2018
Lee [153], 2019
Basaia [158], 2019
Fang [174], 2019
Liu [155], 2020
Wang [159], 2020
Proposed

CN vs AD
BAC
AUC

Dataset
(CN+MCI+AD)

Sens

Spec

232+411+200
755 +755+755
251+299+347
229+401+188
52+99+51
61+120+50
223+396+192
300+300+300
90+105+92
229+398+192
352+763+294
101+204+93
119+233+97
315+297+221
287+646+369

0.9524
0.804
0.9127
0.92
0.9063
0.9889
1.0
0.9632
0.989
0.9826
0.866
0.987
1.0

0.9426
0.882
0.8511
0.98
0.9372
0.9778
0.9565
0.9778
0.995
0.983
0.908
1.0

0.9475
0.843
0.8819
0.95
0.92175
0.9834
0.97825
0.9705
0.992
0.9828
0.887
1.0

0.8
0.9695
0.925
1.0

Acc

Sens

Spec

0.9474
0.9547
0.8377
0.8849
0.9509
0.89
0.9229
0.9833
0.978
0.9874
0.992
0.9858
0.889
0.9883
1.0

0.8407
0.4902
0.8865
0.505
0.9
0.75
0.836
0.8922

0.9211
0.7515
0.8541
0.9267
0.9778
0.9429
0.883
0.9067
0.9428

0.9245
0.8969

MCI vs AD
BAC
AUC

0.8809
0.62085
0.8703
0.7159
0.9389
0.84645
0.8595
0.89945
0.9199

0.66
0.9793

Acc

Sens

Spec

0.881
0.8684
0.6208
0.8703
0.7415
0.64
0.9389
0.853
0.859
0.8998
0.9361
0.9261

0.9223
0.6252
0.8216
0.9389
0.7727
0.9111
0.9
0.873
0.8633
0.795
0.9834
0.9756

0.8145
0.748
0.8162
0.5367
0.6996
0.9222
0.9333
0.865
0.9188
0.698
0.9876

CN vs MCI
BAC
AUC

0.8684
0.6866
0.8189
0.7378
0.73615
0.9167
0.9167
0.869
0.89105
0.7465
0.9816

0.67
0.777
0.775
0.9957

Acc

0.8635
0.9211
0.6945
0.8189
0.8011
0.63
0.7464
0.9167
0.918
0.871
0.8893
0.762
0.9842
0.9839

To use the proposed approach in clinics we assessed the possible
threshold values of DMNA markers. We undertake sequential values of
DMNA and calculated the accuracy of binary classification tasks (CN vs
MCI, MCI vs AD). Table 3.13 lists the thresholds of DMNA markers in the
binary classification models.

The optimal performance is noted on

ADAS-cog scores. It allowed us to distinguish normal aging from MCI and
the latter from AD with a high-level accuracy (above 90%).
Table 3.13: Threshold values of the DMNA markers in binary classification

Cognitive test

CN vs MCI
Threshold Accuracy

MCI vs AD
Threshold Accuracy

MMSE
1.0298
0.7889
4.2011
0.9153
ADAS-cog
5.0856
0.9068
18.1063
0.9172
6.2389
0.7921
18.1036
0.7862
RAVLT
TMT(part B)
37.8308
0.8435
146.1889
0.8079
DSST
1.8726
0.7085
15.747
0.802
*Threshold values are expressed as absolute values of DMNA

Many papers reported a high accuracy of the models that classify
healthy and demented subjects [148, 149, 151, 152, 155, 156, 158, 159]. All
the deep learning models were trained on pre-processed MRI images of the
cognitively preserved and those with cognitive deterioration. In contrast to
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the studies, we trained the model exclusively on CN people.
From our data, the predictive power of an SFA model depends on
the complexity of the cognitive test used for its training. The accuracy is
higher for the tests covering several cognitive domains (MMSE, ADAS,
TMT vs information processing in DSST, memory in RAVLT). This
supports the results of a study by Stonnington et al. [136]. We report that
the model classifying MCI and AD patients has the lowest accuracy (Acc =
0.9261).

Recently different authors received the same results

[148, 151, 170, 174].
A limitation of the current research is that we did not study
convertible and non-convertible to AD MCI cases separately, although some
researchers suggest this [158].

Advances in DL technology allowed

neuroscientists to improve the classification accuracy of CN-versus-MCI
and MCI-versus-AD models [159].

However, the models were biased

because of the data leakage related to the late split [330]. Thus, substantial
work is required to use such algorithms as a diagnostic tool.
3.4.4

Prediction of Progressive MCI. Differentiation Between Alzheimer’s
Disease and Other Neurodegenerative Diseases
Table 3.14 shows the sensitivity and specificity of the conventional

model that classifies MCI cases into stable and progressive ones. As seen
from the table, there is no considerable difference in DMNA values
between the groups (p=0.16÷0.21).

Though the balanced accuracy of

binary classification is above 80%, low specificity can be considered as a
strong limitation of the models. We also identified the difference in DMNA
between demented individuals with A+ and A– subjects (see Table 3.15).
Only in the MMSE test the distinction in DMNA is considerable
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(6.27 ± 1.82 vs 5.32 ± 1.9; p < 0.05). At the same time, there is no
difference between A+ and A– patients with MCI (p = 0.75 − 0.98).
Table 3.14: Performance of binary classification model to distinguish between stable
and progressive MCI

MMSE 2.19[1.15-2.94]
ADAS 11.1[8.32-13.63]
MMSE + ADAS

stable MCI
(N = 114)
2.21 ± 1.41
11.16 ± 4.02

DMNA
progressive MCI
(N = 518)
2.09 ± 1.3
10.82 ± 3.79

stable vs progressive MCI
p

Sens

Spec

BAC

AUC

Acc

0.21
0.16

0.95
0.96
0.96

0.71
0.75
0.67

0.83
0.855
0.815

0.8547
0.8605
0.9475

0.82
0.85
0.81

Table 3.15: Absolute values of DMNA according to A/T/N classification system
Test
MCI

MMSE
ADAS

Dementia

MMSE
ADAS

A-T-N-

A-T-N+

A-T+N-

A-T+N+

MCI due to other pathology (N = 95)
2.29 ±.141
11.22 ± 3.85
Non-Alzheimer’s disease dementia (N = 43)
6.27 ± 1.82
23.87 ± 5.42

A+T-N-

A+T-N+

A+T+N-

A+T+N+

MCI due to accumulation of β amyloid (N = 26)
2.23 ± 1.12
11.47 ± 3.45
Dementia due to Alzheimer’s disease (N = 17)
5.32 ± 1.9
21.17 ± 4.81

p-value
0.98
0.75
p<0.05
0.1

From our data, DMNA cannot be recommended as a tool for
predicting the conversion of MCI to dementia because of its low specificity
(up to 75%). Other existing CSF markers of progressive MCI also do not
ensure the necessary level of prediction: mean diffusivity (average accuracy
of 77%), τ-protein concentration (74%), volumetry data retrieved from the
brain MRI (66%) [331]. There is a considerable difference in DMNA
between demented individuals with Alzheimer’s continuum (A+) and those
with either normal AD biomarkers or non-AD pathologic change (A–).
Hence, the proposed marker can be potentially used for distinguishing
between dementia due to AD and non-AD. To find and justify a reliable
threshold level, further research is required. We failed to identify a strong
distinction between MCI due to the accumulation of β -amyloid and because
of other pathologies (p > 0.05).
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From our data, the biomarker is not

applicable for discriminating MCI cases by underlying pathology (AD vs
non-AD).
Strengths and limitations of DMNA: There is no agreement between
researchers on which non-invasive diagnostic modality is more promising for
screening purposes. The strength of our study is that we chose to focus on
multimodal diagnostics to benefit from both types of data. A limitation of
the current research is that we did not study convertible and non-convertible
to AD MCI cases separately, although some researchers suggest this [158].
DMNA as a prognostic criterium of progressive MCI has strong limitation.
Both the proposed and the existing markers of progressive MCI do not ensure
the necessary level of prediction.
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Chapter 4: Conclusion
1.a. We propose estimates of disproportional changes in cognitive
functions to extend the applicability of ML classification in cognitive
studies (ISD, ISDA, and ISCA). The distribution of the indices and RMO
test values over time shows that different cognitive functions degrade at the
same rate throughout life. The RT variable of the battery of PTs we utilized
was less stable than the major dependent variable of the ISD, ISDA, and
ISCA values throughout lifespan. The indicators preserve fairly constant
values after neurodevelopment and maturation, with a modest trend toward
functional deterioration.

Further research is required to determine the

ratios’ value in distinguishing between normal and accelerated brain aging.
1.b. The optimal number of homogenous age groups, according to
unsupervised ML clustering, is four.

Starting at birth, we divided the

research participants into 20-year age groups: Adolescents aged below 20,
Young adults aged 20 to 40, Midlife adults aged 40 to 60, and Older adults
aged above 60.
1.c. The ISCA index for PT reflects the overall status of an
examinee. We forecasted ISCA values from the results of PTs with high
performance metrics (MAE to range of index values is 3.49 ± 0.14% vs
7.57 ± 0.55% for ISDA and 7.62 ± 0.5% for ISD; p < 0.05). Proportional
age-related developments can be observed in temporal estimates of
information processing speed and inhibitory control in task switching in
normal brain aging.
2.a. WM changes almost linearly throughout life, as does the
percentage of WMHs to total WM. Total GM and its cortical part exhibit
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varied age-related alteration patterns.

The linear slowdown in

decision-making across the lifespan could be explained by a widening of
the interhemispheric fissure. Response inhibition is largely controlled by
the premotor areas of the frontal lobe’s medial wall. The expansion of the
interhemispheric fissure is due to the atrophy of these brain regions.
2.b. Following the presentation of WM brain volume as a
second-degree function of age, the effects can be seen as a U-shaped or
inverted parabola curve.

The inverted parabola indicates that the WM

bundles are changing. The U-shaped line represents GM volume variation
and the structures that penetrate into patches of neuronal cells. It is not
possible to interpret a climb in the second-order curve as irreversible GM
atrophy in advanced age.

As a result, the third-order function of age

matches the data better than the second-order function in terms of GM
nuclei volume.
2.c. There is a strong association of total CSF volume (CSF%) and
RT in the IRT (IRT _mean), which is the most cognitively demanding activity
in our battery (r = 0.36, p < 0.05). It represents the best link between brain
anatomical data and functional outcomes. Switching and inhibitory control,
information processing, and attention are among the cognitive domains and
subdomains tested in this study. The relative volumes of the CSF and GM are
strongly positively correlated with decision-making time, which represents
switching and inhibitory control. The accuracy of the PTs we utilized is
supported by these findings.
3.a. In the healthy population, global cognitive functioning changes
slightly with age. It also remains stable across the disease course. Though
there are patients with reversible or progressive MCI, the real number of
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such cases is quite low. RAVLT scores test are quite stable throughout life
in normal aging and across the disease course with a slight trend towards
lowering in all the study groups. The pace of neurocognitive slowing was
moderately higher in the CN group and MCI patients. Thus, the average
result for all the groups would reach a common value if the observation
lasted several more decades. There are clear signs of malfunctioning in
several cognitive domains assessed with DSST and TMT and the
performance worsens within time. For this reason, the trendlines of test
performance among the CN, MCI, and AD groups converge at the
approximated point of 100 years of age.
3.b. We constructed regression models predicting functional
performance in cognitive tests from brain radiomics. The vulnerability of
distinct neuronal cells to atrophy in accelerated aging differs among distinct
cell groups and brain regions. Logically, the SFA has features specific to the
pathology. The feature selection technique allows us to identify the most
informative structural neuroimaging measures. The models reflect SFA
patterns unique for each study cohort. We analyzed the SFA patterns in the
demented patients of ADNI dataset. As AD accounts for the majority of
dementia cases, we pointed out the structures vulnerable for change in
β -amyloidopathy. Other NDs selectively damage certain neuronal cells and
brain regions, which results in another SFA pattern.
3.c. We classified examinees with the majority voting technique.
According to the pattern of SFA association we distinguished three cohorts:
the cognitively normal elderly, patients with MCI and dementia patients.
The highest accuracy was achieved with the model trained to predict
MMSE from voxel-based morphometry data. In the cognitively normal
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cohort, the model identified 85.06% of individuals as healthy subjects, and
a relatively small portion (14.94%) is misclassified as patients with MCI.
The true prediction rate reached 81.30% in the MCI group. The major
limitation of the constructed classification system was the least accurate
classification of the demented patients (73% accuracy). The classification
based on the model trained to predict ADAS13 from VBM detected
demented patients more accurately than the other considered models
(78.38% true prediction rate).
4.a. There is a strong association between the brain structure of a
subject and their performance in cognitive tests. However, the patterns of
the SFA differ among cognitively preserved people, patients with MCI and
dementia patients. For instance, the coefficient of correlation between the
hippocampal volume and ADAS13 score is −0.18 in the CN cohort, −0.34
in patients with MCI, and −0.20 in the AD group. The same coefficient in
RAV LTimmediate is 0.13, 0.24, and 0.18 in the correspondent cohorts.
4.b. To work out a new marker of neurodegeneration, we predict the
cognitive status of the cognitively preserved examinees from the brain MRI
data. This is an SFA model of normal aging. A big deviation from the model
of normal aging suggests a high risk of accelerated cognitive decline, i.e., a
high level of the error of cognitive score prediction should rise awareness of
a ND.
4.c. The results in the tests reflecting global cognitive functioning ADAS-cog and RAVLT - had the strongest association with the structural
markers of brain atrophy. In line with this, the variability of the deviation
from the model of normal aging in the cognitively preserved subjects, and
patients with MCI and dementia was most apparent in the ADAS-cog and
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MMSE tests and less evident in the tests covering several cognitive
subdomains, namely RAVLT, DSST, and TMT. Diagnosing dementia from
DMNA values is most accurate with a Random Forest classifier jointly
trained on DMNA MMSE and DMNA ADAS-cog. DMNA can accurately
distinguish CN subjects from MCI patients (AUC = 0.9957). We also
achieved a creditable performance in the MCI-versus-AD classification
(AUC = 0.9793). Therefore, DMNA has potential for use as a marker of
dementia and can help to identify the disease.
4.d. There is no marked difference in DMNA values between stable
and progressive MCI cases. DMNA as a prognostic criterium of progressive
MCI has strong limitations. Both the proposed and the existing markers
of progressive MCI do not ensure the necessary level of prediction. The
proposed marker has potential for use in differentiating dementia due to AD
from that not due to AD. We identified a considerable difference in DMNA in
the MMSE test between demented individuals with (A+) and (A–) according
to the ATN-classification (6.27 ± 1.82 vs 5.32 ± 1.9; p < 0.05). To find
and justify a reliable threshold level, further research is required.
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Appendices
Appendix A: Definitions

Cognition is the mental processes involved in gaining knowledge
and comprehension. These cognitive processes include thinking, knowing,
remembering, judging, perceiving, recognizing, conceiving, reasoning and
problem-solving.
Cognitive domains are the domains of cognitive function. They are
hierarchical.

The bottom of the cognitive construct is responsible for

information input and refers to basic sensory and perceptual processes. The
top of the construct is higher-order cognitive functioning. It maintains
information processing that involves synthesis, accumulation, and retrieval
from memory storage. The functions enable goal-driven behavior in an
individual.

The top-level elements are executive functioning (EF) and

cognitive control. The domains are cross-dependent with the prevalence of
top-down versus bottom-up regulation.

Broadly speaking, EF also

encompasses cognitive control and exerts control over the use of more basic
cognitive processes. Cognitive domains can be classified into memory,
attention, language, and EF (e.g., reasoning and problem solving). EF is
further classified into inhibition, task switching, working memory updating,
and information speed processing, which are EF domains, or alternatively,
cognitive subdomains.
Neuropathology is the study of disease of nervous system tissue,
usually in the form of either small surgical biopsies or whole-body autopsies.
Gray matter (GM) is a major component of the central nervous
system. It contains most of the brain’s neuronal cell bodies, specifically
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unmyelinated neurons. It is present in the brain, brainstem and cerebellum,
and present throughout the spinal cord. GM includes regions of the brain
involved in muscle control, and sensory perception such as seeing and
hearing, memory, emotions, speech, decision making, and self-control.
White matter (WM) is an part of the central nervous system. It
mainly made up of myelinated axons.

White matter is composed of

bundles, which connect various GM regions of the brain to each other. WM
is responsible for the transmission of the nerve impulses between neurons.
Brain atrophy refers to a loss of brain cells or a loss in the number
of connections between brain cells. Brain atrophy is a morphological basis
of both aging and Neurodegenerative disorders.
Neurodegenerative disorder is incurable condition that result in
death of neurons and a progressive deterioration, i.e. dementia.
Dementia is a syndrome in which there is a disturbance of higher
mental function, such as reasoning, planning, judgment, and memorization.
Dementia is one of the major causes of disability and dependency among
older people worldwide.
Alzheimer’s disease is the most common form of dementia and it
may contribute to 60–70% of cases.
Mild cognitive impairment

causes a slight but noticeable and

measurable decline in cognitive abilities, including memory and thinking
skills. It can be defined as the transition period from normal aging process
to AD or another type of dementia.
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Appendix B: Evaluation measures

The set of methods we proposed in this research work (e.g. deep
machine learning, computer vision, etc.)

are known to be effective

techniques for improving the current diagnostic approaches. In this case, we
will consider the performance of the proposed models are satisfactory if the
specificity and sensitivity of the classification models are higher than 85%
and the fraction of the MAE over the range of the predicted feature is less
than 10% based on the regression models.
Mean Absolute Error is used to assess the quality of the regression
model. It is a measure of absolute difference between two continuous
variables, which gives a clear understanding of the error between actual and
predicted values for medical decision making community. Considering this
evaluation metric, the MAE is calculated as follow:

MAE(y, ŷ) =

1 N
∑ |yi − ŷi |
N i=1

where yi , ŷi are actual and predicted values of dependent variable
respectively, i = 1, N, N - number of samples.
To assess the quality of the classification models we use sensitivity,
specificity, ROC AUC, accuracy and balanced accuracy metrics.

The

confusion or error matrix is built for each predictive model to show how it
can distinguish between classes.
Receiver Operating Characteristic (ROC) curve and its Area Under
the Curve (AUC) are used for performance evaluation of the classifiers and
memorization of the trade-off between true positive rate (TPR) and false
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positive rate (FPR) using different probability thresholds.
Sensitivity is true positive rate. It refers to an ability of a model to
identify an individual with disease as positive.
Specificity is true negative rate. It refers to an ability of a model to
identify a subject who does not have a disease as negative.

T PR(sensitivity) =

TP
T P + FN

(4.1)

T NR(speci f icity) =

TN
T N + FP

(4.2)

BAC(Balanced Accuracy) =

Sensitivity + Speci f icity
2

(4.3)

The overall accuracy of the model is defined as:

Accuracy =

TP+TN
T P + T N + FP + FN

(4.4)

where T P, T N, FP, FN are the true positive, true negative, false positive and
false negative values representing the confusion matrix of classification
model respectively.
All models are trained using k-fold cross-validation technique. The
metrics are calculated for each fold separately and then averaged values are
used as final measure.
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Appendix C: Development of a CAD System for NDs Diagnosis
The automatic assessment and interpretation of the results of the
brain MRI findings may help doctors to provide a better diagnosis of NDs.
Such tools may serve as an objective quantitative measurement of ND.
CAD may accurately predict the state of the disease and its outcomes.
There are plenty of algorithms available to analyze neuroimaging, however,
they require a heterogeneous collection of specialized applications. There is
no transparent way to incorporate results into one pipeline. The majority of
the existing tools use and assess morphometry features extracted from MRI
such as subcortical volume measurements. Morphometry features may be
extracted from the structural MRI images utilising e.g., the Computational
Anatomy Toolbox CAT12 for SPM [332], FreeSurfer[191], lesion
prediction algorithm (LPA) [333] just to name a few. There are also a few
proprietary solutions [334, 335, 336, 337] related to the assessment of the
MRI images. All the mentioned solutions may help physicians to evaluate
the level of cognitive impairments and memory loss indirectly. However,
NDs are diagnosed with the help of cognitive assessments and this aspect
should be taken in consideration. The incorporation of such tests into the
pipeline of diagnosis may significantly i mprove t he v alue o f s uch CAD
systems. The literature search for existing CAD systems that allow using
cognitive tests results in their pipeline, revealed only one tool [335]. The
cNeuro combines findings from brain MRI T1w and FLAIR modalities with
results of cognitive tests. Its use is limited to the subscribed users only.
The availability of a tool that provides multi-modal analysis of
findings is desired. The overall diagnosis process may be improved if online
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cognitive tests and quantitative and qualitative analysis of the MRI findings
can be incorporated in one pipeline. A comprehensive view of the patients’
data will reduce the burden on the doctors. Such a data blending approach
implemented in the CAD system will lead to more powerful solutions for
healthcare professionals. The strengths and limitations of the available
CAD systems are summarized in Table A1.
The development of the proposed CAD consists of three tasks:
• Design and implement of algorithms to visualize the areas of the brain
which is affected by ND.
• Compose and deploy online version of psychophisiological and
cognitive tests.
• Develop a predictive model to prognosticate the potential diagnosis of
the ND.
The high-level pipeline of the proposed tool is described in
Figure A1 and Figure A2. To solve the first task we will segment brain
areas and highlight the structure with different color similar to Figure A3.
Then we will look at the deviation of the brain structures volumes from
normal aging assessed on our in-house dataset.

These deviations may

indicate an accelerated ageing.
To assess the separability measures between two groups and predict
the final diagnosis we will conduct few steps. We propose to use a similarity
measure by conducting the t-test and finding if there is significant differences
between groups. This will allow us to show the potential of the reviewed
attribute to be used as marker of the disease.
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Online

Stand-alone app

Prediction

Segmentation

Product

Cognitive tests

Table A1: Strengths and limitations of CAD systems to assist doctors in diagnosis of NDs

FAST, FSL[338]

✓

✓

CAT12, SPM [332]

✓

✓

Strengths

+ Segments a 3D image of the brain into
different tissue types (GM, WM, CSF, etc.)
+ It is robust and reliable
+ Compared to most finite mixture
model-based methods + Tissue volume quantification
+ Voxel-wise estimation of the local amount or
volume of a specific tissue compartment
+ Applied to investigate the local distribution of grey matter
+ Permits to use gyrification indices that measure surface
complexity in 3D
+Allows to estimate the cortical thickness

recon-all, FreeSurfer[191]

✓

✓

+ Segmentation and parcelation of brain regions
+ FS uses geometry to do inter-subject registration
+ Much better matching of homologous cortical regions
than VBM techniques
+ FS allows you to look at thickness and surface area

LST, SPM [333]

✓

✓

+ Segments T2 hyperintense lesions in FLAIR images
+ Proven to be useful for the segmentation of brain lesions
in the context of Alzheimer’s disease

Diadem, Brainminer [334]

✓
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✓

✓

✓

cNeuro,Combinostics [335]

✓

✓

✓

✓

Neuroreader, Brainreader[339]

✓

✓

✓

✓

NeuroQuant[337]

✓

✓

✓

✓

Proposed

✓

✓

✓

✓

✓

+ Developed to aid in diagnosis of dementia
+ Can be embedded in the clinical workflow
(Connects directly to the hospital PACS)
+ Automatically detects new MR scans that are suitable
for processing
+ Helps in early diagnosis of neurodegenerative diseases
+Quantitative assessment of brain images for providing
clinical decision support in neurological disorders
+ Cognitive assessment is incorporated into the tool
+ Statistical comparison with a large reference database
cognitively normal subjects
+ Fast processing time
+ Fits into clinical workflows with full PACS integration
+ Includes list of all the structures showing
abnormal volumes
+ Automatic image segmentation from radiographic images
+ Fits into clinical workflows with full PACS integration
+ Allows monitoring structure volumes and visually evaluate changes
+ Accuracy Across All Ages (3-100 y.o)
+ Automatic image segmentation from radiographic images
+ Cognitive assessment is incorporated into the tool
+ Publicly available
+ Diversified normative dataset

Limitations

- Limited number of tissues segmented
- Is not specifically developed for the NDs diagnosis
- Sensitive to noise
- Worse in matching of homologous cortical regions
comparing methods that use geometry
- Limited number of tissues segmented
- No white matter hyperintensities evaluation
- Is not specifically developed for the NDs diagnosis
- Soft and hard-failure segmentation errors
- Sensitive to artifacts due to intensity in
homogeneity, head motion, reduced signal to noise
ratio, and partial volume effects
- Artifacts can all lead to reduced image quality,
alterations in intensity values and,
ultimately, errors in image segmentation
- FLAIR image has to be provided
- Limited number of tissues segmented
- The choice of the initial threshold lead to
different segmentation results
- The ML learning methods the tool is based on are not
properly documented
- All reports are based on in-house dataset
- Proprietary tool, it is not publicly available
- High price of the tool

- Proprietary tool, it is not publicly available
- High price of the tool

- Is not specifically developed for the NDs diagnosis
- Proprietary tool, it is not publicly available
- Cognitive assessment is incorporated into the tool
- High price of the tool
- The tool is not publicly available
- Cognitive tests are not incorporated into the tool
- High price of the tool
- No integration into clinical workflows with PACS
- No standalone application available
- No approval for clinical use
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Figure A1: High-level pipeline of the proposed web-based CAD system

Figure A2: Entity relation diagram of the database of the proposed CAD system
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Figure A3: Sample of expected visualization of the brain structures segmented by
the proposed CAD tool using T1w images

Next, we will build the probability density functions fcohort (x) for
each group from our dataset as it is shown in Figure A4. The studied
subject’s value e will be visualized with the vertical line. We will also
calculate the similarity coefficient s as follows:

s=

PC
,
PC + PD

(4.5)

where PC , and PD of are the probabilities that are calculated by formula 4.6
if expected value µC for group C is smaller than µD and with formula 4.7
otherwise. Here C corresponds to Control normal, and D to Dementia cohort.

PC = PC (x ≤ e) =

Z e
−∞
Z ∞

PD = PD (x ≥ e) =

fC (x) dx
(4.6)
fD (x) dx

e

PC = PC (x ≥ e) =
PD = PD (x ≤ e) =

Z ∞

fC (x) dx

Z

e
e

−∞

(4.7)
fD (x) dx

The similarity coefficient s can obtain values between 0 and 1. If s
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is zero it means that there is no similarity between control normal group C
and our examinee. Meanwhile, when s is one the subject is most probably
belongs to the control normal group. The smaller the value of s(s < 0.5) the
higher the probability of disease state.

Figure A4: Sample of the expected output from proposed web-based CAD tool for
relative hippocampus volume to show the separability measure between cognitively
normal group and cohort diagnosed with dementia

The second task is related to design and implementation of webbased tool composed from cognitive tests for early detection of NDs.
To solve the third task the deep learning model will be developed to
predict the cognitive status from structural data and prognosticate the
diagnosis. As an input, the model may consist of images and numerical
features, we will utilize ensemble modeling approach to enhance the
model’s performance and accuracy.

Specifically, we will design the

feedforward deep learning model. The feedforward regression algorithm
will map an structural images x to a cognitive tests results y as follows:

y = f (x, w)

(4.8)
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where w correspond to the parameters, that need to be optimized in order to
reach the best approximation of function f (x, w). We may present equation
4.8 in a form of:
y = f (n) ( f (n−1) (...( f (1) (x, w))))
where f (i) represents the ith layer out of n layers in NN.
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UAE UNIVERSITY DOCTORATE DISSERTATION NO. 2022: 9
Psychophysiological and cognitive tests as well as other functional studies
When assembled with
can detect pre-symptomatic stages of dementia.
structural
data,
cognitive
tests
diagnose neurodegenerative disorders
more reliably thus becoming a multimodal diagnostic tool. Screening for
dementia can be improved by studying an association between the brain structure
and its function.
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